JARKKO KALLIOVALKAMA

Arterial Reactivity and Cardiac Natriuretic Peptides in Genetic Hypertension, Nitric Oxide Deficiency and Renal Failure

Arterial Reactivity and Cardiac Natriuretic Peptides in Genetic Hypertension, Nitric Oxide Deficiency and Renal Failure

JARKKO KALLIOVALKAMA

Arterial Reactivity and Cardiac Natriuretic Peptides in Genetic Hypertension, Nitric Oxide Deficiency and Renal Failure

■

To Annukka

CONTENTS

LIST OF ORIGINAL COMMUNICATIONS

This thesis is based on the following original communications, which are referred to in the text by Roman numerals I-VI:

I   Kähönen M, Tolvanen J-P, Kalliovalkama J, Wu X, Karjala K, Mäkynen H and Pörsti I (1999): Losartan and enalapril therapies enhance vasodilatation in the mesenteric artery of spontaneously hypertensive rat. European Journal of Pharmacology 368:213-222.

II   Kalliovalkama J, Kähönen M, Tolvanen J-P, Wu X, Voipio J, Pekki A, Doris PA, Ylitalo P and Pörsti I (2000): Arterial responses *in vitro* and plasma digoxin immunoreactivity after losartan and enalapril treatments in experimental hypertension. Pharmacology & Toxicology 86:36-43.

III   Kalliovalkama J, Jolma P, Tolvanen J-P, Kähönen M, Hutri-Kähönen N, Wu X, Holm P and Pörsti I (1999): Arterial function in nitric oxide-deficient hypertension: influence of long-term angiotensin II receptor antagonism. Cardiovascular Research 42:773-782.

IV   Kalliovalkama J, Jolma P, Tolvanen J-P, Kähönen M, Hutri-Kähönen N, Saha H, Tuorila S, Moilanen E and Pörsti I (1999): Potassium channel-mediated vasorelaxation is impaired in experimental renal failure. American Journal of Physiology 277:H1622-H1629.

V   Magga J, Kalliovalkama J, Romppanen H, Vuolteenaho O, Pörsti I, Kähönen M, Tolvanen J-P and Ruskoaho H (1999): Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT_1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats. Journal of Hypertension 17:1543-1552.

VI   Suo M, Kalliovalkama J, Pörsti I, Jolma P, Tolvanen J-P, Vuolteenaho O and Ruskoaho H: Chronic L-NAME-induced hypertension and activation of natriuretic peptide gene expression: Inhibition by AT_1 receptor antagonism. Submitted.

ABBREVIATIONS

AA	Arachidonic acid
ACE	Angiotensin converting enzyme
ACh	Acetylcholine
ADM	Adrenomedullin
ADMA	asymmetrical dimethylarginine
Ang I	Angiotensin I
Ang II	Angiotensin II
Ang-(1-7)	Angiotensin-(1-7)
ANOVA	Analysis of variance
ANP	Atrial natriuretic peptide
AT_1	Subtype 1 angiotensin II receptor
AT_2	Subtype 2 angiotensin II receptor
ATP	Adenosine 5'-triphosphate
ATPase	Adenosine 5'-triphosphatase
BNP	B-type natriuretic peptide
$[Ca^{2+}]_i$	Intracellular free Ca^{2+} concentration
Ca^{2+} pump	Ca^{2+}-ATPase
cAMP	Cyclic adenosine 3',5'-monophosphate
cGMP	Cyclic guanosine 3',5'-monophosphate
CNP	C-type natriuretic peptide
CNS	Central nervous system
COX	Cyclooxygenase
DAG	1,2-diacylglycerol
ECFV	Extracellular fluid volume
EDCF	Endothelium-derived contracting factor
EDHF	Endothelium-derived hyperpolarizing factor
ET	Endothelin
G protein	Guanosine 5'-triphosphate-binding protein
GMP	Guanosine 3',5'-monophosphate
GTP	Guanosine 5'-triphosphate
HPLC	High performance liquid chromatography
5-HT	5-hydroxytryptamine, serotonin
ir	Immunoreactive
IP_3	Inositol 1,4,5-trisphosphate
K_{ATP}	ATP-sensitive K^+ channels
K_{Ca}	Ca^{2+}-activated K^+ channels
K_{IR}	Inward rectifier K^+ channels
K_V	Voltage-dependent K^+ channels

L-NAME	N^G-nitro-L-arginine methyl ester
MLCK	Myosin light chain kinase
NA	Noradrenaline
NEP	Neutral endopeptidase
NO	Nitric oxide
NOS	Nitric oxide synthase
NOx	Nitrite and nitrate
PG	Prostaglandin
PGI_2	Prostacyclin
PIP	Phosphatidylinositol 4,5-bisphosphate
PLC	Phospholipase C
PSS	Physiological salt solution
RAS	Renin-angiotensin system
ROC	Receptor operated Ca^{2+} channel
SHR	Spontaneously hypertensive rats
SNP	Sodium nitroprusside
SOD	Superoxide dismutase
SR	Sarcoplasmic reticulum
SSC	Saline sodium citrate
TEA	Tetraethylammonium
TXA_2	Thromboxane A_2
VOC	Voltage operated Ca^{2+} channel
VSMC	Vascular smooth muscle cell
WKY	Wistar-Kyoto

INTRODUCTION

Hypertension is the most common risk factor for myocardial infarction, stroke, and end-stage renal disease. Approximately one quarter of the entire population in industrialised societies and more than half of the population aged over 65 years are hypertensive (Ruoff 1998). Despite extensive studies carried out in the past decades to elucidate the mechanisms involved in the pathogenesis of hypertension, the origin of high blood pressure remains unknown in 95 % of the patients. It still appears that none of the main genes for essential hypertension have been identified or even mapped to genomic regions (Colhoun 1999). In general, elevated blood pressure has been thought to result from an increase in peripheral arterial resistance, while cardiac output remains normal (Kaplan 1998).

The individual variations in polygenetic disposition and environmental factors in hypertensive patients are substantial, and various pathomechanisms have been suggested to associate with essential hypertension (Lindpaintner et al. 1992). Therefore, numerous experimental models have been used to study the cause and progression of human cardiovascular disease as well as potential therapeutic interventions (Doggrell and Brown 1998). The most commonly used model of essential hypertension is the spontaneously hypertensive rat (SHR). The genetic hypertension in SHR follows the same progression as human hypertension (Adams et al. 1989, Folkow 1993), and as in essential hypertension, the actual cause of the disease in SHR is unknown (Dzau et al. 1995). Furthermore, the defects in the production or action of nitric oxide (NO) may contribute to the essential hypertension (Moncada and Higgs 1993). Therefore, the chronic inhibition of NO synthase (NOS) has been introduced as one of the models for experimental hypertension (Baylis et al. 1992). Moreover, the most common cause of secondary hypertension is renal parenchymal disease (Preston 1999). On the other hand, sustained essential hypertension predisposes to the development of renal failure (Frohlich 1997, Luke 1998, Rahn 1998). Therefore, experimental renal failure is a fascinating model of cardiovascular disease.

The vascular endothelium regulates the contractile state of the underlying smooth muscle by releasing relaxing and contracting factors. The endothelium is therefore an important regulator of local blood flow and peripheral arterial resistance. Abnormal endothelium-dependent vasodilatation has been observed in both patients with essential hypertension and renal failure, as well as in experimental models of these diseases. Furthermore, the natriuretic peptides synthesised in cardiac myocytes contribute to the regulation of blood pressure and fluid homeostasis by forming a humoral link between the heart and kidney (Ruskoaho 1992, Wilkins et al. 1997). These hormones lower blood pressure by promoting natriuresis and vasorelaxation, and by decreasing cardiac output. The atrial and ventricular synthesis, and cardiac and plasma levels of these hormones increase in cardiac hypertrophy and in response to volume expansion and pressure overload of the heart (Levin et al. 1998). Moreover, adrenomedullin (ADM) is a recently discovered peptide that participates in the physiological regulation of circulation. It is a potent vasodilatator, causes diuresis and

natriuresis, and has positive inotropic and chronotropic effects on the heart (Szokodi et al. 1998, Charles et al. 1999, Samson 1999). The synthesis of ADM has been observed to be increased in several cardiovascular diseases (Charles et al. 1999).

The present study was designed to examine arterial reactivity and structure and cardiac hormones in genetic hypertension, NO deficiency and renal failure. In addition, the effects of long-term inhibition of the renin-angiotensin system (RAS) on arteries and cardiac hormones were evaluated in SHR and N^G-nitro-L-arginine methyl ester (L-NAME)-treated Wistar rats.

REVIEW OF THE LITERATURE

I Control of blood pressure

1 General aspects

1.1 Autonomic nervous system

Adaptation of the cardiovascular system to an organism's requirements is achieved by the interaction between central and peripheral regulatory mechanisms (Culman and Unger 1992). The central nervous system (CNS) modifies blood pressure by adjusting the heart rate and contractility as well as peripheral vascular resistance. This occurs mainly via the sympathetic and parasympathetic pathways of the autonomic nervous system, but neuroendocrine pathways, such as the hypothalamo-pituitary axis, are also involved (Reid 1994). The effects of CNS on blood pressure are modified by arterial baroreceptors, which in hypertension are desensitised and reset to a higher level of blood pressure (Sleight 1991, Grassi et al. 1998). Although it is generally accepted that the primary purpose of the cardiac and arterial baroreflexes is to keep blood pressure close to a particular set point over a relatively short period of time, the contribution of the baroreceptor dysfunction to long-term essential hypertension is unclear (Panfilov and Reid 1994, Head 1995).

SHR have consistently shown indications of a centrally mediated increased sympathetic outflow (Reid 1994). In SHR, the release and synthesis of noradrenaline (NA) was found to be enhanced in the posterior hypothalamus (Pacák et al. 1993), an area known to produce marked cardiovascular pressor responses when stimulated (Bunag et al. 1975). In addition, the activity of the sympathoinhibitory neurons was reported to be decreased in both juvenile and adult SHR (Fujino 1984, Chalmers et al. 1992). These results suggest that the enhanced sympathetic activity is involved in the development and maintenance of hypertension in SHR. However, contradictory observations have also been published, indicating that an increase in the sympathetic tone may not always contribute to the development of spontaneous hypertension (Shah and Jandhyala 1995).

Although animal models of hypertension have indicated that high blood pressure is associated with an increase in sympathetic cardiovascular influences, a similar demonstration in humans has been more difficult to obtain for methodological reasons (Mancia et al. 1999). There is now evidence, however, of increased sympathetic activity in essential hypertension (Goldstein 1983, Guzzetti et al. 1988, Mancia et al. 1999). There seems to be a clear relationship between cardiac sympathetic activity and the progression of hypertension in its early stages (Julius 1996, Sakata et al. 1999). Furthermore, plasma NA levels are elevated, the rate of NA spillover from sympathetic nerve terminals increased, and the muscle sympathetic nerve activity enhanced in patients with essential hypertension as compared with normotensive control subjects (Goldstein 1983, Floras and Hara 1993, Rahn et al. 1999).

Sympathetic activity appears to be particularly high in young subjects with borderline hypertension, and increased sympathetic activity has even been found in the normotensive offspring of hypertensive patients, supporting the idea that increased sympathetic outflow is the cause, rather than the consequence, of blood pressure elevation (Floras and Hara 1993, Esler 1995, Noll et al. 1996). Thus, the dysfunction of the autonomic nervous system may contribute to the development of essential and experimental hypertension.

1.2 Kidneys

The kidneys regulate long-term blood pressure by adjusting sodium balance, extracellular fluid volume (ECFV), and blood volume (Navar 1997). When arterial pressure is elevated, pressure natriuresis will result in the renal excretion of sodium and water until the blood volume is decreased sufficiently to return the arterial pressure to normal levels (Guyton et al. 1972). Therefore, hypertension develops when the relationship between sodium excretion and arterial pressure is shifted towards higher pressures (Navar 1997). Furthermore, derangements that compromise the ability of the kidneys to maintain sodium balance can result in the kidney's need for an elevated arterial pressure to re-establish net salt and water balance (Navar 1997). Resetting of pressure natriuresis mechanism has actually been associated with the development of both human and experimental hypertension (Guyton et al. 1972, Cowley and Roman 1996, Cowley 1997).

The associations between renal dysfunction and hypertension are complex and these diseases may coexist at least in three distinct clinical settings (Preston 1999). First, renal parenchymal disease with impaired renal sodium excretion leading to ECFV expansion is a well-established cause of secondary hypertension. In fact, renal parenchymal disease is the most common cause of secondary hypertension, accounting for 2.5 % to 5 % of all cases of systemic hypertension (Preston 1999). Furthermore, hypertension is present in virtually all renal failure patients by the time renal-replacement therapy is initiated (Rabelink and Koomans 1997, Luke 1998). Moreover, disturbed hormonal profiles with increased sympathetic activity, activated RAS, increased levels of catecholamines, vasopressin and endothelin (ET), and decreased NO activity may participate in the high incidence of hypertension in renal failure patients (Bellinghieri et al. 1999, Ligtenberg et al. 1999). Second, it is well known that sustained, poorly controlled essential hypertension induces renal vascular injury and nephrosclerosis and predisposes to the development of renal failure (Frohlich 1997, Luke 1998, Rahn 1998). Hypertension also accelerates the progression of renal injury if it is inadequately controlled (Herrera-Acosta 1994). Hypertension has been suggested to be the cause of end-stage renal disease in 8 % of dialysis patients (Bellinghieri et al. 1999). The third major circumstance in which hypertension and renal failure occur simultaneously is ischemic renal disease followed by bilateral or unilateral arteriosclerotic renal artery stenosis (Preston 1999). Therefore, hypertension may be either a cause or a consequence of renal disease.

1.3 Renin-angiotensin system

RAS has been extensively studied in the past decades as an important mediator of hypertension and hypertensive end-organ damage. Originally, RAS was described as an endocrine system that exerts its action through the effector peptide, angiotensin II (Ang II). Recently, tissue-based RAS, which acts through paracrine-autocrine mechanisms, has been proposed to be a more important pathway (Stock et al. 1995, Rothermund and Paul 1998). The existence of local Ang II production has been demonstrated in many tissues including the brain, kidney, adrenal cortex, heart, and blood vessel wall (Cockcroft et al. 1995, Mulrow and Franco-Saenz 1996, Kubo et al. 1999). However, local synthesis of renin may be limited to very small amounts and it is very likely that there is uptake of renal renin from the circulation (Stock et al. 1995, Danser 1996). This uptake may occur via mannose 6-phosphate receptor (Danser et al. 1999).

Ang II is derived from angiotensinogen, which is synthesised in the liver. Angiotensinogen is cleaved to form angiotensin I (Ang I) by renin, an enzyme synthesised and released by the kidney. Ang I is then converted to Ang II through the action of angiotensin converting enzyme (ACE), which is located in the luminal surface of vascular endothelium (Riordan 1995, Wright et al. 1995). In addition to the conversion of Ang I to Ang II, ACE degrades bradykinin and related kinins to inactive peptides (Vanhoutte et al. 1993). In human, primate and dog tissues the conversion of Ang I to Ang II is also catalysed by chymase, while rat and mouse chymases degrade Ang II (Fukami et al. 1998, Wei et al. 1999). Ang II is not the only active peptide of RAS (Ardaillou 1997), since angiotensin III, angiotensin IV and angiotensin-(1-7) [Ang-(1-7)] also possess biological functions, but the debate continues over their relative importance compared with Ang II (Riordan 1995, Wright et al. 1995, Ardaillou 1997).

Ang II exerts its effects via binding to specific receptors on the cell surface. Ang II receptors of the cardiovascular system are divided into two main subtypes: AT_1 and AT_2, which are specifically blocked by losartan and PD123177, respectively (de Gasparo et al. 1995). To date, most of the known effects of Ang II in adult tissues are attributable to the AT_1 receptor (Horiuchi et al. 1999). These include the contraction of the vascular smooth muscle, positive inotropic and chronotropic actions in the heart, induction of vascular and cardiac hypertrophy, remodelling of arterial wall matrix tissue, reduction of baroreceptor activity in aorta, stimulation of ET production in endothelial cells, activation of superoxide generation in the vascular smooth muscle, enhancement of the Ca^{2+} sensitivity of the contractile apparatus of the smooth muscle, induction of inflammatory response in vascular wall, stimulation of catecholamine release in the adrenal medulla, facilitation of aldosterone biosynthesis and secretion in the adrenal cortex, facilitation of NA biosynthesis and release accompanied by inhibition of its reuptake in sympathetic nerve terminals, augmentation of tubular sodium reabsorption in the kidney and inhibition of renin release (Henrion et al. 1992, Lüscher et al. 1992, Falkenhahn et al. 1994, Griendling et al. 1994, Kang et al. 1994, Cockcroft et al. 1995,

Dieguez-Lucena et al 1996, dos Santos et al. 1998, Otsuka et al. 1998, Unger et al. 1998, Mervaala et al. 1999). In addition, the stimulation of AT_1 receptors in CNS has been reported to activate the sympathetic nervous system and the release of vasopressin from the pituitary gland (Steckelings et al. 1992, Höhle et al. 1995), and to excite pressor neurons in the rostral ventrolateral medulla, thereby increasing arterial pressure (Tagawa and Dampney 1999). (The main cardiovascular effects of Ang II are summarised in table 1).

Until recently, the functional role of the AT_2 receptor in cardiovascular system has been unknown. Mice lacking the AT_2 receptor have been shown to have slightly elevated systolic blood pressure compared with that of wild-type mice (Siragy et al. 1999). In rats, the stimulation of AT_2 receptors has been proposed to reduce blood pressure via vasodilatation (Scheuer and Perrone 1993, Carey et al. 2000), increase cyclic guanosine 3',5'-monophosphate (cGMP) production in the aorta (Munzenmaier and Greene 1994), inhibit proliferation of cultured endothelial cells (Stoll et al. 1995) and reduce arterial hypertrophy and fibrosis *in vivo* (Levy et al. 1996). The AT_2 receptor may thus play a counterregulatory role against the actions of Ang II at the AT_1 receptor (Horiuchi et al. 1999, Siragy et al. 1999).

Table 1. The main cardiovascular effects of angiotensin II mediated via AT_1 and AT_2 receptors.

AT_1 receptor		
	Vasculature	Contraction
		Hypertrophy
		Remodelling of vascular wall tissue
		Increased synthesis of extracellular matrix
		Inflammatory response
	Heart	Positive chronotropic action
		Positive inotropic action
		Hypertrophy
		Increased synthesis of extracellular matrix
	Adrenal medulla	Catecholamine release
	Adrenal cortex	Aldosterone release
	Kidney	Increased sodium reabsorption
		Decreased renin secretion
AT_2 receptor		
	Vasculature	Dilatation
		Inhibition of cell proliferation
		Reduction of hypertrophy
		Reduction of fibrosis
		Induction of apoptosis

It has been suggested that RAS is involved in the pathophysiology of genetic hypertension (Timmermans et al. 1993, Riordan 1995). The cultured vascular smooth muscle cells (VSMCs) from SHR, but not from normotensive Wistar-Kyoto (WKY) rats, produce

Ang II (Fukuda et al. 1999). In addition, VSMCs derived from SHR have a higher affinity for AT_1 receptor ligands and a greater AT_1 receptor density than those derived from WKY rats (Bunkenburg et al. 1992). In agreement, the Ang II-induced increase of extracellular Ca^{2+} uptake and release of intracellular Ca^{2+} have been found to be amplified in VSMCs from SHR when compared with those from WKY rats (Orlov et al. 1993). When evaluated by plasma measurements of Ang II and renin activity, a hyperactive RAS is not a consistent feature of essential hypertension, and in SHR the activity of the circulating RAS is not elevated (Paran et al. 1995). In contrast, SHR appear to have higher arterial ACE activities and concentrations than WKY rats (Nakata et al. 1987, Saavedra et al. 1992, Vicaut and Hou 1994). The arterial reactivity to Ang II has been reported to be either unaffected or enhanced in SHR and in essential hypertensive patients when compared with the respective normotensive controls (Chatziantoniou et al. 1990, Angus et al. 1992, Vicaut and Hou 1994, Tschudi and Lüscher 1995). It has even been suggested that the vascular reactivity to Ang II is enhanced in the initial phase of the development of hypertension in SHR, but it becomes attenuated as hypertension progresses (Endemann et al. 1999).

The findings in rats whereby the production of Ang II plays a significant role in the maintenance of basal vasomotor tone (Caputo et al. 1995), and arterial ACE activity positively correlates with blood pressure, support the crucial role of RAS in blood pressure control (Nakata et al. 1987, Cockcroft et al. 1995). Furthermore, an interruption of RAS activity at the genetic level, by a single intracardiac injection of AT_1 receptor antisense cDNA by a retrovirally mediated delivery system, causes a permanent cardiovascular protection against hypertension as a result of genomic integration of the transgene and germ line transmission in the SHR offspring (Reaves et al. 1999). Moreover, ACE antisense treatment prevents alterations in renal vascular pathophysiology and causes a modest lowering of blood pressure in SHR (Gelband et al. 2000). In male subjects, allelic variation in the ACE gene has been suggested to influence interindividual blood pressure variability (Fornage et al. 1998). In addition, the effectiveness of RAS inhibitors in reducing blood pressure in SHR and in patients with essential hypertension strongly supports the view that RAS is involved in the pathophysiology of genetic hypertension (Timmermans et al. 1993, Riordan 1995).

1.4 Natriuretic peptides and adrenomedullin

The natriuretic peptide family consists of three peptides, atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). The natriuretic peptides contribute to the regulation of blood pressure and fluid homeostasis by forming a humoral link between the heart and kidney (Ruskoaho 1992, Wilkins et al. 1997, Levin et al. 1998). ANP is mainly synthesised by the atrial myocytes of normal adult heart, but synthesis in ventricles and various extracardiac tissues including CNS, lung, adrenal gland, kidney and vasculature, have also been demonstrated (Gardner et al. 1986, Gerbes et al. 1994). BNP is synthesised by both atria and ventricles, although it is also produced in CNS, and CNP is

synthesised in CNS, kidney and vascular endothelium (Levin et al. 1998). The major determinant of ANP secretion is atrial wall stretch, while for BNP secretion it is both atrial and ventricular wall stretch. In addition, several hormones and neurotransmitters, such as ET, Ang II, vasopressin, and catecholamines, stimulate the secretion of ANP (Ruskoaho 1992, Levin et al. 1998, Thibault et al. 1999). The ventricular synthesis of ANP and BNP and the plasma concentrations of these peptides increase in cardiac hypertrophy and in response to volume expansion and pressure overload of the heart (Levin et al. 1998). However, the plasma concentration of CNP changes very little with cardiac overload (Furuya et al. 1991, Levin et al. 1998).

In mammalian tissues, the effects of natriuretic peptides are mediated by three receptors (A, B, and C) (Levin et al. 1998). The A receptor binds both ANP and BNP, with a preference for ANP, while CNP is the natural ligand for the B receptor. The A receptor is the most abundant type in large blood vessels, but there are also some B receptors. The B receptors predominate in the brain. Both receptors are present in the adrenal glands and kidneys. Receptors A and B mediate many of the cardiovascular and renal effects of the natriuretic peptides, and receptor C seems to be involved in clearance of the peptides and thus regulates the plasma natriuretic peptide concentrations (Maack et al. 1987). All three natriuretic peptides are also cleared by neutral endopeptidase (NEP) in several tissues (Wilkins et al. 1997).

The cardiovascular effects of ANP and BNP are very similar, but the effects of CNP are different, since it is not natriuretic but it possesses vasorelaxant activity (Wilkins et al. 1997, Chun et al. 1997). Natriuretic peptides counterbalance the effects of RAS, defend against excess salt and water retention, inhibit the production and action of vasoconstrictor peptides, promote vascular relaxation and inhibit sympathetic outflow (Levin et al. 1998). Thus, the blood pressure-lowering action of ANP is based on the reduction of the peripheral vascular resistance and decrease in cardiac output and is most apparent in states of volume excess (Levin et al. 1998). The natriuretic and diuretic actions of the natriuretic peptides are due to both renal haemodynamic and direct tubular actions (Levin et al. 1998). ANP causes vasodilatation of afferent renal arterioles and vasoconstriction of efferent arterioles, leading to increased filtration pressure within the glomerular capillaries (Marin-Grez et al. 1986). Natriuretic peptides have also antimitogenic and antitrophic activity in the cardiovascular system, and are suggested to inhibit the structural remodelling of heart and blood vessels in hypertension (Ruskoaho and Leppäluoto 1988, Furuya et al. 1991). Abnormalities of genes for the natriuretic peptides or their receptors have not been clearly linked to cardiovascular disease in human beings (Wilkins et al. 1997). However, studies with transgenic mice have shown that overexpression of the ANP gene decreases arterial blood pressure, while the deletion of the ANP gene leads to hypertension and cardiac hypertrophy (Steinhelper et al. 1990, John et al. 1995, Oliver et al. 1997).

ADM is a peptide recently identified in extracts of cultured pheochromocytoma cells, and it participates in the control of fluid and electrolyte homeostasis and circulation (Kitamura

et al. 1993, Autelitano et al. 1999). In the vasculature, ADM is synthesised and secreted from both smooth muscle and endothelial cells in response to shear stress, hypoxia and various growth factors and hormones (Chun et al. 1997, Cormier-Regard et al. 1998). Its bioactivity is mediated through different mechanisms including cyclic adenosine 3',5'-monophosphate (cAMP), NO, Ca^{2+} and tissue prostaglandins (Kato et al. 1995, Kureishi et al. 1995, Miura et al. 1995, Yang et al. 1996). It also inhibits ET-1 production (Kohno et al. 1995), and acts as an antiproliferative (Kano et al. 1996) and anti-smooth muscle migratory factor (Kohno et al. 1997). In the vasculature, ADM elicits a potent and long lasting hypotensive effect (Kangawa et al. 1996, Charles et al. 1999). Within the kidney it is diuretic and natriuretic and plays a role in the regulation of renal artery tone (Seguchi et al. 1995), and the control of mitogenesis in the glomeruli (Charles et al. 1999). ADM also inhibits water intake, salt appetite and aldosterone secretion, and thus the peptide facilitates the loss of plasma volume. Moreover, it elevates sympathetic tone and has positive inotropic and chronotropic effects on the heart (Szokodi et al. 1996, Szokodi et al. 1998, Romppanen 1999, Samson 1999). ADM is suggested to be degraded by NEP (Lisy et al. 1998).

Plasma ADM is elevated in association with increases in sympathetic nervous activity and body fluid volume (Ishimitsu et al. 1994). ADM levels in plasma are raised in patients with impaired renal function, in some patients with essential hypertension or primary aldosteronism, in poorly controlled diabetes, after acute myocardial infarction, in congestive heart failure, in sepsis and in thyreotoxicosis. ADM levels are also increased through normal pregnancy (Charles et al. 1999). The ADM may participate, along with ANP and BNP, in mechanisms counteracting a further elevation of blood pressure and the development of left ventricular hypertrophy in patients with essential hypertension (Kato et al. 1999a, Morimoto et al. 1999).

Vasopeptidase inhibitors, which simultaneously inhibit NEP and ACE, are effective in lowering blood pressure in various models of experimental hypertension and in essential hypertension. They also seem to offer advantages over ACE inhibition in improving cardiac performance, providing target organ protection and prolonging survival in essential hypertension and in heart failure. Therefore, ANP, BNP, CNP and ADM all seem to be involved in the pathophysiology of hypertension (Burnett 1999).

2 Vascular endothelium

The vascular endothelium, ideally situated at the interface between blood and the underlying smooth muscle, regulates vascular function by sensing the physical and chemical environment and releasing factors, which act on itself or on other vascular cells. The endothelium takes part in the regulation of various physiological functions including coagulation, lipid transport, immunological reactivity, vascular structure and vascular tone (Busse and Fleming 1993, Haynes and Webb 1998). The degree of contraction or relaxation of VSMCs characterises the general vasomotor tone, which governs the local blood pressure level and distributes the flow

according to metabolic needs. Therefore, by releasing vasoactive substances such as NO, hyperpolarizing factor, cyclooxygenase (COX) metabolites, ET and other contracting factors the endothelium continuously adjusts the balance between vasoconstriction and vasodilatation and maintains an adequate blood flow (Busse and Fleming 1993, Boulanger 1999).

A number of studies have demonstrated that endothelium-mediated arterial relaxation is impaired in patients with essential hypertension (Panza et al. 1990, Taddei et al. 1997a, Schmieder et al. 1997) although this view is not supported by all investigators (Cockcroft et al. 1994, Hutri-Kähönen et al. 1999). The impairment of endothelium-mediated vasodilatation has also been observed in various models of experimental hypertension including SHR (Cohen 1995, Küng and Lüscher 1995, Nava and Lüscher 1995). The manifestation of endothelial dysfunction has been shown to occur before the development of hypertension in SHR (Jameson et al. 1993), and endothelial function has been reported to be impaired even in the normotensive offspring of hypertensive parents (Taddei et al. 1996). On the contrary, the endothelium-dependent vasodilatation has been found to be preserved during the developmental phase of hypertension in SHR, suggesting that endothelial dysfunction provides no significant pathogenetic contribution to the onset of hypertension (Radaelli et al. 1998). In addition, endothelial dysfunction in humans seems to be independent of the degree of vascular structural alterations and of the aetiology of hypertension, and it is probably more linked to the haemodynamic load (Rizzoni et al. 1998a). The pathophysiological basis of endothelial dysfunction is still largely unknown, and it is even uncertain whether there is any association between endothelial dysfunction and hypertension (Van Zwieten 1997). However, endothelial dysfunction in cardiovascular disease may be reversed by drug treatments (Muiesan et al. 1999), and the risk of acute cardiovascular events can thus be decreased (Celermajer 1997).

2.1 Endothelium-derived vasodilatory factors

2.1.1 Nitric oxide

The discovery of endothelium-derived relaxing factor and its identification as NO, a highly reactive free radical gas, was one of the most exciting discoveries of biomedical research in the 1980s (Furchgott and Zawadzki 1980, Palmer et al. 1987). In 1992, Science picked NO as the Molecule of the Year, and over the past years NO has become established as a universal intercellular messenger that serves a variety of biomodulatory functions in many physiological and pathophysiological states (Beck et al. 1999). In addition to being a potent vasodilator, endothelium-derived NO also inhibits the proliferation and induces apoptosis of smooth muscle cells, reduces platelet activation and aggregation, and prevents leukocyte adhesion to the vascular surface. Thus NO protects blood vessels against remodelling, atherosclerosis and thrombosis (Moncada and Higgs 1993, Fukuo et al. 1996, Rudic et al. 1998, Taddei et al. 1998a, Papapetropoulos et al. 1999).

NO is synthesised from L-arginine by the NOSs. Three distinct NOS isoforms, endothelial, neuronal and inducible, exist in mammalian cells (Palmer et al. 1988, Singh and Evand 1997). The endothelial subtype accounts for the majority of the basal and stimulated NO synthesis in endothelial cells throughout the vasculature (Umans and Levi 1995). The synthesis of NO can be stimulated by an increase in endothelial Ca^{2+} concentration following physical and chemical stimuli such as shear stress and hypoxia, activation of cell surface receptors by a variety of endogenous substances like acetylcholine (ACh) and bradykinin, or application of Ca^{2+} channel agonists (Busse and Fleming 1995, Vanhoutte et al. 1995; Figure 1).

NO relaxes vascular smooth muscle via the activation of soluble guanylate cyclase that converts guanosine 3',5'-monophosphate (GMP) to cGMP (Moncada et al. 1991; Figure 1). In smooth muscle cells, cGMP has been reported to activate the cGMP-dependent protein kinase that regulates several pathways involved in Ca^{2+} homeostasis, the end result being a reduction in the concentration of Ca^{2+} available for contraction and a decrease in the sensitivity of contractile proteins to Ca^{2+} (Lincoln et al. 1994, Busse and Fleming 1995). In addition, NO has been reported to hyperpolarize vascular smooth muscle via cGMP-dependent mechanisms as well as by directly activating Ca^{2+}-activated K^+ channels (K_{Ca}) and Na^+-K^+ adenosine 5'-triphosphatase (ATPase) (Bolotina et al. 1994, Gupta et al. 1994, Cohen 1995). Furthermore, NO attenuates NOS activity by a negative feedback mechanism (Ignarro 1996). The activity of NOS can also be inhibited by analogues of L-arginine such as L-NAME, N^G-monomethyl-L-arginine and the asymmetrical dimethylarginine (ADMA) (Moncada et al. 1991, Vallance et al. 1992).

There appears to be a continuous basal release of NO from the endothelium, which significantly contributes to the maintenance of arterial tone (Schulz and Triggle 1994). This view is supported by the findings that chronic treatment of experimental animals with NOS inhibitors leads to a persistent hypertension (Baylis et al. 1992, Deng et al. 1993), and the disruption of endothelial NOS gene induces hypertension in mice (Huang et al. 1995, Shesely et al. 1996). Moreover, it has been suggested that there is diminished basal NO synthesis in the vasculature of patients with essential hypertension as well as in experimental hypertension (Calver et al. 1992, Cohen 1995, Forte et al. 1997). In contrast, studies in genetically hypertensive rats suggest that the vascular synthesis and release of NO is unaffected or it may even be enhanced (Grunfeld et al. 1995, Tschudi et al. 1996, Wu et al. 1996, Le Marquer-Domagala and Finet 1997). However, in these animals the excessive vascular production of superoxide anion has been reported to increase the decomposition of NO and, thus, attenuate endothelium-dependent vasodilatation (Jameson et al. 1993, Grunfeld et al. 1995, Tschudi et al. 1996). Potential enzymatic sources of superoxide in blood vessels include the mitochondrial electron transport chain, xanthine oxidase, COX, lipoxygenase, NOS, and NADH and NADPH oxidases, in endothelial, vascular smooth muscle and adventitial cells (Kojda and Harrison 1999). In physiological conditions, the concentration of superoxide radicals remains low within the organism as a result of its reaction with the superoxide

dismutase (SOD) enzyme. However, in pathological situations, such as hypertension, there may be an increase in the production of these radicals or a deficiency of SOD (De Artinano and Gonzalez 1999).

2.1.2 Prostacyclin

Prostacyclin (PGI_2) is a member of the prostaglandin (PG) family. It causes vasodilatation and inhibition of platelet aggregation (Busse et al. 1994). It also inhibits VSMC proliferation *in vitro* (Weber et al. 1998a). The formation of PGs begins with the liberation of arachidonic acid (AA) from cell membrane phospholipids by phospholipase A_2. COX then converts AA into PGG_2 and PGH_2. Finally, PGH_2 is converted into PGI_2 by PGI_2 synthase (Cohen 1995, Gryglewski 1995; Figure 1). Although other PGs (PGE_2, $PGF_{2\alpha}$ and PGD_2) are also synthesised in the endothelial cells, PGI_2 is the major prostanoid produced in all the vascular cells (Busse et al. 1994). The production of PGs can be blocked by non-steroidal anti-inflammatory drugs, which inhibit COX (Vane and Botting 1993).

Endothelial cells release PGI_2 in response to shear stress, hypoxia, and stimulation of various receptors such as muscarinic, B_2-kinin and purinergic P_{2Y} receptors (Gryglewski 1995, Lüscher and Noll 1995). Physiologically, PGI_2 is a local rather than a circulating hormone, because its blood levels are too low to have any general effects (Vane and Botting 1993). PGI_2 exerts its actions by binding to membrane receptors on the smooth muscle, which activate adenylate cyclase and subsequently increase the intracellular concentration of cAMP (Busse et al. 1994). The elevation of intracellular cAMP leads to the hyperpolarization of cell membrane, reduction of intracellular Ca^{2+} concentration, and to a decrease in the sensitivity of contractile proteins to Ca^{2+} (Bülbring and Tomita 1987, Ushio-Fukai et al. 1993, Cohen and Vanhoutte 1995; Figure 1). When compared with the inhibition of NOS, the blockade of COX has negligible impact on blood pressure (Ruoff 1998). However, the inhibition of COX has been found to enhance endothelium-mediated vasodilatation in SHR as well as in essential hypertensive patients (Jameson et al. 1993, Taddei et al. 1993, Takase et al. 1994, Taddei et al. 1997b). In addition, it has been proposed that in the hypertensive rat endothelium, the conversion of PGH_2 into PGI_2 is diminished, resulting in the accumulation of the vasoconstrictor PGH_2 (Cohen 1995). Therefore, genetic hypertension appears to be associated with an imbalance in the endothelial production of COX-derived vasodilator and vasoconstrictor factors, with the balance tilting to vasoconstriction.

2.1.3 Endothelium-derived hyperpolarizing factor

Endothelium-derived hyperpolarizing factor (EDHF) is defined as that substance, which produces vascular smooth muscle hyperpolarization and relaxation that cannot be explained by NO or PGI_2 (Edwards and Weston 1998). EDHF has been reported to be a diffusible factor, which causes the opening of K^+ channels in the smooth muscle membrane (Bray and Quast

1991, Garland et al. 1995). Involvement of adenosine 5'-triphosphate (ATP)-sensitive K^+ channels (K_{ATP}) and Na^+,K^+-ATPase has been reported in some vessels, but in the majority of the studies EDHF has been suggested to act through K_{Ca} (Quayle and Standen 1994, Cohen and Vanhoutte 1995, Garland et al. 1995, Kagota et al. 1999). The action of EDHF can be inhibited by K^+ channel blockers or by depolarizing the smooth muscle with high K^+ concentrations (Adeagbo and Triggle 1993).

In recent years, the most popular candidates for EDHF have been the nonprostanoid products of the metabolism of AA, namely epoxyeicosatrienoic acids (Cohen and Vanhoutte 1995, Garland et al. 1995, Campbell et al. 1996, Vanhoutte and Mombouli 1996, Fisslthaler et al. 1999, Bolz et al. 2000). They are produced by the endothelium, released in response to vasoactive hormones and elicit vasorelaxation via stimulation of K_{Ca} (Quilley et al. 1997). Studies have also indicated that endocannaboid agonists, such as anandamide, may be EDHFs, since they induce K^+ channel activation-mediated vasorelaxation in isolated vascular preparations (Randall and Kendall 1998). The K^+ ion itself has also been suggested to be EDHF in small mesenteric resistance arteries of rats (Edwards et al. 1998), although not all investigators are convinced of this claim (Lacy et al. 2000). Moreover, the electrotonic propagation of endothelial cell hyperpolarization via gap junctions between endothelial and smooth muscle cells has been suggested to play some role in the EDHF response in rat hepatic and mesenteric arteries, and to be the sole mechanism underlying the EDHF response in the guinea-pig internal carotid artery (Edwards et al. 1999). Therefore, the nature of the responses attributed to EDHF seem still to be unsolved, but the evidence from several sources suggests that there are multiple EDHFs, and that the chemical mediator of the EDHF response may vary with the vascular bed (Edwards and Weston 1998, Campbell and Harder 1999).

The release of EDHF, like that of NO and PGI_2, is initiated by an increase in intracellular free Ca^{2+} concentration ($[Ca^{2+}]_i$) in the endothelial cell (Busse et al. 1994, Cohen 1995; Figure 1). Consequently, many autacoids and hormones that release NO and PGI_2 have also been shown to release EDHF (Cohen and Vanhoutte 1995). The mechanisms whereby hyperpolarization causes relaxation remain controversial. Most likely, the hyperpolarization of the smooth muscle cell membrane reduces Ca^{2+} influx through voltage dependent Ca^{2+} channels, which allows the Ca^{2+} sequestration and removal mechanisms to lower $[Ca^{2+}]_i$ (Busse et al. 1994, Cohen 1995). However, it has been suggested that the inhibition of voltage dependent Ca^{2+} channels does not entirely account for the relaxations attributed to EDHF in all the vessels (Cohen and Vanhoutte 1995). The hyperpolarization induced by potassium channel openers has been suggested to decrease the phospholipase C (PLC)-mediated inositol trisphosphate (IP_3) production, reduce the sensitivity of contractile elements to Ca^{2+}, enhance Ca^{2+} extrusion via Na^+/Ca^{2+} exchanger, and increase the binding of intracellular Ca^{2+} to the internal side of the plasmalemma (Quast et al. 1994).

The importance of EDHF in endothelium-dependent relaxations has been reported to increase as the artery size decreases (Shimokawa et al. 1996, Urakami-Harasawa et al. 1997). NO has been shown to inhibit both the production and action of EDHF (Bauersachs et al.

1996, McCulloch et al. 1997). Therefore, in pathophysiological states, such as hypertension, which may be associated with the decreased bioavailability of endothelium-derived NO, EDHF-mediated vasorelaxation could be enhanced and of greater importance than under physiological conditions (Bauersachs et al. 1996). Nevertheless, decreased endothelium-mediated hyperpolarization has been observed in many forms of experimental hypertension including genetic hypertension (Van de Voorde et al. 1992, Fujii et al. 1992, Mäkynen et al. 1996, Sunano et al. 1999).

Figure 1. Schematic diagram shows major mechanisms of endothelium-dependent arterial relaxation. Abbreviations: AA, arachidonic acid; ACh, acetylcholine; ATP, adenosine 5-triphosphate; $[Ca^{2+}]_i$, intracellular free Ca^{2+} concentration; cAMP, cyclic adenosine 3',5'-monophosphate; cGMP, cyclic guanosine 3',5'-monophosphate; EDHF, endothelium-derived hyperpolarizing factor; GTP, guanosine 5'-triphosphate; MLCK, myosin light chain kinase; NO, nitric oxide; NOS, nitric oxide synthase; PGG_2, prostaglandin G_2; PGH_2, prostaglandin H_2; PGI_2, prostacyclin; ⇑, increase; ⇓, decrease.

2.2 Endothelium-derived contractile factors

In addition to being a source of relaxing factors, endothelial cells also produce contractile factors such as vasoconstrictor prostanoids, ET-1 and Ang II. The production of endothelium-derived contracting factors (EDCFs) is induced by hypoxia, stretch, pressure, and various local and circulating hormones, and a marked heterogeneity of these responses exists among species, strains, and different vascular beds (Lüscher et al. 1992, Rubanyi 1993).

2.2.1 Cyclooxygenase-derived contractile factors

COX produces several EDCFs, the most potent of which are thromboxane A_2 (TXA_2) and the PG endoperoxide intermediates PGG_2 and PGH_2, which all act via the same receptor (Cohen 1995). Several agonists including ACh and 5-hydroxytryptamine (5-HT) can induce the release of COX-derived contractile factors in SHR (Lüscher and Vanhoutte 1986, Auch-Schwelk and Vanhoutte 1991, Ito and Carretero 1992), whereas such responses are absent in WKY rats (Lüscher and Vanhoutte 1986, Jameson et al. 1993). The release of COX-derived contractile factors can be inhibited by COX inhibitors such as diclofenac (Auch-Schwelk and Vanhoutte 1991).

Numerous studies in SHR and some in patients with essential hypertension have found that endothelium-dependent vasodilatation is impaired due to the production of COX-derived factors (Jameson et al. 1993, Taddei et al. 1993, Takase et al. 1994, Küng and Lüscher 1995, Taddei et al. 1997a). However, the blockade of TXA_2/PG endoperoxide receptor has no or only a minimal effect on systemic blood pressure in SHR or in patients with essential hypertension (Ritter et al. 1993, Tesfamariam and Ogletree 1995, Ruoff 1998). The COX inhibition has been found to enhance endothelium-mediated dilatation in essential as well as in experimental hypertension (Jameson et al. 1993, Taddei et al. 1993, Takase et al. 1994, Taddei et al. 1997b). However, the production of COX-dependent EDCFs does not seem to occur in young essentially hypertensive patients, suggesting that COX-derived EDCFs do not participate in the development of human hypertension (Taddei et al. 1997a).

2.2.2 Endothelin-1

ETs (ET-1, ET-2, ET-3) are peptides that possess characteristically sustained vasoconstrictor properties (Haynes and Webb 1998). They are synthesised from larger precursors, preproendothelins via the formation of proendothelin, which in turn is cleaved to form the mature ET-1 by ET converting enzymes (Haynes and Webb 1998). The predominant member of the ET family appears to be ET-1 generated by vascular and cardiac endothelial and smooth muscle cells, kidney, posterior pituitary and CNS (Lüscher et al. 1992, Haynes and Webb 1998, Rothermund and Paul 1998). ET-2 produced in endothelial cells, heart and kidney, and ET-3 produced in the endocrine, gastrointestinal and central nervous systems are probably less

important mediators of the cardiovascular effects of ETs (Haynes and Webb 1998, Masaki 1998).

The production and release of ET-1 occurs in response to many stimuli, including adrenaline, Ang II, vasopressin, interleukin-1, transforming growth factor-β, cyclosporine, lipoproteins, free radicals, thrombin, endotoxin, and physical factors such as stretch, hypoxia and low shear stress (Kuchan and Frangos 1993, Lüscher and Noll 1995, Haynes and Webb 1998, Rothermund and Paul 1998). On the other hand, high shear stress and the formation of cGMP and cAMP within the endothelium have been shown to inhibit ET-1 production (Haynes and Webb 1998, Rothermund and Paul 1998). Endothelial cells secrete synthesised ET-1 mainly onto the abluminal side towards the vascular smooth muscle rather than into the lumen (Wagner et al. 1992, Rothermund and Paul 1998). This has lead to the concept that ETs predominantly act locally in a paracrine or autocrine manner (Rothermund and Paul 1998).

The haemodynamic effects of ETs can be explained by the activation of two receptor subtypes, ET_A and ET_B (Sakurai et al. 1990, Nava and Lüscher 1995). The intracellular mechanisms of action of ETs involve the activation of phosphatidylinositol metabolism, mobilisation of intracellular Ca^{2+} stores, and promotion of Ca^{2+} entry through plasmalemmal Ca^{2+} channels (Schiffrin 1995). The ET_A receptor has a high affinity for ET-1, is present in VSMCs and cardiomyocytes, and predominantly mediates contraction (Rothermund and Paul 1998). The ET_B receptor is equally sensitive to the three ET isoforms, is present both in the endothelium, where it releases NO and PGI_2, resulting in vasodilatation, and in VSMCs, where it mediates vasoconstriction (Clozel et al. 1992, Lüscher et al. 1993a, Masaki 1998).

ET-1 is one of the most potent known endogenous vasoconstrictors, and it has inotropic, trophic and mitogenic properties, influences the homeostasis of salt and water, alters central and peripheral sympathetic activity, and stimulates RAS and sympathetic nervous system (Yanagisawa et al. 1988, Haynes and Webb 1998, Moreau 1998). Moreover, ET-1 is able to potentiate the contractile responses to other vasoconstrictors such as 5-HT and NA at subthreshold concentrations, and it may also provoke the release of free radicals and COX-derived vasoconstrictor factors (Lüscher et al. 1993b, De Artinano and Gonzalez 1999).

In view of the multiple cardiovascular actions of ET-1, there has been much interest in its contribution to the pathogenesis of hypertension and renal disorders (Haynes and Webb 1998, Barton and Lüscher 1999). ET-1 is overexpressed in the vascular wall in certain models of experimental hypertension including deoxycorticosterone acetate salt-treated rats, stroke-prone SHR, Ang II-infused rats and 1-kidney 1 clip Goldblatt rats, but it is not overexpressed in SHR, 2-kidney 1-clip hypertensive rats or L-NAME-treated rats (Schiffrin 1999). The vascular ET activity in patients with essential hypertension has also been found to be increased and could be of pathophysiological relevance to their increased vascular tone (Cardillo et al. 1999). ET-1 may also have a role in the onset of hypertension-induced remodelling in conduit arteries (Cattaruzza et al. 2000). Furthermore, ET-1 has been involved in the progression of renal failure in rats with subtotal nephrectomy, and ET receptor blockade has reduced protein excretion in these rats (Wolf et al. 1999). Moreover, the administration of

anti-ET agents produces vasodilatation and lowers blood pressure in hypertensive humans and experimental animals, and reduces end-organ damage in animal studies, irrespective of whether vascular ET activity is increased in hypertension (Brunner 1998, Haynes and Webb 1998, Verhagen et al. 1998, Webb and Strachan 1998). Therefore, ET-1 may contribute to the functional and structural changes associated with hypertension and renal failure (Barton and Lüscher 1999).

3 Vascular smooth muscle

3.1 Contraction

Vasoconstricting neurotransmitters and hormones bind to their receptors on the cell surface and initiate a series of processes leading to the contraction of vascular smooth muscle. Most receptors activate various types of guanosine 5-triphosphate (GTP) binding proteins (G proteins), which are coupled to different ion channels and enzymes, and modulate their activities. These enzymes include both phospholipase C (PLC), which metabolises phosphatidylinositol 4,5-bisphosphate (PIP) and produces inositol 1,4,5-triphosphate (IP$_3$) and 1,2-diacylglycerol (DAG), and adenylate cyclase, which metabolises ATP to produce cAMP (Abdel-Latif 1986, Nishizuka 1995). IP$_3$ releases Ca^{2+} from intracellular stores whereas DAG activates protein kinase C (PKC), which phosphorylates a number of proteins (Nahorski et al. 1994). In addition to the activation of the phosphatidylinositol metabolism, vasoconstrictors, such as NA and 5-HT, have been shown to depolarize the arterial smooth muscle and consequently activate voltage operated Ca^{2+} channels (VOCs) in the plasma membrane of the smooth muscle, leading to an increased influx of Ca^{2+}. Moreover, the existence of receptor operated Ca^{2+} channels (ROCs) has been proposed in VSMCs (Nelson et al. 1990). The activation of the above mechanisms increases $[Ca^{2+}]_i$, which is the primary signal for smooth muscle contraction (Allen and Walsh 1994).

As a consequence of the elevated $[Ca^{2+}]_i$ concentration, Ca^{2+} binds to calmodulin to form a Ca^{2+}-calmodulin complex, which removes the autoinhibition of myosin light chain kinase (MLCK; Allen and Walsh 1994). The activated MLCK phosphorylates reversibly the light chain of myosin and activates the myosin ATPase (Walsh 1994, Winder et al. 1998). The phosphorylated myosin cyclically binds to actin filaments producing force or the shortening of the smooth muscle (Walsh 1994). On the other hand, a fall in $[Ca^{2+}]_i$ inactivates the MLCK, permits dephosphorylation of myosin by myosin light chain phosphatase and causes relaxation (Stull et al. 1991, Cirillo et al. 1992, Rembold 1992, Allen and Walsh 1994). The contractile force does not, however, depend directly on $[Ca^{2+}]_i$, since the force may be enhanced by augmenting the responsiveness of the contractile machinery or the sensitivity of the myofilaments to $[Ca^{2+}]_i$ (Andrea and Walsh 1992, Ruegg 1999). Changes in free calmodulin concentrations, myosin light chain phosphorylation elicited by small G proteins (e.g. Rho A) and the enzymes associated with them (Rho-associated kinase), regulation of myosin

phosphatase activity and thin filament-associated proteins, such as calponin and caldesmon, are the possible mechanisms for regulation of Ca^{2+} sensitivity (Hori and Karaki 1998, Winder et al. 1998). These modulatory mechanisms for changing the Ca^{2+} sensitivity, together with the major regulatory mechanism for cellular Ca^{2+} metabolism, play an important role in the regulation of vascular smooth muscle tone (Walsh 1994, Takuwa 1996, Somlyo et al. 1999).

Increased receptor-mediated arterial smooth muscle contractility has often been observed in experimental hypertension (Longhurst et al. 1988, Perry and Webb 1988, Brodde and Michel 1992, Orlov et al. 1993). However, in many recent reports only minor differences have been detected in the contractile responses between hypertensive and normotensive animals (Bockman et al. 1992, Tolvanen et al. 1996). Enhanced responsiveness of G proteins (Kanagy and Webb 1994, Feldman et al. 1995), increased turnover and accumulation of inositol phosphates (Vila et al. 1993) and augmented release of Ca^{2+} from sarcoplasmic reticulum (SR) by IP_3 (Kawaguchi et al. 1993) have been suggested to mediate increased vascular contractility in experimental hypertension. In addition, the generation of DAG stimulated by vasoconstrictor agents and subsequent activation of protein kinase C have been reported to contribute to the enhanced vascular reactivity (Turla and Webb 1990, Okamura et al. 1992, Nguyen et al. 1993, Nahorski et al. 1994). Therefore, an overactive receptor-mediated contraction pathway may play some role in the pathogenesis of hypertension.

3.2 Cellular calcium regulation

The Ca^{2+} metabolism plays a central role in many cellular functions including growth, proliferation and contraction of the vascular smooth muscle. Contraction is initiated by an increase in $[Ca^{2+}]_i$ (Karaki and Weiss 1988). Since the Ca^{2+} stores of the vascular smooth muscle are both extracellular and intracellular (Cirillo et al. 1992), the $[Ca^{2+}]_i$ is adjusted by a complex interaction between Ca^{2+} entry and extrusion across the plasmalemma, and Ca^{2+} release from and uptake to SR (Marks 1992). Both the plasmalemma and SR form a barrier to an approximately 10 000-fold Ca^{2+} concentration gradient. The plasmalemmal Ca^{2+} permeability is under the control of membrane potential and various agonists, whereas SR is controlled by second messengers (Van Breemen and Saida 1989; The major mechanisms involved in the cellular Ca^{2+} regulation are summarised in figure 2).

Ca^{2+} influx across the plasmalemma under physiological conditions occurs through ion channels or via exchangers. Plasmalemmal Ca^{2+} channels are either voltage-gated or receptor-operated (Horowitz et al. 1996). Voltage-gated Ca^{2+} channels have been divided by electrophysiological and pharmacological techniques into two different subgroups: one type is activated by small depolarizations and is inactivated quickly (T-type), whereas the other requires stronger depolarizations and inactivates more slowly (L-type) (Spedding and Paoletti 1992). The L-type Ca^{2+} current can selectively be blocked by dihydropyridine Ca^{2+} channel antagonists like nifedipine, and T-type Ca^{2+} channels can be blocked by mibefradil (Nelson et al. 1990, Spedding and Paoletti 1992, Mishra and Hermsmeyer 1994). Some Ca^{2+} ions enter

VSMCs also due to the low passive permeability of the plasma membrane to Ca^{2+} (Cirillo 1992). Moreover, the plasma membrane has a capacity to bind Ca^{2+} and thus buffer an increase in $[Ca^{2+}]_i$, and it has been suggested that an elevation in both extra- and intracellular Ca^{2+} makes the plasma membrane less permeable to Ca^{2+} (Dominiczak and Bohr 1990, Cirillo et al. 1992). In vascular smooth muscle, Ca^{2+} can be extruded from the cell by the plasmalemmal Ca^{2+}-ATPases (Ca^{2+} pump) or the Na^+/Ca^{2+} exchanger (Allen and Walsh 1994, Horowitz et al. 1996). The Ca^{2+} pump uses energy provided by ATP hydrolysis and accounts for most of the Ca^{2+} efflux at normal $[Ca^{2+}]_i$. The Na^+/Ca^{2+} exchange is an antiporter which under basal conditions permits the efflux of one Ca^{2+} ion coupled with the influx of three Na^+ ions (Cirillo 1992).

A large capacity for total Ca^{2+} storage in VSMCs is achieved mainly by SR, although special Ca^{2+} binding molecules are also present (Karaki and Weiss 1988, Horowitz et al. 1996). SR can actively sequester Ca^{2+} (Martonosi et al. 1990, DeLong and Blasie 1993) and release it following plasmalemmal receptor activation (Minneman 1988). IP_3 formed in response to the activation of cell surface receptors releases Ca^{2+} by binding to IP_3-receptors in SR (Marks 1992, Allen and Walsh 1994, Somlyo et al. 1999). Intracellular Ca^{2+} stores can also be mobilised by Ca^{2+}-induced Ca^{2+} release, a mechanism in which the influx of a small amount of Ca^{2+} releases more Ca^{2+} from SR via ryanodine receptors (Marks 1992, Allen and Walsh 1994, Horowitz et al. 1996). The physiological significance of Ca^{2+}-induced Ca^{2+} release may be the amplification of IP_3-induced Ca^{2+} release, since Ca^{2+} is a coagonist of IP_3-induced Ca^{2+} release (Finch et al. 1991, Nahorski et al. 1994). The membrane of SR contains also a Ca^{2+} pump, which transports Ca^{2+} ions from the cytosol into SR (Van Breemen and Saida 1989, Allen and Walsh 1994, Horowitz et al. 1996).

The $[Ca^{2+}]_i$ has been found to be abnormally high in blood cells, cultured aortic and mesenteric arterial smooth muscle cells, and also in intact aortas and renal arteries of hypertensive animals (Spieker et al. 1986, Jelicks and Gupta 1990, Sada et al. 1990, Sugiyama et al. 1990, Oshima et al. 1991, Papageorgiou and Morgan 1991, Bendhack et al. 1992, Arvola et al. 1993, Ishida-Kainouchi et al. 1993), whereas some studies have failed to observe this abnormality (Liu et al. 1994, Neusser et al. 1994). However, since the studies on VSMCs from resistance arteries have shown no difference in the basal $[Ca^{2+}]_i$ between SHR and WKY rats (Storm et al. 1992, Bukoski et al. 1994, Bian and Bukoski 1995), the elevations in $[Ca^{2+}]_i$ found in aortic smooth muscle cells and in several other cell types of hypertensive animals are unlikely to contribute to the heightened peripheral resistance in SHR (Dominiczak and Bohr 1990, Bian and Bukoski 1995).

Contractile responsiveness of VSMCs from large arteries of SHR have been shown to be enhanced to depolarization and Bay K 8644, an agonist of dihydropyridine-sensitive Ca^{2+} channel, when compared with WKY rats (Aoki and Asano 1986, Aoki and Asano 1987, Bruner and Webb 1990). In addition, increased vascular sensitivity to the effects of nifedipine has been found in prehypertensive and adult SHR (Aoki and Asano 1986, Aoki and Asano 1987, Asano et al. 1995). In resistance arteries, an increase in the Ca^{2+} influx by the voltage-

dependent Ca^{2+} channels has been found in the early hypertensive stage, but not in prehypertensive SHR (Arii et al. 1999). The increased amplitude of the whole-cell Ca^{2+} current in the arterial smooth muscle cells from SHR compared with WKY rats has been suggested to be attributed to enhanced sensitivity of dihydropyridine receptors in the channels in SHR, while the opening of single Ca^{2+} channels has been suggested to be unaltered (Kubo et al. 1998). These results indicate that Ca^{2+} entry through VOCs is enhanced in SHR when compared with WKY rats, which could partially account for altered Ca^{2+} homeostasis and increased vascular reactivity, and thus contribute to the genesis of hypertension and increased peripheral resistance (Arii et al. 1999).

In SHR and in patients with essential hypertension, less Ca^{2+} than normal seems to be bound to the plasma membrane, and the Ca^{2+} permeability of plasma membrane seems to be increased (Lamb et al. 1988, Dominiczak and Bohr 1990). The extrusion of Ca^{2+} through the plasmalemma by the Na^+/Ca^{2+} exchange has been reported to be enhanced in aortic VSMCs of SHR (Ashida et al. 1989), whereas depressed activities have been found in tail arteries (Thompson et al. 1990). Studies on the Ca^{2+} pump-mediated Ca^{2+} efflux in VSMCs of SHR have also yielded contradictory results (Kwan and Daniel 1982, Ashida et al. 1989, Monteith et al. 1996, Monteith et al. 1997). Furthermore, the ability of SR to sequester Ca^{2+} has been proposed to be attenuated in SHR (Dohi et al. 1990, Kojima et al. 1991). In addition, SR of SHR appears to have a larger capacity to store Ca^{2+}, but the filling of SR is slower when compared with WKY rats (Kanagy et al. 1994). These findings could result from a reduced activity of SR Ca^{2+} pump. Nevertheless, the activity and density of SR Ca^{2+} pump have been reported to be increased in VSMCs of SHR (Levitsky et al. 1993), and the levels of SR Ca^{2+} pump mRNA were shown to be higher in VSMCs from SHR than in those from WKY rats (Monteith et al. 1997).

Taken together, if $[Ca^{2+}]_i$ is to be elevated, then the Ca^{2+} entry must be increased, or the storage of Ca^{2+} into SR must be decreased, or the extrusion of Ca^{2+} must be decreased. There is no clear evidence whether any of these abnormalities are present in hypertensive VSMCs (Gonzalez and Suki 1995). Finally, it has recently been suggested that one link between the metabolism of Ca^{2+} and the control of arterial tone could be the extracellular Ca^{2+} receptor in the perivascular sensory nerves, the activation of which can cause vasorelaxation via the release of a hyperpolarizing mediator (Bukoski 1998, Ishioka and Bukoski 1999).

3.3 Na^+-K^+-ATPase

A significant part of the membrane potential in VSMC can be attributed to the electrogenic action of the Na^+,K^+-ATPase, which generates a hyperpolarizing current by extruding three Na^+ ions for every two K^+ ions pumped in. Vascular Na^+,K^+-ATPase can be inhibited by cardiac glycosides such as digoxin and ouabain (Blaustein 1993, O'Donnell and Owen 1994). The activity of Na^+,K^+-ATPase is proposed to influence $[Ca^{2+}]_i$ in VSMC via VOCs and Na^+/Ca^{2+} exchange. Thus, decreased Na^+,K^+-ATPase activity leads to membrane

depolarization and increased Ca^{2+} influx through VOCs. In addition, decreased activity promotes Na^+ retention in VSMC, which reduces the driving force of Na^+/Ca^{2+} exchange leading to attenuated Ca^{2+} extrusion (Bova et al. 1990, Rayson and Gilbert 1992). However, it has been suggested that the latter mechanism does not play an important role in the modification of $[Ca^{2+}]_i$ in VSMCs of SHR (Zhu et al. 1994).

Altered Na^+,K^+-ATPase function has been proposed to play a role in the pathogenesis of both essential and experimental hypertension (Hermsmeyer 1987), but the findings supporting this view are still very controversial. The activity of Na^+,K^+-ATPase has been reported to be either decreased, normal, or increased in VSMCs of SHR when compared with those of WKY rats (Tamura et al. 1986, Manjeet and Sim 1987, Rinaldi and Bohr 1989, Kuriyama et al. 1992, Orlov et al. 1992, Redondo et al. 1995). The reason for depressed activity of Na^+,K^+-ATPase in hypertension may either be an inherent defect or a circulating digitalis- or ouabain-like inhibitor of the pump (Blaustein 1993, Hamlyn et al. 1996). The plasmas from patients with essential hypertension have been claimed to contain ouabain-like factors (Masugi et al. 1987), and the concentrations of these Na^+,K^+-ATPase inhibitors may be increased, especially in chronic renal insufficiency (Kelly et al. 1986). Circulating sodium pump inhibitor concentrations have even been suggested to be sufficient to affect the Na^+,K^+-ATPase in human mesenteric artery, thus the interaction of digitalis-like Na^+,K^+-pump inhibitors with the Na^+,K^+-ATPase could be of importance (Bagrov and Fedorova 1998). However, the existence of such circulating Na^+,K^+-ATPase inhibitors in human plasma is still not clear (Pidgeon et al. 1996), and the level of endogenous ouabain is reported to be lower in SHR when compared with WKY rats (Doris 1994). Moreover, in both rats and humans, studies on the effects of ouabain on blood pressure have produced inconsistent results, and therefore, it is not clear whether the inhibition of Na^+,K^+-ATPase could elevate blood pressure (Pidgeon et al. 1996).

Increased activity of the Na^+,K^+-ATPase has been linked to the increased vascular tone and smooth muscle growth found in SHR (Berk et al. 1989, Davies et al. 1991, Kemp et al. 1992). The activity of Na^+,K^+-ATPase may be enhanced in hypertension because of an increase in passive membrane permeability to Na^+, and since the pump does not appear to fully compensate for this, the vascular tone can be elevated (O'Donnell and Owen 1994). Taken together, these contradictory results on vascular Na^+,K^+-ATPase in hypertension possibly reflect the fact that the pump's functional, enzymatic and biochemical properties may not be uniformly altered in hypertension (Young et al. 1988), and that the type and duration of hypertension profoundly affect these results. It remains to be clarified whether the altered activity of the Na^+,K^+-ATPase in vascular smooth muscle is a key factor in hypertension (O'Donnell and Owen 1994).

3.4 K$^+$ channels

The intracellular concentration of K$^+$ in the vascular smooth muscle is approximately 25-fold higher when compared with the extracellular concentration of K$^+$, and therefore the opening of K$^+$ channels is accompanied by an efflux of K$^+$ from the cytosol, resulting in a loss of positive charge and hyperpolarization of the cell membrane (Quast et al. 1994, Ackerman and Clapham 1997). The K$^+$ channels play an essential role in the regulation of smooth muscle membrane potential, which in turn controls [Ca^{2+}]$_i$ and thus contraction of the vascular smooth muscle (Kitazono et al. 1995, Standen and Quayle 1998). Therefore, the factors that regulate the activity of K$^+$ channels in arterial smooth muscle significantly influence arterial tone, arterial diameter, vascular resistance, blood flow and blood pressure (Standen and Quayle 1998). Four types of K$^+$ channels have been described in arterial smooth muscle on the basis of their electrophysiological and pharmacological properties: K$_{Ca}$, K$_{ATP}$, voltage-activated K$^+$ channels (K$_V$) and inward rectifier K$^+$ channels (K$_{IR}$) (Figure 2). The modulation and expression of K$^+$ channels varies within vascular bed and between larger arteries and resistance vessels (Nelson and Quayle 1995).

K$_{Ca}$ oppose the pressure induced depolarization and myogenic tone of arterial smooth muscle by causing re- and hyperpolarization, the triggers being increased intracellular Ca^{2+} and membrane depolarization (Edwards and Weston 1990, Guia et al. 1999). K$_{Ca}$ are divided into large, intermediate and small according to their conductance. Large-conductance K$_{Ca}$ appear to be the most important K$^+$ channels in the regulation of arterial tone and are inhibited by tetraethylammonium (TEA), charybdotoxin and iberiotoxin whereas the small-conductance K$_{Ca}$ are blocked by apamin (Nelson 1993, Kitazono et al. 1995; Figure 2). The activity of K$_{Ca}$ has been shown to be increased in VSMCs of SHR when compared with those of WKY rats (Shoemaker and Worrel 1991, Asano et al. 1993a, Asano et al. 1993b, England et al. 1993, Rusch and Runnells 1994). In SHR, this phenomenon has been suggested to be caused by increased Ca^{2+} influx through L-type voltage-dependent Ca^{2+} channels, increased Ca^{2+} sensitivity of K$_{Ca}$, and increased expression of K$_{Ca}$ (Shoemaker and Worrel 1991, Asano et al. 1993a, Asano et al. 1993b, England et al. 1993, Liu et al. 1998). This elevated activation of K$_{Ca}$ has been proposed to represent a compensatory mechanism activated during the development of hypertension to counteract abnormal arterial excitability and prevent further vasoconstriction (England et al. 1993, Rusch and Runnels 1994, Rusch et al. 1996). Furthermore, EDHF is suggested to function via K$_{Ca}$ in many blood vessels (Cohen and Vanhoutte 1995).

K$_{ATP}$ have been identified by and named after their sensitivity to inhibition by intracellular ATP (Nelson 1993). Elevation in cytosolic adenosine 5'-diphosphate or intracellular acidification increases the open state probability of these channels (Nelson 1993, Ishizaka et al. 1999). K$_{ATP}$ can be inhibited by glibenclamide and tolbutamide, and activated by a variety of compounds such as cromakalim, levcromakalim, diazoxide and pinacidil (Quast et al. 1994; Figure 2). K$_{ATP}$ appear to contribute to the vasodilatory effects of several

endogenous and exogenous substances, in particular to those acting at receptors linked to cAMP-dependent protein kinase (Quayle and Standen 1994, Prieto et al. 1996). These include adenosine, calcitonin gene-related peptide, PGI_2 and β-adrenoceptor agonists (Standen and Quayle 1998). In addition, β-adrenoceptor agonists and PGI_2 have been reported to stimulate K_{ATP} independently of cAMP (Randall and McCulloch 1995, Vanhoutte and Mombouli 1996). Moreover, the vasorelaxation induced by adenosine, NO and EDHF involves the activation of K_{ATP} in some vessels whereas the vasoconstrictors Ang II and ET appear to inhibit these channels (Quayle and Standen 1994, Murphy and Brayden 1995). The basal opening state of coronary vascular K_{ATP} appears to be activated to a greater extent in SHR than WKY rats (Numaguchi et al. 1996), and K_{ATP} have been found to show reduced sensitivity to ATP in VSMCs of SHR (Furspan and Webb 1993). In addition, increased sensitivity to the effects of cromakalim and diazoxide and decreased sensitivity to the action of glibenclamide have been reported in the arteries of SHR when compared with those of WKY rats (Miyata et al. 1990, Furspan and Webb 1993). Therefore, SHR have been suggested to express a different subtype of K_{ATP} from WKY rats (Furspan and Webb 1993). In contrast, an impaired action of levcromakalim on K_{ATP} was recently found in SHR, and this impairment was restored by the normalisation of blood pressure with hydralazine. This finding suggests that the impairment can be attributed to high blood pressure rather than to the existence of a different subtype of K_{ATP} (Ohya et al. 1996).

K_V are activated by depolarization, but unlike K_{Ca}, the open state probability of these channels is decreased by elevation of intracellular Ca^{2+} concentration (Nelson and Quayle 1995, Cox and Petrou 1999). K_V can be inhibited by 4-aminopyridine. In addition to K_{Ca}, also K_V appear to oppose the depolarization of arterial smooth muscle by returning the membrane potential towards the resting level (Kitazono et al. 1995). K_{IR} are opened by pronounced hyperpolarization and exhibit a sustained inward current and are inhibited by extracellular Ba^{2+} (Nelson and Quayle 1995; Figure 2). These channels may play a role in maintaining resting membrane potential and regulating excitability of VSMCs (Kitazono et al. 1995, Brayden 1996). The roles of K_V and K_{IR} in the regulation of membrane potential in hypertension remain to be elucidated.

In summary, almost every physiological vasodilator and vasoconstrictor has been shown to modulate K^+ channels of one type or another in arterial smooth muscle (Standen and Quayle 1998). Most vasodilators and vasoconstrictors have multiple pathways of action, and the K^+ channels contribute to the changes in contractile tone by altering the cellular membrane potential. Such effects usually occur in concert with changes in Ca^{2+} channel activity, intracellular Ca^{2+} release and Ca^{2+} sensitivity of contractile proteins (Standen and Quayle 1998).

Figure 2. Schematic diagram shows the major mechanisms involved in the cellular Ca^{2+} regulation and some physiological and pharmacological properties of smooth muscle K^+ channels. Abbreviations: ADP, adenosine 5'-diphosphate; ATP, adenosine 5'-triphosphate; IP_3, inositol 1,4,5-trisphosphate; ROC, receptor operated Ca^{2+} channel; VOC, voltage operated Ca^{2+} channel; $[Ca^{2+}]_i$, intracellular free Ca^{2+} concentration, K_{ATP}, ATP-sensitive K^+ channels; K_{Ca}, Ca^{2+}-activated K^+ channels; K_{IR}, inward rectifier K^+ channels; K_V, voltage-dependent K^+ channels; -, inhibition; + stimulation; ⇑, increase; ⇓, decrease.

II Arterial tone and structure in experimental hypertension and renal failure

Animals have been used by humans for centuries to understand our own biology. In cardiovascular research, animal models allow the study of the mechanisms of the pathogenesis of cardiovascular disease and the effects of drug interventions. The aim of the studies is to provide clear concepts for selected investigations in humans. Human hypertension is difficult to study as there is substantial individual variation in the two triggering elements of hypertension, polygenetic disposition and excitatory environmental factors, leading to many variations in the direct and indirect effects on the cardiovascular system that are difficult to differentiate (Lindpaintner et al. 1992). The use of relevant models for human cardiovascular disease provides useful information allowing an understanding of the cause and progression of the disease state as well as increasing our knowledge of potential therapeutic interventions (Doggrell and Brown 1998).

1 Genetic hypertension

The most commonly used model of essential hypertension is SHR often with WKY rat as the normotensive control. SHRs are descendants of an outbred Wistar male with spontaneous hypertension from a colony in Kyoto, Japan, mating with a female with an elevated blood pressure, and then brother - sister mating continued with selection for spontaneous hypertension (Okamoto and Aoki 1963, Dzau et al. 1995). From 1968, this inbred strain of SHRs was further developed in the USA. The WKY controls were established later, in 1971, as a normotensive control strain by the National Institutes of Health as an inbreed of the Wistar Kyoto colony (Kurtz and Morris 1987).

Within each colony, SHRs have uniform polygenetic disposition and excitatory factors, leading to uniform changes in the cardiovascular system. This lack of inter-individual variation is one of the major advantages of the SHR (Lindpaintner et al. 1992). Another advantage of the SHR is that it follows the same progression of hypertension as human hypertension with pre-hypertensive, developing and sustained hypertensive phases (Adams et al. 1989, Folkow 1993). In the early stages of hypertension, SHRs have an increased cardiac output with normal total peripheral resistance. As SHR progresses into the established hypertension state, the cardiac output returns to normal and the hypertrophied and dysfunctional blood vessels produce an increase in the total peripheral resistance (Smith and Hutchins 1979). However, SHR differs from human hypertension in that SHRs develop hypertension in young adulthood rather than in middle age as is the case in humans (Folkow and Svanborg 1993). Importantly, the compounds that lower blood pressure in SHR also lower blood pressure in hypertensive humans.

A common criticism of SHR is that it can only model one of many possible causes of human hypertension, and it has been available for a long time but we still know little about the cause of the onset of hypertension (Dzau et al. 1995). The functional alterations of RAS and

sympathetic nervous system are suggested to be involved in hypertension in SHR (K-Laflamme et al. 1997). On the other hand, the development of hypertension in SHR does not seem to be due to an impairment of NO production, since the L-arginine/NO pathway is upregulated, and the NO production is actually increased in SHR both before and after the onset of hypertension (Vaziri et al. 1998a). However, endothelium-dependent relaxations are impaired in SHR arteries. This can, in part, be explained by reduced endothelium-dependent hyperpolarization (Fujii et al. 1992). Thus, alterations in the EDHF system may play a pivotal role in endothelial dysfunction in SHR (Onaka et al. 1998). Furthermore, enhanced sensitivity to vasoconstrictors in vascular smooth muscle from SHR has been found (Keaton et al. 1998).

The mesenteric resistance arteries from young and adult SHR have shown increased stiffness and media/lumen ratio, and smaller lumen diameter than arteries from WKY rats (Intengan et al. 1999). The wall components of resistance arteries further stiffen with age in SHR (Intengan et al. 1999). An increase in collagen/elastin ratio is also seen in SHR (Intengan et al. 1999). Moreover, decreased incidence of cellular apoptosis has been observed in the wall of mesenteric arteries from SHR compared with WKY rats, which could be responsible for the larger media volume found in older SHR and contribute to the development of hypertension in these animals (Dickhout and Lee 1999). Furthermore, interrupting the RAS has normalising effects on the stiffness and growth of the arterial wall in SHR (Intengan et al. 1999).

2 Hypertension induced by nitric oxide deficiency

Variants of the endothelial NOS gene may be associated with elevated blood pressure (Wang et al. 1997), although some recent reports do not support this view (Kato et al. 1999b, Takami et al. 1999). Nevertheless, the endothelial production of NO appears to be essential for the maintenance of normal blood pressure (Huang et al. 1995), and defects in the production or action of NO may be associated with essential hypertension (Moncada and Higgs 1993). Thus, chronic inhibition of NOS by L-NAME is an interesting model of hypertension (Baylis et al. 1992). Chronic administration of L-NAME has been shown to result in sustained hypertension in normotensive rats (Baylis et al. 1992, Deng et al. 1993), with an associated impairment of endothelium-dependent arterial relaxations (Küng et al. 1995, Dowell et al. 1996, Henrion et al. 1996, Henrion et al. 1997), and arterial remodelling (Deng et al. 1993, Li and Schiffrin 1994, Takemoto et al. 1997). The findings concerning endothelium independent arterial relaxations and contractile responses have been inconsistent (Küng et al. 1995, Dowell et al. 1996, Henrion et al. 1996). Changes in cardiac chamber geometry and myocardial diastolic mechanical properties may also be induced in L-NAME hypertension (Akuzawa et al. 1998, Matsubara et al. 1998). Moreover, chronic administration of L-NAME produces nephrosclerosis and impairs renal function in rats (Hropot et al. 1994, Akuzawa et al. 1998).

Substantial levels of constitutive NOS activity have been shown to remain in the aorta of WKY rats during chronic L-NAME administration (Zhao et al. 1999). Therefore, other

mechanisms than simple inhibition of endothelium-derived NO synthesis may be involved in the long-term cardiovascular effects of L-NAME in the rat arteries (Zhao et al. 1999). Recently the pathogenesis of cardiovascular remodelling in this model has been suggested to result from increased oxidative stress in endothelium (Usui et al. 1999). Excessive production of superoxide radicals may thus underlie the vascular RAS activation and in particular the increase in local ACE expression in rats with long-term NOS inhibition (Takemoto et al. 1997, Usui et al. 1999). Furthermore, hypertension and cardiovascular remodelling induced by NOS blockade have been suggested to be in part due to an elevation of plasma aldosterone concentration secondary to increased Ang II type 1 receptor expression in the adrenal gland (Usui et al. 1998). However, since the role of decreased NO production in human hypertension is unclear, it remains to be established whether NOS inhibition is an appropriate model of hypertension.

3 Renal failure

The patients with renal failure are characterised by abnormal elastic properties of large arteries, reflected as decreased distensibility and compliance (Barenbrock et al. 1994, London et al. 1996). These changes are independent of the level of blood pressure and tensile stress but are related to the uremic state itself (Luik et al. 1997, Mourad et al. 1997). Furthermore, in patients with end-stage renal disease, carotid arterial stiffness is a strong independent predictor of mortality (Blacher et al. 1998). In experimental renal failure, the increase in arterial wall thickness has been suggested to result primarily from an increase in extracellular matrix, although smooth muscle cell hyperplasia may also be involved (Amann et al. 1997). Plasma ET levels are elevated in patients with renal failure (Warrens et al. 1990), which is suggested to underlie the associated vascular remodelling (Demuth et al. 1998). However, in addition to the structural changes, alterations in arterial function contribute to increased vascular stiffness (Mourad et al. 1997). The functional changes have been attributed to the impaired NO-mediated endothelium-dependent vasodilatation as observed in brachial arteries of hemodialysis patients (Joannides et al. 1997, van Guldener et al. 1997). In the arteries of reduced renal mass hypertensive rats, not only the endothelium-dependent relaxations mediated by NO, but also those evoked by EDHF, have been attenuated (Kimura and Nishio 1999). Nevertheless, unaltered reactivity to endothelium-dependent vasodilators has also been observed (Verbeke et al. 1994, Liu et al. 1997). The increased oxygen-derived free radical activity and reduced enzymatic antioxidant defence mechanisms have been suggested to result, in part, from the altered arterial function and hypertension in renal failure (Durak et al. 1994, Vaziri et al. 1998b). Nevertheless, increased plasma levels of SOD and catalase have also been observed in renal failure (Martin-Mateo et al. 1998). It is noteworthy that endothelial dysfunction may also contribute to the development and progression of renal failure, and because endothelial dysfunction is detected at an early phase in the process of renal injury, it appears to be an attractive target for therapy (Rabelink and Koomans 1997).

In recent years several reports have discussed the role of NO synthesis and its inhibition in the development and progression of renal failure. The NO synthesis can be inhibited by analogues of arginine, including endogenous ADMA (Vallance et al. 1992). ADMA is present in normal human plasma, but it accumulates in renal failure (Vallance et al. 1992, Kielstein et al. 1999), suggesting changes in biosynthesis or excretion (Marescau et al. 1997). In chronic renal failure, circulating concentrations of ADMA are thought to rise sufficiently to inhibit NO synthesis, the inhibition of which might contribute to the changes in arterial function and to the hypertension associated with chronic renal failure (Vallance et al. 1992, MacAllister et al. 1996, Kielstein et al. 1999). However, the clinical role of ADMA is still questionable (Anderstam et al. 1997). Moreover, dietary L-arginine supplementation has been suggested to increase NO generation and enhance vasodilatation (Peters and Noble 1996), and to prevent the progression of glomerular sclerosis by ameliorating glomerular capillary hypertension in experimental models of kidney disease (Katoh et al. 1994). Nevertheless, elevated or unaltered plasma levels of L-arginine have been observed in uremic patients even without dietary supplementation (Noris et al. 1993, Kielstein et al. 1999), and both increased and decreased basal NO production have been reported in the vasculature of rats with reduced renal mass (Aiello et al. 1997, Vaziri et al. 1998b). The enhanced endothelial NOS expression and the larger amount of NO formed in arteries of reduced renal mass rats can serve as a defence mechanism to limit systemic blood pressure elevation in experimental renal failure (Aiello et al. 1997).

III Arterial tone and cardiovascular structure following inhibition of the renin-angiotensin system

The ideal antihypertensive drug should be effective in lowering blood pressure, well tolerated, safe in the long term and easy to use. Most importantly, it should reduce the risk of the adverse effects of high blood pressure, such as myocardial infarction, heart failure, stroke, and renal damage (Kendall 1998). One of the most important issues in the field of hypertension research centres on the therapeutic use of inhibitors of the RAS (Blaine et al. 1998). One reason for the interest in treating hypertension with drugs that not only reduce blood pressure but also have an inhibitory effect on the RAS is that hypertensive patients with inappropriately high renin levels have an increased risk of cardiovascular events (Weber 1997). Blockade of the RAS has proved to be a powerful therapeutic tool for lowering blood pressure and improving kidney function in disorders such as hypertension and chronic renal disease (Hall et al. 1999). Moreover, inhibitors of the RAS have potent antihypertensive effects, even in experimental models of hypertension and in essential hypertension, where the activity of the peripheral RAS is low or normal (Blaine et al. 1998).

1 Angiotensin converting enzyme inhibition

One possible intervention to interrupt the deleterious effects of the RAS is suppression of Ang II formation by the inhibition of ACE. The first ACE inhibitor was introduced more than twenty years ago (Nicholls et al. 1994). Since then, ACE inhibitors have been widely used and an enormous number of studies concerning their cardiovascular effects have been published. ACE inhibitors have proved to be effective in the treatment of essential hypertension, and in various models of experimental hypertension including genetic, L-NAME, reduced renal mass, and two-kidney-one-clip hypertension (Bao et al. 1992, Kanagy and Fink 1993, Novosel et al. 1994, Takase et al. 1996, Brown and Vaughan 1998). Long-term treatment with ACE inhibitors lowers blood pressure even in normotensive WKY rats (Bunkenburg et al. 1991, Kähönen et al. 1995b), but not in normotensive humans (Mancini et al. 1996). Furthermore, age, gender or plasma renin activity do not influence the antihypertensive response to ACE inhibition in humans (Weir and Saunders 1998).

The inhibition of Ang II formation by ACE inhibitors is far from complete, and the reduction of blood pressure by ACE inhibitors is better correlated with the inhibition of local ACE activity in tissues than with its activity in the plasma (Stock et al. 1995). ACE inhibitors also decrease the degradation of bradykinin, prolonging and potentiating its effects in endothelial cells (Auch-Schwelk et al. 1993, Auch-Schwelk et al. 1995, Hornig et al. 1997, Kohno et al. 1999). The modulation of the interaction between bradykinin and its receptor has been suggested (Hecker et al. 1994), and the ACE inhibitor ramiprilat has been shown to interfere with the sequestration of the B_2 kinin receptor within the plasma membrane of porcine aortic endothelial cells (Benzing et al. 1999). Bradykinin may also contribute to the acute effects of ACE inhibition on blood pressure in hypertensive humans, because coadministration of a specific B_2-receptor antagonist, icatibant, significantly attenuated the antihypertensive effect of captopril (Gainer et al. 1998). However, kinins do not appear to have a significant role in the chronic blood pressure-lowering effect of ACE inhibitors in SHR or in aortic coarctation hypertensive mice, since B_2 kinin receptor blockade or absence of the B_2 receptor gene have no effect on the antihypertensive action of long-term ACE inhibition (Bao et al. 1992, Gohlke et al. 1994, Cachofeiro et al. 1995, Rizzoni et al. 1998b, Rhaleb et al. 1999).

Both COX and NOS inhibition attenuate the long-term blood pressure-lowering effect of ramipril in SHR and of enalapril in patients with essential hypertension (Salvetti et al. 1987, Cachofeiro et al. 1995, Dijkhorst-Oei et al. 1998). Long-term lisinopril treatment also increases plasma levels of NO and 6-keto $PGF_1\alpha$, a stable metabolite of PGI_2, in hypertensive patients (Kohno et al. 1999). Furthermore, Ang II blockade diminishes the production of the superoxide anion, an inactivator of NO (De Artinano and Gonzalez 1999). Therefore, endogenous PGs and NO may be involved in the antihypertensive effect of ACE inhibitors. In addition, plasma catecholamine concentrations and cardiac sympathetic nervous activity have been shown to decrease in essential hypertensive patients responsive to ACE inhibitor therapy

(Prats et al. 1996, Sakata et al. 1998). Moreover, in cultured endothelial cells and cardiac myocytes ACE inhibitors can upregulate β-adrenoceptors (Graf et al. 1993, Yonemochi et al. 1998). The chronic antihypertensive action of ACE inhibitors may thus be partly mediated through the normalisation of sympathetic hyperreactivity and the restoration of β-adrenergic signalling pathway sensitivity (K-Laflamme et al. 1997). Furthermore, the inhibition of ACE leads to the accumulation of Ang I and its vasoactive metabolite Ang-(1-7) (Yamamoto et al. 1992, Kohara et al. 1993), which may also contribute to the effects of ACE inhibitors, since Ang-(1-7) has been found to release NO and vasodilatory PGs from the endothelium (Jaiswal et al. 1992, Pörsti et al. 1994, Brosnihan et al. 1996), inhibit endothelial ACE activity (Li et al. 1997b), and potentiate the effects of bradykinin (Ferrario and Iyer 1998, Oliveira et al. 1999). Ang-(1-7) has also been suggested to exhibit opposite effects on the regulation of VSMC growth than Ang II (Freeman et al. 1996).

Numerous studies have shown that long-term ACE inhibitor treatment improves endothelium-dependent vasodilatation in rats with experimental hypertension (Novosel et al. 1994, Bennett et al. 1996, Henrion et al. 1997, Sharifi et al. 1998), and in patients with essential hypertension (Schiffrin and Deng 1995, Rizzoni et al. 1997, Millgard et al. 1998, Taddei et al 1998b, Prasad et al. 1999). However, the improvement has not been detected in all studies (Creager and Roddy 1994, Bijlstra et al. 1995, Kiowski et al. 1996). It is noteworthy that chronic treatment with perindopril, quinapril or enalapril improved endothelium-mediated vasorelaxation in SHR, whereas no effect was found with hydralazine or amlodipine despite equal lowering of blood pressure (Bennett et al. 1996, Onaka et al. 1998). Moreover, ACE inhibition with quinapril, which did not reduce blood pressure, has been reported to improve endothelial dysfunction in normotensive patients with coronary artery disease (Mancini et al. 1996). An increase in NO production has been suggested to underlie the improvement in the endothelium-dependent relaxation by ACE inhibitors in both experimental and essential hypertension (Wiemer et al. 1997, Higashi et al. 1998). However, in the mesenteric arteries of SHR, the ACE inhibitor enalapril especially seems to improve EDHF-mediated hyperpolarization (Onaka et al. 1998). Thus, alterations in the EDHF system may play a pivotal role in the improvement of endothelial dysfunction with ACE inhibitor therapy (Onaka et al. 1998). Collectively, the above results suggest that ACE inhibitors may have beneficial effects on endothelial function which are independent of the reduction of blood pressure.

Long-term ACE inhibition has also been reported to modulate arterial responses to different vasoconstrictors in SHR. The majority of the studies have shown that contractions to NA are reduced after ACE inhibitor therapy (Lee et al. 1991, Arvola et al. 1993, Major et al. 1993, Kähönen et al. 1995b, Bennett et al. 1996), though some workers have failed to observe this effect (Dohi et al. 1994, Novosel et al. 1994). Contractile responses to another receptor-mediated agonist 5-HT have also been found to be either attenuated (Major et al. 1993, Berkenboom et al. 1995, Keaton et al. 1998) or unaffected (Tschudi et al. 1994, Hutri-Kähönen et al. 1997). In contrast, ACE inhibitor-treated SHR have shown no changes in

vasoconstriction induced by ET-1 (Dohi et al. 1994, Novosel et al. 1994, Rodrigo et al. 1997) or depolarization with KCl (Sada et al. 1990, Major et al. 1993, Dohi et al. 1994, Berkenboom et al. 1995). However, an enhancement of the response to ET-1 was reported in the blood vessels of patients with essential hypertension (Schiffrin and Deng 1995). In addition to the withdrawal of Ang II-induced amplification of vasoconstriction (Story and Ziogas 1987, Henrion et al. 1992, Qiu et al. 1994), the mechanisms underlying the attenuation of the contractile responses after ACE inhibition may involve normalised function of L-type Ca^{2+} channels (Sada et al. 1990, Arvola et al. 1993), decreased smooth muscle cell membrane permeability to ions (Arvola et al. 1993), and improved modulatory action of the endothelium on vasoconstriction (Kähönen et al. 1995b).

Arterial wall thickness and stiffness appear to be increased during hypertension and renal failure, which may contribute to the increased risk of cardiovascular complications. In essential hypertension and in animal models of genetic hypertension, the resistance vessels are considered to undergo inward eutrophic remodelling, e.g. rearrangement of the normal amount of vascular tissue (normal-sized smooth muscle cells, extracellular matrix) around a smaller lumen diameter (Mulvany 1999; Figure 3). On the other hand, in human renal hypertension, an inward hypertrophic response has been reported (Rizzoni et al. 1996). Reduced radial artery wall hypertrophy and improved carotid artery compliance, and decreased media to lumen ratio in the subcutaneous small resistance arteries have been observed in hypertensive patients treated with ACE inhibitors (Rizzoni et al. 1997, Girerd et al. 1998). Reduced media to lumen ratio has also been found in mesenteric resistance arteries of SHR after ACE inhibitor treatment (Rizzoni et al. 1998b). The correction of hypertensive structural remodelling by ACE inhibitors has been suggested to be either outward hypotrophic or eutrophic (Rizzoni et al. 1998c, Mulvany 1999). The structural matrix changes in the arterial wall after ACE inhibition may include decreased collagen accumulation and reduced collagen/elastin ratio (Benetos et al. 1997, Sharifi et al. 1998, Intengan et al. 1999). ACE inhibitors have also been suggested to enhance apoptosis in the vascular wall in SHR (Sharifi and Schiffrin 1998). Taken together, long-term treatment with ACE inhibitors seems to be effective in correcting vascular structural alterations in both SHR and patients with essential hypertension.

ACE inhibitors are also effective in normalising cardiac mass in SHR (Rizzoni et al. 1998b, Rizzoni et al. 1998c, Sharifi et al. 1998), and in patients with essential hypertension (Gonzalez-Juanatey et al. 1998). They appear to limit the hypertension-induced remodelling of both myocytes and interstitial tissues, with a subsequent reduction in myocardial passive stiffness (Grimm et al. 1998, Matsubara et al. 1998). Furthermore, ACE inhibitors protect against renal damage in experimental and essential hypertension (Akuzawa et al. 1998, Linz et al. 1998, Shionoiri et al. 1998). This renoprotective effect has been attributed to the reduction in Ang II formation (Lafayette et al. 1992). In addition, the beneficial effect of ACE inhibitors on cardiovascular structure and renal function in hypertension may be due to the effect of these drugs on the proliferation/cell death balance (Buemi et al. 1999).

hypotrophic **eutrophic** **hypertrophic**

inward

outward

wall:lumen

wall:lumen

Figure 3. The figure shows the manner in which remodelling can modify the cross-sections of blood vessels. The starting point is the vessel at the centre. Remodelling can be hypertrophic (e.g. increase of cross-sectional area, vessels in right column), eutrophic (no change in cross-sectional area, vessels in centre column), or hypotrophic (e.g. decrease of cross-sectional area, vessels in left column). These forms of remodelling can be inward (i.e. reduction in lumen diameter, vessels in top row), or outward (i.e. increase in lumen diameter, vessels in bottom row. Along a diagonal axis from top left to bottom right the media:lumen ratio of vessels does not change. Upward and to the right of the axis, the media:lumen ratio increases. Below and to the left of the axis, the media:lumen ratio decreases.

2 Angiotensin II receptor antagonism

AT_1 receptors are believed to mediate the known deleterious effects of Ang II. Therefore, AT_1 receptor antagonists have been introduced to the therapy of hypertension. Losartan, the prototype of this class of drugs, was synthesised in 1990 (Nicholls et al. 1994). Since then, numerous novel AT_1 receptor antagonists have been developed, and the literature about the cardiovascular effects of these compounds has expanded rapidly. These drugs induce a dose-dependent blockade of Ang II effects, resulting in reduced blood pressure, decreased urinary protein excretion, and prevention of glomerular sclerosis (Unger et al. 1998). The blood pressure-lowering effect has been observed in patients with essential hypertension and in various forms of experimental hypertension, including genetic, L-NAME and reduced renal mass hypertension (Pollock et al. 1993, Timmermans and Smith 1996). Similarly to ACE inhibition, long-term AT_1 receptor antagonism reduces blood pressure in normotensive WKY rats (Bunkenburg et al. 1991, Gillies et al. 1997, Medina et al. 1997), but not in normotensive humans (Kang et al. 1994). When compared with ACE inhibitors, the AT_1 receptor antagonists have been suggested to be more effective antihypertensive agents (Unger et al.

1996). However, in general, the antihypertensive effect of different AT_1 receptor antagonists has been comparable to that of different ACE inhibitors (Bunkenburg et al. 1991, Tschudi et al. 1994, Rodrigo et al. 1997).

The antihypertensive effect of AT_1 receptor antagonists has mainly been attributed to the inhibition of the binding of Ang II to AT_1 receptor. In addition, recent studies have pointed to the involvement of PGs and NO in the antihypertensive effect of losartan in SHR (Cachofeiro et al. 1995, Maeso et al. 1996, Gohlke et al. 1996). The mechanisms underlying the participation of PGs and NO in this effect have not been established, but losartan stimulates the synthesis of PGE_2 and PGI_2 in cultured endothelial cells (Jaiswal et al. 1991), and has antagonistic effect on the vascular TXA_2/PGH_2 receptor (Li et al. 1997c, Li et al. 1998). Furthermore, an interference with the negative feedback control of renin release by AT_1 receptor antagonists results in the accumulation of Ang II (Bunkenburg et al. 1991, Goldberg et al. 1993). This increases the stimulation of unopposed Ang II receptors, such as the AT_2 receptor (Chung et al. 1996), and the AT_2 receptor stimulation may increase the vascular production of bradykinin, NO and cGMP (Wiemer et al. 1993, Munzenmaier and Greene 1994, Seyedi et al. 1995, Gohlke et al. 1998). However, in mice AT_1 receptor blockade decreases tissue Ang II despite increased plasma levels, suggesting that Ang II may be protected from metabolisation by binding to its receptor (Mazzolai et al. 2000). During AT_1 receptor blockade the Ang I metabolite Ang-(1-7) can also release NO and vasodilatory PGs from the endothelium, an effect which is not mediated via AT_1 or AT_2 receptors (Jaiswal et al. 1992, Pörsti et al. 1994, Brosnihan et al. 1996).

AT_1 antagonists also inhibit Ang II-mediated catecholamine release from presynaptic sympathetic nerves and the adrenal medulla (Dendorfer et al. 1998). Moreover, the excitatory synaptic inputs to pressor neurons in the rostral ventrolateral medulla arising from the activation of the paraventricular nucleus are mediated predominantly by AT_1 receptors, the activation of which results in an increase in arterial pressure (Tagawa and Dampney 1999). The inhibition of these receptors may partly account for the blood pressure-lowering action of AT_1 receptor antagonists, since systemically administered irbesartan and losartan have access to central angiotensin receptors (Culman et al. 1999).

Long-term AT_1 receptor antagonism has been shown to beneficially influence arterial vasodilator function in experimental hypertension (Soltis 1993, Dohi et al. 1994, Tschudi et al. 1994, Vacher et al. 1996, Rodrigo et al. 1997), and when comparisons with ACE inhibitors have been made, the effects on vasorelaxation have been surprisingly similar (Dohi et al. 1994, Tschudi et al. 1994, Rodrigo et al. 1997). In addition to the reduced blood pressure, the enhanced endothelium-dependent vasodilatation following long-term AT_1 receptor antagonism has been attributed to increased endothelial production of NO (Dohi et al. 1994, Tschudi et al. 1994) and decreased production of EDCFs (Rodrigo et al. 1997).

The studies that have elucidated the effects of long-term AT1 receptor antagonism on vasoconstrictor responses in SHR have yielded inconsistent results. Vasoconstrictions elicited by 5-HT have either been reported to be unaffected (Tschudi et al. 1994), increased (Vacher et

al. 1996), or decreased (Soltis 1993) whereas the responses to KCl have either been unaffected (Dohi et al. 1994, Rodrigo et al. 1997) or increased (Vacher et al. 1996). NA-induced contractions have been found to be unaffected (Dohi et al. 1994, Gillies et al. 1997) or reduced (Soltis 1993), while those induced by ET have been reported to remain unchanged (Dohi et al. 1994, Rodrigo et al. 1997). Nevertheless, contractile responses to Ang II have always been found to be attenuated after AT_1 receptor antagonist therapy (Soltis 1993, Dohi et al. 1994, Rodrigo et al. 1997).

Chronic AT_1 receptor antagonist treatment, even at a dose that only moderately reduces blood pressure, induces regression of cardiovascular hypertrophy in hypertensive rats (Li et al. 1997a). It has been postulated that the selective blockade will directly decrease the growth-promoting actions of Ang II via the AT_1 receptor, while leaving the growth-inhibitory effects of the AT_2 receptor unaffected (Weber 1997, Unger et al. 1998). However, the blockade of AT_1 receptor-mediated effects of Ang II appears to be the main mechanism in the prevention of hypertensive cardiovascular remodelling (Mazzolai et al. 2000). Furthermore, losartan and irbesartan have normalising effects on stiffness, growth, and the collagen/elastin ratio of the mesenteric resistance artery wall in SHR (Benetos et al. 1997, Intengan et al. 1999). Losartan therapy also induces outward remodelling of mesenteric resistance arteries in SHR (Rizzoni et al. 1998c).

A reduction in left ventricular mass in hypertensive patients and in SHR has been observed after losartan therapy (Tedesco et al. 1998, Varo et al. 1999). The remodelling of cardiac tissue induced by AT_1 receptor antagonist treatment seems to be associated with a decrease in the synthesis of collagen and a subsequent reduction in tissue fibrosis (Varo et al. 1999). AT_1 receptor antagonists also exert clear renoprotective effects and have an antiproteinuric action in various models of experimental hypertension (Heller and Hellerova 1998, Kobayashi et al. 1999).

AIMS OF THE PRESENT STUDY

The objective of the present study was to examine arterial function and structure and cardiac natriuretic peptides in genetic hypertension, NO deficiency and renal failure. In addition, the effects of long-term inhibition of RAS on arteries and cardiac natriuretic peptides were evaluated in SHR and L-NAME-treated Wistar rats.

The detailed aims were:

1. To compare the effects of losartan and enalapril therapies, the two inhibitors of RAS with different mechanisms of action, on arterial relaxation in SHR.

2. To study the effects of losartan and enalapril treatments on mesenteric arterial structure, dihydropyridine-sensitivity, potassium relaxation and circulating sodium pump inhibitor in SHR.

3. To examine the influences of losartan treatment on the control of arterial tone in NO deficiency.

4. To investigate the effects of renal failure on the function of the vascular endothelium and arterial smooth muscle and on cardiac natriuretic peptides in WKY rats.

5. To compare the effects of AT_1 receptor antagonism and ACE inhibition on the regulation of ADM and natriuretic peptide gene expression in SHR and WKY rats.

6. To examine the effects of AT_1 receptor antagonism on cardiac natriuretic peptides in NO deficiency.

MATERIALS AND METHODS

1 Experimental animals

Normotensive Wistar rats were obtained from the colony of the Medical School at the University of Tampere (III, VI), whereas SHR (Okamoto-Aoki strain) and WKY rats were obtained from Møllegaard's Breeding Centre, Ejby, Denmark (I, II, V), and WKY rats also from M&B A/S, Ry, Denmark (IV). The rats were housed two (IV) or four (I, II, III, V, VI) to a cage in a standard animal laboratory room (temperature +22°C, a controlled environmental 12 h light-dark cycle). The studies were approved by the Animal Experimentation Committee of the University of Tampere, and by the Provincial Government of Western Finland, Department of Social Affairs and Health (IV).

2 Drug treatments

All the rats in study IV, and the untreated rats in studies I, II, III, V and VI were freely provided with tap water. Losartan (15 mg/kg/day) (I, II, V) and (20 mg/kg/day) (III, VI), enalapril (4 mg/kg/day) (I, II, V), and L-NAME (20 mg/kg/day) (III, VI) were administered in drinking fluid. The daily prepared drug solutions were kept in light-proof bottles. To obtain the desired daily drug dose, the concentration in drinking water was adjusted according to 24 h fluid consumption measurements.

3 Blood pressure measurements

The systolic blood pressures of the conscious rats restrained in plastic holders were measured indirectly by the tail cuff method at +28°C. All the measurements were performed with an IITC Inc. Model 129 Blood Pressure Meter (Woodland Hills, CA, USA) equipped with a photoelectric pulse detector. The blood pressure of each rat was obtained by averaging three reliable recordings.

4 Urine collection and measurement of fluid intake

Urine was collected for 24 h individually in metabolic cages where animals had free access to food and water (IV). Urine volumes were measured and samples stored at -20°C. The consumption of drinking fluid was measured by weighing the bottles in two consecutive mornings.

5 Blood and heart samples

The rats were anaesthetised by the intraperitoneal administration of urethane (1.3 g/kg) and

the carotid arteries cannulated. Blood samples were drawn into chilled tubes on ice containing 2.7 mM ethylenediaminetetraacetic acid (III, VI), and into tubes and glass capillaries containing heparin (IV), after which the samples were centrifuged, and the plasma stored at -70°C until analysis. After exsanguination, the thoracic and abdominal cavities of the animals were opened, the hearts removed and weighed. The tissue samples were frozen in liquid nitrogen and stored at -70°C until analyses.

6 Biochemical determinations

6.1 Total peroxyl radical-trapping and vitamin E (III)

Total peroxyl radical-trapping capacity was determined by the chemiluminescense method which has been described elsewhere (Alanko et al. 1993). Briefly, the production of peroxyl radicals by 2,2'-azobis(2-amidinopropane) hydrochloride induces luminol-enhanced chemiluminescence, and the time during which the added test sample extinguishes the reaction is directly proportional to its peroxyl radical-trapping antioxidant capacity. The test reaction was initiated by mixing 475 µl of oxygen-saturated sodium phosphate buffer (100 mM, pH 7.4) with 50 µl of 400 mM 2,2'-azobis (2-amidinopropane) hydrochloride (prepared in 100 mM phosphate-buffer) and 50 µl of 10 mM luminol in 20 mM boric acid-Borax-buffer in a cuvette (pH 9.0). The cuvette was placed in a luminometer (37°C), and the plasma sample (25 µl) was injected after the luminescence had stabilised, whereafter the chemiluminescence was measured at 40 second intervals. The water-soluble tocopherol was used as a standard. Vitamin E concentration was determined by modified high performance liquid chromatography (HPLC) (Catignani and Bieri 1983), and in our modification the UV detection of antioxidants was replaced by an LC-4 amperometric detector (Bioanalytical Systems Inc. West Lafayette, USA).

6.2 Nitrite and nitrate (IV)

To measure nitrite and nitrate (NOx) concentrations in plasma and urine, vanadium chloride in HCl was used to convert nitrite and nitrate to NO, which was quantitated by the ozone-chemiluminescence method (Braman and Hendrix 1989). The samples were first treated with ethanol at -20°C for two hours to precipitate proteins. Then a 20 µl sample was injected into a cylinder containing saturated VCl_3 solution (0.8 g VCl_3 per 100 ml of 1 M HCl) at 95°C, and NO formed under these reducing conditions was measured by the NOA 280 analyser (Sievers Instruments Inc., Boulder, CO, USA) using sodium nitrate as the standard.

6.3 Sodium, potassium, urea nitrogen, phosphate, creatinine, calcium and haemoglobin (IV)

Plasma sodium and potassium concentrations were measured by potentiometric direct dry

chemistry, urea nitrogen by colorimetric enzymatic dry chemistry, and phosphate by colorimetric end-point dry chemistry (Vitros 950 analyzer, Johnson & Johnson Clinical Diagnostics, Rochester, NY, USA). Creatinine was determined by the kinetic colorimetric assay according to Jaffe (Cobas Integra analyzer, F. Hoffman-La Roche Ltd, Diagnostics Division, Basel, Switzerland). Ionised calcium was measured by an ion selective electrode (Ciba Corning 634 Ca^{2+}/pH Analyzer, Ciba Corning Diagnostics, Sudbury, UK). Haemoglobin was determined by photometric analysis using Technicon cyanide free haemoglobin reagent (Technicon H*2™, Technicon Instruments Corporation, Tarrytown, NY, USA).

6.4 Digoxin-like immunoreactivity (II)

Plasma digoxin-like immunoreactivity was determined by ELISA of C18 (Bond Elut, Varian, Harbor City, CA, USA) extracts of plasma. The ELISA employed a digoxin antibody with cross-reactivity characteristics which have been reported previously (Doris 1992). The antibody was raised in rabbits against digoxin coupled via reductive amination after periodate oxidation to bovine serum albumin. ELISA plates were coated with digoxin coupled to ovalbumin. The assay was incubated at room temperature for 2 h. Unbound antibody was removed by washing. Peroxidase-coupled goat-anti-rabbit gammaglobulin was added to each well. After a further 30 min incubation the plates were rinsed and TMB reagent (Kirkegaard and Perry, Gaithersburg, MD, USA) added as a colour indicator of peroxidase activity. Assays were read at end-point after the addition of phosphoric acid to stop the peroxidase reaction. Standard curves were fitted to a 4-parameter logistic model and unknown values interpolated using Delta-Soft software.

6.5 Isolation and analysis of cytoplasmic RNA (V, VI)

RNA was isolated from ventricular and atrial samples by the guanidine thiocyanate-CsCl method (Chirgwin et al. 1979). For the RNA Northern blot and dot blot analysis, 3 μg samples of the RNA from atria and 22 μg (V) or 20 μg (VI) from ventricles were transferred to the Schleicher & Schuell BAS 85 nitrocellulose membrane (V) or to the Hybond N+ nylon membrane (VI) (Amersham Pharmacia Biotech). A 390 bp fragment of rat BNP cDNA probe (Ogawa et al. 1991), full-length rat ANP cDNA probe (Flynn et al. 1985), full-length cDNA probe complementary to glyceraldehyde 3-phosphate-dehydrogenase (Fort et al. 1985), an oligonucleotide probe complementary to rat 18S ribosomal RNA, and cDNA probe for ADM made by RT-PCR (Romppanen et al. 1997) were labelled with [^{32}P]-dCTP with Quick Prime Kit (Pharmacia LKB Biotechnology, Uppsala, Sweden). The membranes were hybridised overnight at +42°C in 5 x SSC (saline sodium citrate, 1 x SSC = 0.15 mol/l NaCl, 0.015 mol/l trisodium citrate, pH 7), 0.5 % sodium dodecyl sulphate, 5 x Denhardt's solution, 50 % formamide and 100 μg/ml sheared herring sperm DNA. After hybridisation, the membrane

was washed in 0.1 x SSC, 0.1 % sodium dodecyl sulphate three times for 20 min at +50°C (V) or +60°C (VI) and exposed to Phosphor Screen (Molecular Dynamics, Sunnyvale, USA) at room temperature. Phosphor Screens were scanned with Phosphor Imager (Molecular Dynamics, Sunnyvale, USA). The hybridisation signal of ANP, BNP and ADM mRNA was normalised to that of glyceraldehyde 3-phosphate-dehydrogenase mRNA (V) and that of ANP and BNP mRNA to 18S (VI) for each sample to correct for potential differences in loading and/or transfer. The samples in the renal failure experiments were treated similarly as samples in study VI.

6.6 Radioimmunoassays (V, VI)

Tissue and plasma samples were extracted by Sep-Pak C_{18} cartridges as previously described (Kinnunen et al. 1993, Magga et al. 1994). Eluates were lyophilised and redissolved in radioimmunoassay buffer. Plasma immunoreactive (ir-) NT-proANP and atrial ir-ANP were determinated by radioimmunoassay without prior extraction. For the BNP radioimmunoassay, the atrial and ventricular guanidine thiocyanate extracts were diluted 200- (VI) or 100-fold (V) and 50-fold, respectively. For the ANP radioimmunoassay, the atrial and ventricular guanidine thiocyanate extracts were diluted 5×10^4-fold and 50- (VI) or 400-fold (V), respectively. The extracted samples were incubated in duplicate with the specific rabbit BNP (Kinnunen et al. 1993) or ANP antiserum (Vuolteenaho et al. 1985). Synthetic rat BNP_{51-95}, synthetic rat ANP_{99-126}, and synthetic human pro- ANP_{79-98} were incubated as standards. The BNP, ANP and NT-proANP tracers were prepared by chloramine-T iodination of synthetic rat $[Tyr_0]$-BNP_{51-95}, rat ANP_{99-126} and human $[Tyr_0]$-human pro- ANP_{79-98} followed by reverse phase HPLC purification. After incubation for 48 h at +4°C, the ^{125}I -labelled rat $[Tyr_0]$- BNP_{51-95} and rat ANP_{99-126} with normal rabbit serum were added (VI). After incubation for another 24 h (VI) or for 48 h (V) at +4°C the immunocomplexes were precipitated with sheep antiserum directed against rabbit gammaglobulin in the presence of 8 % polyethylene glycol 6000, pH 7, followed by centrifugation at 3000 g for 30 min. The plasma samples were incubated with the rabbit NT-proANP antiserum and ^{125}I -labeled $[Tyr_0]$-human pro- ANP_{79-98} overnight at +4°C and the bound and free fractions were separated with double antibody in the presence of polyethylene glycol. The sensitivities of the BNP, ANP and NT-ANP assays were 0.5 (VI) or 2 fmol/tube (V), 1 fmol (V) or 2 pg/tube (VI), and 0.75 fmol/tube, respectively. 50 % displacements of the respective standard curve occurred at 16 (V) or 34.5 (VI) fmol/tube for ANP, at 4.3 (VI) or 25 fmol/tube (V) for BNP and at 0.5 fmol/tube for NT-ANP. The intra- and interassay variations were less than 15 %. Serial dilutions of tissue extracts showed parallelism with the standards. The ANP antiserum recognised ANP and proANP with equal avidity but did not cross-react with BNP or CNP. The BNP antiserum did not recognise ANP or CNP.

For the ADM radioimmunoassay, guanidine thiocyanate supernatants were diluted 100-fold with 0.1 % trifluoroacetic acid and extracted with Sep-Pak C_{18} cartridges (Magga et al.

1994). The extracts were dried and redissolved in radioimmunoassay buffer. Synthetic rat ADM-(1-50) standards (Phoenix Pharmaceuticals Inc., Mountain View, CA, USA) and the tissue extracts were incubated 16-24 h at +4°C with rabbit anti-rat ADM serum. ^{125}I-rat ADM-(1-50) was added and the incubation was continued for another 16-24 h. The free and bound fractions were separated by double antibody precipitation. The rat ADM antiserum (Phoenix Pharmaceuticals) does not cross-react with rat ADM-(1-20), human amylin or ET-1. The sensitivity of the ADM assay was 1 fmol/tube and the intra- and interassay coefficients of variation were <10 % and <15 %, respectively. The samples in the renal failure experiments were treated similarly as samples in study VI.

7 Mesenteric arterial responses *in vitro*

7.1 Arterial preparations and organ bath solutions

The superior mesenteric arteries were carefully cleaned of adherent connective tissue, excised, and placed on a Petri dish containing physiological salt solution (PSS) (pH 7.4) of the following composition (mM): NaCl 119.0, NaHCO$_3$ 25.0, glucose 11.1, KCl 4.7, CaCl$_2$ 1.6, KH$_2$PO$_4$ 1.2 and MgSO$_4$ 1.2, and aerated with 95 % O$_2$ and 5 % CO$_2$. Standard sections of the mesenteric artery (3 mm in length) were cut, beginning 5 mm distally from the mesenteric artery-aorta junction. The endothelium was either left intact or removed by gently rubbing it with a jagged injection needle (Arvola et al. 1992). The rings were placed between stainless steel hooks (diameter 0.3 mm) and mounted in an organ bath chamber (volume 20 ml) in PSS described above. The preparations were aerated with 95 % O$_2$ and 5 % CO$_2$ at +37°C, and rinsed with fresh solutions at least every 20 min, during which time the pH in the baths remained stable. In solutions containing high concentrations of K$^+$ (20-125 mM), NaCl was replaced with KCl on an equimolar basis. In Ca^{2+}-free solutions, CaCl$_2$ was omitted without substitution. K$^+$-free solutions were prepared by replacing KH$_2$PO$_4$ and KCl with NaH$_2$PO$_4$ and NaCl, respectively, on an equimolar basis.

7.2 Arterial contractile and relaxation responses

The rings were initially equilibrated for 1 h at +37°C with a resting force of 1.5 g. The force of contraction was measured with an isometric force-displacement transducer and registered on a polygraph (FT 03 transducer and Model 7 E Polygraph; Grass Instrument Co., Quincy, MA, USA). The presence of the functional endothelium in vascular preparations was confirmed by a clear relaxation response to 1 μM ACh in 1 μM NA-precontracted arterial rings, and the absence of endothelium by the lack of this response. If any relaxation was observed in the endothelium-denuded rings, the endothelium was further rubbed.

Agonist-induced contractions. The contractions of the endothelium-intact preparations to NA were studied in the absence (I, IV) and presence of L-NAME (0.1 mM) (III, IV), and in

the presence of diclofenac (3 μM) plus L-NAME (I, III, IV). In study IV, the contractions to NA were also elicited in the presence of L-arginine (1 mM). The contractions elicited by 5-HT were investigated in the endothelium-intact preparations in the absence and presence of diclofenac, and in the presence of diclofenac plus L-NAME (II).

Depolarization-induced contractions. The concentration-response curves of the endothelium-denuded rings to KCl were determined in the absence (I, II, IV) and presence (II) of phentolamine (1 μM) and atenolol (10 μM). In study III, the responses to KCl were performed in the presence of L-NAME.

Ca^{2+} *contractions*. The contractile responses of the endothelium-denuded rings to cumulative addition of Ca^{2+} to the organ bath after precontraction with KCl (125 mM) in Ca^{2+}-free buffer in the absence (III) and presence (II, IV) of phentolamine (1 μM) and atenolol (10 μM) were studied. Thereafter, the effects of nifedipine (0.5 nM) (II, III, IV), and nifedipine plus mibefradil (0.05 μM) (III) on these responses were examined. In study III, these responses were performed in the presence of L-NAME.

Endothelium-dependent relaxations to ACh. Mesenteric arterial relaxations were studied in response to ACh in rings precontracted with NA (1 μM) (I, IV). The ACh-induced relaxations after NA-precontraction were also elicited in the presence of diclofenac (I); L-NAME (III, IV); diclofenac and L-NAME (I, III, IV); diclofenac, L-NAME and TEA (1 mM) (I); diclofenac, L-NAME, and apamin (50 nM) plus charybdotoxin (0.1 μM) (IV). The responses to ACh were further studied in the presence of SOD (50 U/ml) (IV); L-NAME plus SOD (III); SOD plus catalase (100 U/ml) (IV); and in the presence of L-NAME, SOD plus catalase (III). The ACh-induced relaxations were also examined in the presence of L-arginine (IV). Moreover, the relaxations to ACh were investigated in rings precontracted with KCl (50 mM) in the absence (I) and presence (I, III) of diclofenac plus L-NAME.

Endothelium-independent relaxations to sodium nitroprusside (SNP), isoprenaline and cromakalim. The relaxation responses of NA-precontracted endothelium-denuded (I, III, IV) rings to SNP were examined. The responses to SNP were also studied in KCl-precontracted endothelium-denuded preparations (I, III) and in NA-precontracted rings in the presence of TEA (I). The vasorelaxations elicited by isoprenaline and cromakalim were studied in endothelium-denuded rings precontracted with NA (I, III, IV) and with KCl (I).

Potassium relaxation. The relaxations of K^+-free solution-contracted endothelium-denuded rings to the return of K^+ (1 mM) were determined in the absence and presence of 1 mM ouabain (II).

8 Morphological studies

In studies III and VI, and in unpublished experiments with the renal failure rats, the third order mesenteric arterial branches were chosen from the vascular bed that feeds the small intestine 2-6 cm prior to the ileocecal junction. A segment (2 mm in length) of the mesenteric artery was isolated under a dissection microscope (Nikon SMZ-2T, Nikon Inc., Japan) and

transferred to the myograph chamber (Living Systems Instrumentation Inc., Burlington, VT, USA) containing 8 ml of PSS (pH 7.4) of the following composition (mM): NaCl 119.0, NaHCO$_3$ 25.0, glucose 11.1, CaCl$_2$ 2.5, KCl 4.7, KH$_2$PO$_4$ 1.2, MgSO$_4$ 1.2, Na$_2$EDTA 0.4. The proximal end of the vessel was cannulated with a micropipette and flushed to remove the remaining blood before the cannulation of the distal end. At the beginning of the study, the arterial wall thickness and lumen diameter of the unpressurised vessels were recorded by the use of a video monitoring system (Video dimension analyzer, Living Systems Instrumentation Inc., Burlington, VT, USA). The artery was superfused at a rate of 10 ml/min and aerated with 95 % O$_2$ and 5 % CO$_2$. Thereafter the intraluminal pressure was slowly raised to 60 mmHg (III) and to 100 mmHg (VI and renal failure experiments). The pressure in the proximal end of the artery segment was monitored by a pressure transducer and controlled by a servo perfusion system (Pressure servo control, Living Systems Instrumentation Inc., Burlington, VT, USA). After the vessel had equilibrated for 40 min the arterial dimensions were recorded.

From five animals in each group in study II, vascular rings were prepared for light microscopy from the most proximal part of the remaining section of each superior mesenteric artery. The rings were fixed in 2 % glutaraldehyde at +4°C and postfixed in 2 % osmiumtetroxide. After washing, they were stained with 1 % uranyl acetate and dehydrated with acetone series. Thereafter the samples were embedded in Epon (LX-112 Resin, Ladd, Burlington, VT, USA). Thin (2 μM) transverse sections were stained with 1 % toluidine blue, examined, and photographed under light microscopy (Nikon Microphot-FXA, Japan). In each vascular ring, the diameter of lumen and thickness of medial smooth muscle were measured from the photographs.

9 Compounds

The following drugs and chemicals were used: acetylcholine chloride, apamin, catalase, charybdotoxin, cromakalim, 5-hydroxytryptamine, isoprenaline hydrochloride, noradrenaline bitartrate, N^G-nitro-L-arginine methyl ester hydrochloride, superoxide dismutase, ouabain, tetraethylammonium chloride (Sigma Chemical Co., St. Louis, MO, USA), phentolamine, diclofenac (Voltaren$^®$ injection solution, Ciba-Geigy AG, Basel, Switzerland), atenolol (Leiras Pharmaceutical, Turku, Finland), enalapril maleate, losartan potassium (Merck Pharmaceutical Company, Wilmington, DE, USA), ethylenediaminetetraacetic acid, noradrenaline hydrogentartrate, sodium nitroprusside (Fluka Chemie AG, Buchs SG, Switzerland), diazepam, nifedipine (Orion Pharma Ltd., Espoo, Finland), ketamine (Parke-Davis Scandinavia, Solna, Sweden), and buprenorphine (Reckitt and Colman, Hull, UK). The stock solutions of the compounds used in the *in vitro* studies were made by dissolving the compounds in distilled water, with the exception of ouabain (directly in physiological salt solution), and cromakalim and nifedipine (in 50 % ethanol). Drinking fluids containing losartan, enalapril and N^G-nitro-L-arginine methyl ester hydrochloride were made by dissolving the compounds in tap water. All solutions were freshly prepared before use and

protected from light. The chemicals used in the preparation of PSS were of the highest grade available and obtained from E. Merck AG (Darmstadt, Germany).

10 Analysis of results

The statistical analysis was performed using a one-way analysis of variance (ANOVA) supported by Bonferroni test when carrying out pairwise comparisons between the study groups. For comparison of statistical significance between two test groups in natriuretic peptide and ADM studies Student's *t* test was used. ANOVA for repeated measurements was applied for data consisting of repeated observations at successive time points. All the results are expressed as mean $\pm$ SEM. The data were analysed with BMDP Statistical Software version PC90 (Los Angeles, CA, USA).

Table 2. Summary of the experimental design of the studies on arterial reactivity and cardiac natriuretic peptides.

Study	Rats Treatment	E+ relaxations (precontraction)	E- relaxations (precontraction)	Contractions	Natriuretic peptides
Genetic hypertension					

I	SHR and WKY rats
	
	Losartan
	Enalapril
		ACh (NA)
		 + diclofenac
		 + L-NAME
		 + TEA
		ACh (KCl)
		 + diclofenac and
		  L-NAME
			Isoprenaline
			(NA, KCl)
			Cromakalim
			(NA, KCl)
			Nitroprusside (KCl)
			Nitroprusside (NA)
			 + TEA
				NA
				 + diclofenac and
				  L-NAME
				KCl	

II			K$^+$ (K$^+$-free) + ouabain	KCl + phentolamine and atenolol Calcium + nifedipine K$^+$-free + ouabain 5-HT + diclofenac + L-NAME	
V					ANP, BNP, ADM
Nitric oxide deficiency					

III	L-NAME
	hypertensive
	Wistar rats
	
	Losartan
		ACh (NA)
		 + L-NAME and
		  diclofenac
		 + (KCl)
		ACh (NA)
		 + SOD
		 + catalase
			Isoprenaline (NA)
			Cromakalim (NA)
			Nitroprusside
			(NA and KCl)
				KCl
				Calcium
				 + nifedipine
				 + mibefradil
				NA
				 + L-NAME and
				  diclofenac	

VI					ANP, BNP
Renal failure					
IV	5/6 nephrectomized WKY rats	ACh (NA) + L-NAME + diclofenac + apamin and charybdotoxin ACh (NA) + SOD + catalase ACh (NA) + L-arginine	Nitroprusside (NA) Isoprenaline (NA) Cromakalim (NA)	NA + L-NAME + diclofenac KCl Calcium + nifedipine	
					ANP, BNP, ADM

ACh, acetylcholine; ADM, adrenomedullin; ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; E+, endothelium-dependent; E-, endothelium-independent; 5-HT, 5-hydroxytryptamine; L-NAME, N^G-nitro-L-arginine methyl ester; NA, noradrenaline; SHR, spontaneously hypertensive rats; SOD, superoxide dismutase; TEA, tetraethylammonium; WKY, Wistar-Kyoto.

RESULTS

1 Blood pressure, arterial morphology, heart weight, drinking fluid and urine volumes

Blood pressure. The systolic blood pressures of untreated SHR and WKY rats were 234 and 143 mmHg, respectively, when measured at the end of the follow up periods (I, II, V). The long-term administration of L-NAME resulted in the elevation of blood pressure up to 198 mmHg in Wistar rats (III, VI). Both losartan and enalapril completely prevented the development of hypertension in SHR, but had no effect on blood pressure in WKY rats (I, II, V). Losartan treatment also prevented the development L-NAME induced hypertension (III, VI). The chronic renal failure in WKY rats was not associated with the elevation of blood pressure (IV).

Arterial morphology. Chronic L-NAME hypertension resulted in an increase in small mesenteric arterial wall to lumen ratio, but losartan treatment was without an effect on it (III, VI). An increased media to lumen ratio was also observed in mesenteric arteries of untreated SHR when compared with WKY rats (II). However, in SHR both losartan and enalapril treatments effectively corrected the observed arterial remodelling (II). The chronic renal failure was not associated with alterations in mesenteric arterial morphology (Unpublished observation, Table 3).

Table 3. Morphological characteristics of mesenteric arteries at 100 mmHg.

	Control (n=8)	Renal failure (n=7)
Wall thickness (μm)	28±2	29±2
External diameter (μm)	398±12	375±10
Wall to lumen ratio	0.08±0.01	0.09±0.01
Wall cross-sectional area (μm^2)	33288±2524	32248±2789

Values are mean ± SEM.

Heart weight. Genetic hypertension was associated with clear cardiac hypertrophy (I, II, V). Losartan and enalapril therapies completely prevented the development of cardiac hypertrophy in SHR, and reduced the relative heart weights also in WKY rats (I, II, V). In contrast, the heart-body weight ratios were comparable in L-NAME hypertensive and normotensive Wistar rats, whereas losartan therapy reduced relative heart weights in both of these groups (III, VI). Furthermore, the chronic renal failure did not change heart weights in WKY rats (IV).

Drinking fluid and urine volumes. At the end of the study, the intake of drinking fluid and the output of urine were higher in the rats with chronic renal failure when compared with the control WKY rats (IV).

2 Total peroxyl radical-trapping, vitamin E, sodium, potassium, urea nitrogen, phosphate, creatinine, calcium, haemoglobin, nitrite and nitrate, and digoxin-like immunoreactivity

L-NAME hypertension or losartan treatment did not influence the plasma total peroxyl radical-trapping capacities or vitamin E concentrations (III). In rats with chronic renal failure, the plasma creatinine and urea nitrogen values were increased, while plasma sodium, haemoglobin and calcium concentrations were decreased when compared with control rats (IV). Renal failure did not have any influence on plasma potassium, phosphate, pH or NOx (IV). Plasma digoxin-like immunoreactivity did not differ between untreated SHR and WKY rats, and neither losartan nor enalapril treatment did affect plasma digoxin-like immunoreactivity in SHR or WKY rats (II).

3 Control of arterial tone *in vitro*

3.1 Arterial tone in genetic hypertension and the influences of long-term angiotensin receptor antagonism and angiotensin converting enzyme inhibition (I, II)

3.1.1 Arterial contractile responses

Maximal tissue dry weight-related contractile force generation to NA in the absence and presence of L-NAME and diclofenac was attenuated in endothelium-intact rings of untreated SHR when compared with WKY, although the sensitivity to NA was comparable in these groups (I). In contrast, the maximal contractions to NA in losartan- and enalapril-treated SHR (both in the absence and presence of L-NAME and diclofenac) did not differ from those of WKY (I). There were no significant differences in the sensitivity to NA between untreated SHR and losartan- and enalapril-treated SHR, while in the presence of diclofenac and L-NAME, the sensitivity was somewhat lower in enalapril-treated SHR when compared with the untreated controls (I). Furthermore, enalapril-treated SHR showed lower sensitivity to NA than losartan-treated SHR both in the absence and presence of L-NAME and diclofenac (I). Maximal contractile force generation of endothelium-denuded arterial rings to KCl was comparable in all SHR and WKY groups, and untreated SHR showed increased sensitivity to KCl when compared with all WKY groups (I). Losartan, but not enalapril, further diminished the sensitivity to KCl in WKY, while in SHR the treatments were without effect on the sensitivity to KCl (I).

Differing from study I, the arterial contractile responses in study II were expressed as maximal wall tensions in mN/mm instead of expressing forces as g/mg. Maximal wall tension and sensitivity of endothelium-denuded arterial rings to KCl were increased in untreated SHR when compared with WKY rats (II). Losartan and enalapril treatments decreased maximal wall tension to KCl in SHR, but not in WKY rats (II). Furthermore, neither of the treatments

affected the sensitivity to KCl in SHR, while losartan, but not enalapril, diminished the sensitivity to KCl in WKY rats (II). When the responses to KCl were induced in the presence of phentolamine and atenolol, no differences in maximal wall tension or sensitivity were found between SHR and WKY rats (II).

The endothelium-intact vascular rings of untreated SHR showed comparable maximal wall tension and sensitivity in response to 5-HT in the absence and presence of diclofenac and L-NAME when compared with WKY rats (II). Neither losartan nor enalapril treatment significantly affected the maximal wall tension elicited by 5-HT when compared with untreated controls, while the response was higher in enalapril- than in losartan-treated SHR, and this difference was also observed in the presence of L-NAME and diclofenac (II). Losartan, but not enalapril, slightly increased the sensitivity to 5-HT in SHR (II). Diclofenac elicited a more pronounced decrease in sensitivity to 5-HT in losartan-treated SHR than in untreated and enalapril-treated SHR, while L-NAME comparably increased the sensitivity to 5-HT in all groups (II).

In the absence of the dihydropyridine Ca^{2+} entry blocker nifedipine, the contractile sensitivity of isolated mesenteric arterial rings induced by cumulative addition of Ca^{2+} did not differ between SHR and WKY rats, and losartan and enalapril were without effect on these responses (II). However, in the presence of nifedipine, the responses were clearly less effectively inhibited in losartan- and enalapril-treated SHR and WKY rats than in untreated SHR (II). Thus, the contractile response induced by the addition of Ca^{2+} showed higher dependency on dihydropyridine-sensitive Ca^{2+} entry in untreated SHR (II). The maximal wall tension induced by Ca^{2+} cumulation was higher in untreated SHR when compared with losartan- and enalapril-treated SHR and untreated WKY rats, and this difference was also abolished by nifedipine (II). Furthermore, maximal wall tension elicited by K^{+}-free solution in the absence and presence of ouabain did not differ in untreated SHR and WKY rats, and losartan and enalapril were without effect on these responses (II).

3.1.2 Arterial relaxation responses

Endothelium-independent relaxations. The relaxations of NA-precontracted endothelium-denuded mesenteric arterial rings to SNP were attenuated in SHR when compared with WKY rats (I). The responses to SNP remained decreased in SHR in the presence of K_{Ca} blocker TEA (I). However, when the arterial rings were precontracted with KCl the relaxations induced by SNP were comparable to those of WKY rats (I). The vasodilatations of NA-precontracted rings to isoprenaline and cromakalim were also attenuated in SHR when compared with WKY rats (I). When the precontractions were elicited by KCl, the responses to isoprenaline and cromakalim were completely abolished in SHR and WKY rats (I).

Losartan and enalapril therapies improved the relaxations of NA-precontracted rings to SNP in SHR (I). However, the addition of TEA to the organ bath as well as KCl-induced precontractions abolished this improvement in losartan- and enalapril-treated rats (I). The

vasodilatations induced by isoprenaline and cromakalim were also improved in losartan- and enalapril-treated SHR (I) (see table 4). Furthermore, in the normotensive WKY rats losartan or enalapril treatments were without effect on endothelium-independent relaxation (I).

After the return of potassium to the organ bath upon the K^+-free precontractions the rate of the subsequent relaxation was faster in WKY rats than in SHR (II). Furthermore, both losartan and enalapril enhanced the potassium relaxation in SHR (II) (see table 4). This relaxation was effectively inhibited by the Na^+,K^+-ATPase inhibitor ouabain in all groups, although a significant difference was still detected between untreated SHR and WKY rats (II). The calculated ouabain-sensitive part of the potassium relaxation was initially (during the first 4 min after K^+ repletion) lower in untreated SHR when compared with WKY rats (II). Furthermore, both losartan and enalapril treatments especially enhanced the ouabain-sensitive part of the potassium relaxation in SHR (II).

Endothelium-dependent relaxations. The relaxations induced by ACh in the absence and presence of diclofenac were clearly attenuated in NA-precontracted mesenteric arterial rings of SHR when compared with those of WKY rats (I). The addition of L-NAME to the organ bath practically abolished the relaxation to ACh in SHR, whereas distinct relaxations were observed in WKY rats (I). The addition of TEA further reduced the diclofenac and L-NAME-resistant relaxations to ACh in WKY rats, but the relaxations in WKY rats still remained more pronounced than those in SHR (I). When the relaxations to ACh were elicited in KCl-precontracted rings, no differences were observed between SHR and WKY rats (I). In addition, none of the relaxations induced by ACh in losartan- and enalapril-treated SHR differed from those in control WKY rats (I) (see table 4). Furthermore, losartan and enalapril treatments did not affect endothelium-dependent relaxations in WKY rats.

3.2 Arterial tone in L-NAME hypertension and the influence of long-term angiotensin receptor antagonism (III)

3.2.1 Arterial contractile responses

The maximal contractile force generation and contractile sensitivity in response to NA in the presence of L-NAME was comparable in L-NAME hypertensive and control rats. Losartan treatment decreased the maximal contractile force generation to NA in control rats, but not in L-NAME treated rats. In Wistar rats, L-NAME hypertension or losartan treatment did not alter the maximal contractile force generation to KCl. However, losartan treatment increased the contractile sensitivity to KCl in L-NAME treated rats.

The contractile sensitivity of arterial smooth muscle to the cumulative addition of Ca^{2+} during depolarization with KCl was similar in L-NAME treated rats as in control rats and losartan treatment did not affect this response. Moreover, the L-type Ca^{2+} entry blocker nifedipine equally decreased arterial contractile sensitivity to Ca^{2+} in the control and L-NAME treated rats, and the effect of nifedipine was smaller in losartan treated L-NAME rats. In

contrast, the T-type Ca^{2+} entry blocker mibefradil, when added after nifedipine, reduced the Ca^{2+} sensitivity of arterial smooth muscle more effectively in the L-NAME hypertensive rats than in control rats. Losartan treatment was without effect on the inhibitory effect of mibefradil on the Ca^{2+} sensitivity in either group.

3.2.2 Arterial relaxation responses

Endothelium-independent relaxations. The relaxations of endothelium-denuded NA-precontracted rings to SNP, isoprenaline and cromakalim, were impaired in L-NAME hypertensive rats when compared with normotensive control rats. In addition, when hyperpolarization of smooth muscle was prevented by precontractions with KCl, the relaxations to SNP were still impaired in L-NAME rats. Furthermore, in L-NAME treated rats, but not in control rats, the vasodilatations to SNP, isoprenaline and cromakalim were clearly improved by the losartan treatment (see table 4).

Endothelium-dependent relaxations. The relaxations induced by ACh in NA-precontracted arterial rings in the presence of L-NAME were markedly impaired in the L-NAME treated rats when compared with the control rats, while these responses were clearly improved by losartan treatment in both of these groups (see table 4). The addition of diclofenac to the organ bath improved the relaxations to ACh in all other groups, but not in the losartan treated normotensive group, and abolished the difference between the control and losartan treated groups, while the relaxations still remained impaired in the L-NAME treated group when compared with the other groups. On the other hand, diclofenac caused a 5.2-fold increase in the maximum relaxation to ACh in the L-NAME hypertensive group when compared with the 1.6-fold change in the losartan treated L-NAME group. The responses to ACh were almost abolished in all groups when induced in KCl-precontracted rings in the presence of L-NAME and diclofenac.

When SOD was added to the organ bath, the relaxations to ACh were enhanced in all other groups, but not in the losartan-treated normotensive group, while the responses to ACh remained impaired in the L-NAME treated group when compared with the other groups (see table 4). However, the addition of SOD caused a 3.4-fold increase in the maximum response to ACh in the L-NAME group when compared with the 1.5-fold change in the losartan-treated L-NAME group. In addition, SOD abolished the difference in response to ACh between the control rats and losartan-treated control rats. The further addition of catalase had no significant effects on the relaxation to ACh in any of the study groups.

3.3 Effects of renal failure on the control of arterial tone (IV)

3.3.1 Arterial contractile responses

Vasoconstrictor responses. The chronic renal failure did not modulate arterial contractile

sensitivity to NA or KCl. The maximal contractions to NA in the absence and presence of L-NAME were also comparable between renal failure and control rats. However, in the presence of L-NAME and diclofenac the maximal contractile force generation induced by NA was higher in the renal failure rats, and the maximal contractions to KCl were also more pronounced in the renal failure rats when compared with the control rats.

3.3.2 Arterial relaxation responses

Endothelium-independent relaxations. The chronic renal failure did not alter arterial relaxations to SNP. However, the relaxations to isoprenaline and cromakalim were impaired in rats with chronic renal failure when compared with the control rats (see table 4).

Endothelium-dependent relaxations. The relaxations induced by higher concentrations of ACh (1-10 µM) in NA-precontracted arterial rings were impaired in the renal failure rats when compared with the control rats. L-NAME diminished the relaxations in both study groups, but the attenuation was more pronounced in the renal failure group than in the control group. Diclofenac was without significant effects on ACh-induced relaxations in both groups. The addition of apamin and charybdotoxin further reduced the relaxations to ACh in the control rats but not in the renal failure rats, and in that way the difference between the groups in the remaining relaxation to ACh was abolished (see table 4).

4 Regulation of adrenomedullin and natriuretic peptides

4.1 Cardiac synthesis of adrenomedullin in losartan- and enalapril-treated spontaneously hypertensive and Wistar-Kyoto rats (V)

The concentrations of ADM mRNA and ir-ADM in the left ventricle and atrium were similar in untreated SHR and WKY rats. Losartan or enalapril treatments had no effect on ADM mRNA or ir-ADM levels in the left ventricle in either strain. However, in SHR both losartan and enalapril increased left atrial concentration of ir-ADM. Furthermore, an increase in left atrial ADM mRNA levels was noted in enalapril-treated SHR and in losartan-treated WKY rats when compared to their respective control groups (V).

4.2 Cardiac synthesis of atrial natriuretic peptide and B-type natriuretic peptide in losartan- and enalapril-treated spontaneously hypertensive and Wistar-Kyoto rats (V)

The left ventricular concentrations of ANP mRNA and ir-ANP were similar in untreated SHR and WKY rats. In WKY rats, losartan treatment reduced left ventricular levels of ANP mRNA and ir-ANP. Similar decreases in levels of ANP mRNA and ir-ANP were noted in enalapril-treated WKY rats. In SHR, both losartan and enalapril treatments reduced levels of ANP mRNA. This reduction in left ventricular ANP mRNA levels was greater in the losartan-

treated SHR than in the WKY rats. Furthermore, left ventricular ir-ANP levels were lower in losartan- and enalapril-treated SHR than in the untreated SHR.

The concentration of ir-ANP in the left atrium was lower in SHR than in WKY rats. In SHR, losartan, but not enalapril, increased left atrial ir-ANP concentration. Left atrial ir-ANP concentrations remained unchanged in WKY rats in response to losartan and enalapril treatments. Furthermore, the left atrial levels of ANP mRNA were similar in SHR and WKY rats, and drug-treatments had no effects on left atrial ANP mRNA levels in either strain.

The left ventricular BNP mRNA level was higher in SHR than in WKY rats, whereas the ir-BNP concentration in the left ventricle was lower in SHR than in WKY rats. Losartan and enalapril treatments decreased significantly the BNP mRNA concentration in SHR, but had no effect on left ventricular BNP mRNA levels in WKY rats. Furthermore, the decrease in left ventricular BNP mRNA levels was more pronounced in losartan-treated SHR than in enalapril-treated SHR. Overall, the changes in left ventricular concentrations of ir-BNP during drug treatments were small when compared to those induced by losartan and enalapril in left ventricular ir-ANP concentrations. A slight decrease in the concentration of ir-BNP in the left ventricles was noted in both losartan- and enalapril-treated WKY rats, while the left ventricular ir-BNP concentration was higher in enalapril-treated SHR than in untreated SHR.

The left atrial ir-BNP concentration was higher in SHR than in WKY rats, whereas there was no difference in left atrial BNP mRNA levels between the strains. Losartan and enalapril decreased consistently left atrial ir-BNP levels in both strains, but had no effect on left atrial BNP mRNA levels. In WKY rats, losartan and enalapril treatments reduced left atrial ir-BNP concentration when compared with untreated WKY rats. Similar decreases in levels of ir-BNP during losartan and enalapril treatments were noted in SHR.

4.3 Effect of losartan on cardiac and plasma natriuretic peptide levels in L-NAME-treated rats (VI)

To characterise the role of Ang II in the NO deficiency-induced ANP gene activation, the effect of losartan on L-NAME-stimulated changes in ANP mRNA and ir-ANP levels were studied. Ventricular ANP mRNA and ir-ANP levels increased by L-NAME treatment. Losartan treatment attenuated the increase in ANP gene expression induced by L-NAME, but did not affect the ir-ANP levels in the ventricles. Losartan treatment decreased ventricular ir-ANP concentration in control rats. L-NAME hypertensive rats showed decreased ir-ANP concentrations in left and right atria when compared with the control group. These changes in atrial ir-ANP concentrations were prevented by concomitant losartan therapy. Furthermore, the left and right atrial ANP mRNA levels were not affected by L-NAME or losartan.

L-NAME hypertensive rats showed an increase in ventricular BNP mRNA and ir-BNP levels when compared with the control rats. In losartan treated L-NAME rats, ventricular BNP mRNA levels did not differ from control, although losartan therapy did not prevent the increase of ir-BNP levels induced by L-NAME. However, losartan decreased ventricular

ir-BNP concentrations in control rats. No changes in the right or left atrial BNP mRNA levels were observed. In the left atria, L-NAME treatment decreased ir-BNP concentrations when compared with the control rats.

Losartan treatment decreased plasma ir-NT-proANP concentrations in both control and L-NAME rats. In L-NAME rats, plasma ir-BNP concentrations were increased when compared with the control rats, the increase of which was prevented by concomitant losartan treatment.

4.4 Synthesis of natriuretic peptides and adrenomedullin in experimental renal failure

Plasma concentrations of NT-ANP were increased in rats with renal failure when compared with the control rats. Ventricular ANP and BNP mRNA levels were also increased in rats with renal failure. Furthermore, renal failure rats showed increased ventricular ir-BNP concentrations when compared with control rats. However, the ir-ANP concentrations in the ventricles were not significantly changed in experimental renal failure (Unpublished observation, Figure 4). Moreover, ANP mRNA levels in both right and left atrium and ir-ANP levels in right atrium were comparable in control and renal failure rats. However, ir-ANP levels in left atrium were increased in rats with renal failure. The concentrations of ir-ADM in ventricles and atria were comparable in renal failure and control rats. However, the ventricular levels of ADM mRNA were increased in renal failure rats. Furthermore, ADM mRNA levels in left, but not in right, atrium were decreased in rats with renal failure when compared with control rats (Unpublished observation, Figure 5).

Figure 4. Plasma levels of NT- atrial natriuretic peptide (ANP), and ventricular levels of ANP mRNA, B-type natriuretic peptide (BNP) mRNA, immunoreactive (ir)-ANP, and ir-BNP in Control and Renal failure rats. The ANP and BNP mRNA results are expressed as the ratio of ANP mRNA to 18S ribosomal mRNA, and BNP mRNA to 18S ribosomal mRNA, respectively, as determined by northern blot analysis. Data represent mean ± SEM, $n = 7$ in Renal failure and 12 in Control group; *$P<0.05$ versus Control group (Student's t-test).

Figure 5. The levels of adrenomedullin (ADM) mRNA and immunoreactive (ir)-ADM in ventricles and atria in Control and Renal failure rats. The mRNA results are expressed as the ratio of ADM mRNA to 18S ribosomal mRNA as determined by northern blot analysis. Data represent mean ± SEM, $n = 7$ in Renal failure and 12 in Control group; *$P<0.05$ versus Control group (Student's t-test).

Table 4. Summary of the alterations in arterial relaxations in hypertensive rats after losartan and enalapril treatments when compared with untreated hypertensive controls, and in renal failure rats when compared with sham-operated controls.

Variable	Genetic hypertension Losartan	Enalapril	Nitric oxide deficiency Losartan	Renal failure
E+ relaxations (precontraction)				
Acetylcholine (NA)	↑	↑		↓
+ L-NAME			↑	↓
+ diclofenac	↑	↑		
+ L-NAME and diclofenac	↑	↑	↑	↓
+ L-NAME, diclofenac, tetraethylammonium	↑	↑		
+ L-NAME, diclofenac, apamin and charybdotoxin				↔
+ superoxide dismutase			↑	↓
Acetylcholine (KCl)	↔	↔		
+ diclofenac and L-NAME	↔	↔	↔	
E- relaxations (precontraction)				
Nitroprusside (NA)	↑	↑	↑	↔
+ tetraethylammonium	↔	↔		
Nitroprusside (KCl)	↔	↔	↑	
Isoprenaline (NA)	↑	↑	↑	↓
Isoprenaline (KCl)	↔	↔		
Cromakalim (NA)	↑	↑	↑	↓
K^+ (K^+-free)	↑	↑		
+ ouabain	↔	↔		

E+, endothelium-dependent; E-, endothelium-independent; L-NAME, N^G-nitro-L-arginine methyl ester; NA, noradrenaline. ↑, ↓ and ↔ indicate an increase, reduction and no change when compared with the corresponding control group, respectively.

DISCUSSION

The present investigation examined the effects of long-term AT_1 receptor antagonism and ACE inhibition on arterial responses and on cardiac natriuretic peptide and ADM gene expression in SHR, and the effects of long-term AT_1 receptor antagonism on arterial function and on cardiac natriuretic peptide production in L-NAME hypertension. In addition, the influence of chronic renal failure on the control of arterial tone and on cardiac natriuretic peptide and ADM synthesis in WKY rats was evaluated.

1 Experimental models of the study

SHR is the most commonly studied animal model of human essential hypertension often with WKY as the normotensive control (Okamoto and Aoki 1963). Although SHR and WKY rats have been derived from the same colony, the amount of genetic variation between these strains is nowadays comparable to the maximum divergence possible between unrelated humans (Johnson et al. 1992). Therefore, some of the differences observed between SHR and WKY rats are likely to be unrelated to hypertension (St. Lezin et al. 1992). The present study showed that treatment with either losartan or enalapril completely prevented the development of hypertension in SHR. The result agrees with previous investigations which have stressed the importance of the RAS in the pathogenesis of high blood pressure in this model of genetic hypertension (Oddie et al. 1993, Schoemaker et al. 1994). The other model of experimental hypertension in this study was chronic inhibition of NOS (Baylis et al. 1992). NO deficiency is an interesting model of hypertension, since the endothelial production of NO is essential for the maintenance of normal blood pressure (Huang et al. 1995), and several disease states including essential hypertension have been associated with defects in the production or action of NO (Moncada and Higgs 1993). In this study, in agreement with previous experiments, oral administration of L-NAME resulted in a marked hypertension, which reached its maximum within four weeks, whereas losartan therapy totally prevented the elevation of blood pressure (Ribeiro et al. 1992, Jover et al. 1993). The third experimental model in this study was 5/6 nephrectomy in rats. The WKY rat strain is known to be resistant to the elevation of blood pressure (Bidani et al. 1990), and it was chosen in order to avoid the development of hypertension after the induction of renal failure and the subsequent changes in vascular function caused by elevated blood pressure. Accordingly, the moderate renal failure was not associated with the development of hypertension in WKY rats in this study.

2 Cardiovascular remodelling in experimental hypertension and renal failure

Cardiac hypertrophy is the primary chronic compensatory mechanism to increased haemodynamic overload in hypertension, and it was also observed in SHR in this study. In agreement with previous findings, losartan and enalapril therapies prevented cardiac

hypertrophy in SHR and decreased heart weights also in WKY rats (Mizuno et al. 1992, Oddie et al. 1993, Soltis 1993). Hypertension induced by chronic L-NAME administration would also be expected to induce cardiac hypertrophy. However, the heart weight-body weight ratios did not differ between L-NAME hypertensive and normotensive control rats. This surprising finding agrees with recent reports, and it is probably explained by the negative metabolic effects of L-NAME on protein synthesis (Arnal et al. 1993, Bartunek et al. 2000). Despite the absence of cardiac hypertrophy in the L-NAME rats, losartan therapy reduced heart weights in both L-NAME-treated and normotensive control rats. The influence of losartan on cardiac weight can be explained by the blockade of the AT_1 receptor-mediated growth-promoting actions of Ang II (Mazzolai et al. 2000).

A characteristic morphological change in the resistance arteries of patients with essential hypertension and SHR is inward eutrophic remodelling, i.e. increased wall to lumen ratio with unaltered media cross-sectional area (Mulvany 1999), which was also seen in SHR in this study. In concert with previous observations, both losartan and enalapril therapies decreased the media to lumen ratio, but were without significant effect on the media cross-sectional area in the mesenteric artery of SHR (Rizzoni et al. 1998c). Therefore, the changes in vascular structure induced by losartan and enalapril are compatible with outward eutrophic remodelling of arteries. Chronic L-NAME hypertension induced inward hypertrophic remodelling of the mesenteric resistance arteries in Wistar rats, i.e. increased wall to lumen ratio and media cross-sectional area. Losartan therapy did not reduce arterial hypertrophy in the L-NAME rats even though it normalised their blood pressure. Therefore, vascular hypertrophy in this model of hypertension appears to be independent of blood pressure, and may result from decreased vascular NO production, since a defect in the NOS/NO pathway has been suggested to promote abnormal remodelling and to facilitate pathological changes in vessel wall morphology associated with hypertension (Rudic et al. 1998). However, it is noteworthy that NOS inhibitors cannot completely block the production of endothelium-derived NO (Simonsen et al. 1999, Ge et al. 2000).

The patients with renal failure are characterized by abnormal elastic properties of large arteries, reflected as decreased distensibility and compliance (Barenbrock et al. 1994, London et al. 1996). The increased stiffness of the arteries has even been seen in the absence of structural changes (Mourad et al. 1997). Consistent with this, the experimental renal failure in our study was not associated with morphological changes of the mesenteric arteries. Moreover, no changes in cardiac weight were observed in rats with renal failure when compared with control rats.

3 Arterial contractions in experimental hypertension and the influences of long-term antihypertensive treatments

Various approaches can be applied to investigate the vasoconstrictor responses. The arterial contractile forces can be related to segment length, segment weight, media cross sectional

area, or lumen diameter, and thus the findings depend on the experimental setting which has been applied (Mulvany et al. 1991, Arvola et al. 1993, Bennett et al. 1996). Different approaches to report arterial contractions were also applied in separate original communications of this study. In study I, the contractile forces were related to artery segment dry weight (g/mg), in studies II and III the contractions were expressed as the actual forces that were recorded (g), and in study IV the contractile forces were related to the arterial segment length and expressed as wall tensions (mN/mm). Therefore, the numerical values obtained from the separate studies cannot be compared as such. Furthermore, in the present literature there is no complete consensus regarding the method of the expression of arterial contractile forces.

In the present study, losartan and enalapril treatments normalised the maximal contractile force generated by NA in arterial preparations from SHR. The NA-induced vasoconstrictor responses have also previously been beneficially influenced by chronic ACE inhibition in SHR (Bennett et al. 1996). The maximal contractile force to KCl was comparable in SHR and WKY rats, and neither losartan nor enalapril affected the responses to KCl in SHR. In agreement with this finding, maximal contractions to KCl have been found to remain unaffected by both Ang II antagonist and ACE inhibitor treatment in the aorta of SHR (Rodrigo et al. 1997). However, when maximal contractions were expressed as wall tensions, the arterial preparations from SHR showed increased contractile force generation when compared with WKY rats. Both losartan and enalapril treatments normalised the increased maximal wall tensions to KCl in SHR. Thus, the present results suggest that both losartan and enalapril therapies restored the impaired receptor-mediated contractions to NA and normalised the increased depolarization-mediated contractions to KCl in the mesenteric artery of SHR.

Some differences in vasoconstrictor sensitivity following the present treatments were observed. In the presence of diclofenac and L-NAME the sensitivity to NA was somewhat lower in enalapril-treated SHR when compared with the untreated controls. Furthermore, enalapril-treated SHR showed lower sensitivity to NA than losartan-treated SHR both in the absence and presence of L-NAME and diclofenac. However, the individual effects of diclofenac and L-NAME on NA-induced contractions were not studied and cannot be estimated. Moreover, losartan, but not enalapril, increased the sensitivity to 5-HT in SHR, and diclofenac elicited a more pronounced decrease in sensitivity to 5-HT in both losartan-treated groups than in the other groups, suggesting that the products of the COX pathway differentially modulated the responses to 5-HT in the study groups. On the other hand, L-NAME induced a corresponding shift in constrictor sensitivity to 5-HT in all groups, which suggests that endothelium-derived NO similarly modulated arterial constrictor responses in all study groups. Moreover, the contractile sensitivity to KCl was higher in SHR when compared with WKY, but neither of the therapies affected the responses to KCl in SHR. Taken together, since the long-term antihypertensive therapies in the present study somewhat differently modulated the sensitivity to NA and 5-HT in SHR, other factors in addition to the reduction of blood pressure and inhibition of Ang II may have contributed to these effects, one candidate

being the potentiation of the actions of bradykinin following the enalapril treatment (Minshall et al. 1997, Benzing et al. 1999).

The arteries of SHR are more sensitive to the actions of dihydropyridine Ca^{2+} channel blockers than those of WKY rats (Arvola et al. 1992, Kähönen et al. 1996), which was also confirmed in the present study. Moreover, the proportions of voltage-dependent Ca^{2+} currents are different in blood vessels of hypertensive and normotensive rats: in SHR the L-type current is greater whereas in WKY rats the T-type predominates (Rusch and Hermsmeyer 1988). Accordingly, nifedipine less effectively inhibited the Ca^{2+}-induced contractions in losartan- and enalapril-treated SHR and WKY rats than in untreated SHR in the present study. Thus, losartan and enalapril treatments normalised the function of voltage-dependent Ca^{2+} channels in the vascular smooth muscle of SHR. The present study also confirmed the earlier finding whereby L-NAME hypertension does not affect vasoconstrictor responses to NA (Küng et al. 1995). The constrictor sensitivity of arterial smooth muscle to cumulative addition of Ca^{2+} was also comparable in L-NAME hypertensive and control rats, and the response remained unaffected by losartan. The L-NAME rats did not show any increased sensitivity to the action of nifedipine, while the T-type Ca^{2+} entry blocker, mibefradil, elicited a more pronounced shift in the Ca^{2+} sensitivity of arterial rings from L-NAME rats, which suggests increased Ca^{2+} influx via T-type channels in this model of experimental hypertension.

4 Arterial relaxations in experimental hypertension and the influences of long-term antihypertensive treatments

ACh relaxes arterial smooth muscle by releasing several dilatory factors from the vascular endothelium, the most prominent of these being NO, PGI_2 and EDHF (Busse and Fleming 1993). In the present study, the relaxations to ACh in NA-precontracted rings were attenuated in SHR, whereas these responses were completely normalised by losartan and enalapril, in accordance with previous findings (Tschudi et al. 1994). The relaxations of arterial rings to ACh were also impaired in the L-NAME hypertensive rats, and effectively improved by losartan therapy. The finding concerning the impaired ACh-induced relaxation in L-NAME hypertension is not new. However, the influence of losartan on arterial relaxations in L-NAME hypertension has not been previously reported, although ACE inhibitor trandolapril has improved ACh-induced relaxations in L-NAME hypertension (Küng et al. 1995). Since both losartan and enalapril treatments augmented endothelium-dependent relaxations, this beneficial effect on the vasculature was probably mediated via the reduction of blood pressure and inhibition of the actions of Ang II.

One explanation to the attenuated relaxations in hypertension is enhanced release of EDCFs (Lüscher and Vanhoutte 1986, Küng et al. 1995). Previously, endothelium-dependent vasoconstrictor responses have been shown to be blocked by COX inhibition in SHR (Takase et al. 1994). In the present study, the COX inhibitor, diclofenac, enhanced the relaxations to

ACh in SHR and in L-NAME hypertensive rats. This suggests that there is an imbalance in the production of vasoconstrictor and vasodilator prostanoids in the vessels of hypertensive rats, which favours vasoconstriction. Since diclofenac had no effect on the response to ACh in losartan- or enalapril-treated SHR, the present antihypertensive therapies appeared to correct this imbalance of the COX pathway in SHR. However, diclofenac enhanced the relaxations to ACh in losartan-treated L-NAME rats, although less than in untreated L-NAME hypertensive rats. Therefore, losartan appeared to improve the imbalance of the COX pathway also in L-NAME rats.

The chemical antagonism between superoxide and NO is recognised as an important modulator of vascular tone. In addition, superoxide has been reported to inhibit the vascular synthesis of PGI_2 without affecting that of the vasoconstrictor TXA_2 (Katusic 1996). Therefore, superoxide production or decreased antioxidant activity in the cardiovascular system could increase arterial tone and contribute to the development of hypertension. In the present study, the total peroxyl radical-trapping capacity and vitamin E concentration in plasma were comparable in L-NAME hypertensive rats and in control rats, suggesting that L-NAME hypertension is not associated with changes in circulating antioxidant capacity. In contrast, losartan treatment appeared to reduce the production of superoxide in the arteries of L-NAME rats, since the enhancing effect of SOD, the superoxide anion scavenger, on the relaxations to ACh was more pronounced in the L-NAME hypertensive rats when compared with losartan-treated L-NAME rats. Moreover, the difference in the relaxation induced by ACh between untreated and losartan-treated normotensive control rats was abolished by SOD, suggesting that losartan therapy reduced the production of superoxide also in control rats. The view of reduced superoxide production by losartan is in agreement with previous results whereby losartan treatment decreased the production of superoxide and normalised the ACh-induced arterial relaxations in Ang II hypertensive rats (Rajagopalan et al. 1996). It is noteworthy that decreased superoxide production may also have contributed to the enhanced endothelium-mediated vasodilatation after diclofenac administration, since COX is a significant source of superoxide (Katusic 1996).

ACE inhibition has been suggested to potentiate endothelium-dependent dilatation in the aorta of normotensive and hypertensive animals by enhancing the availability of NO (Berkenboom et al. 1995). In addition, Ang II antagonism and ACE inhibition have been found to comparably improve endothelial function in the aorta and coronary arteries of SHR, the underlying mechanism possibly being increased availability of NO (Tschudi et al. 1994, Rodrigo et al. 1997). In the present study, however, the mesenteric arteries of losartan- and enalapril-treated SHR and all WKY groups showed distinct NOS inhibitor-resistant relaxations to ACh, suggesting that endothelial products other than NO were mediating the enhanced endothelium-dependent vasodilatations.

Recent investigations have indicated that endothelium-mediated relaxations which remain resistant to both NOS and COX inhibitions are mediated by EDHF (Cohen and Vanhoutte 1995). The action of EDHF can be eliminated by K^+ channel blockers or by cell

membrane depolarization with high K^+ concentration (Adeagbo and Triggle 1993). In this study, losartan and enalapril treatments enhanced ACh-induced relaxations in NA-precontracted preparations in SHR, but these treatments did not alter ACh-induced relaxations in KCl-precontracted preparations. This suggests that the improvement of endothelium-dependent relaxation following long-term Ang II antagonism and ACE inhibition was largely mediated via hyperpolarization mechanisms. Furthermore, the NOS and COX inhibitor-resistant relaxations to ACh were attenuated in the L-NAME hypertensive rats when compared with the control rats, while the responses in the losartan-treated L-NAME rats did not differ from the normotensive control rats. Thus, losartan prevented the impairment of endothelium-dependent hyperpolarization in L-NAME-treated rats. The precontraction of arterial rings with KCl virtually abolished the remaining NOS and COX inhibitor-resistant relaxations to ACh, suggesting that these responses were mediated by EDHF. It is noteworthy that NO has been shown to inhibit the production and action of EDHF (Bauersachs et al. 1996, McCulloch et al. 1997). Therefore, in pathophysiological states like hypertension, which may be associated with decreased bioavailability of NO, EDHF-mediated vasorelaxation could be of greater importance than under normal conditions (Bauersachs et al. 1996). Nevertheless, decreased endothelium-dependent hyperpolarization has been reported in genetic, renal, and mineralocorticoid-NaCl forms of experimental hypertension (Van de Voorde et al. 1992, Fujii et al. 1992, Mäkynen et al. 1996), and the results of this study suggest that the same also holds true for L-NAME hypertension.

Impaired endothelium-dependent hyperpolarization could result from reduced sensitivity of smooth muscle to EDHF or from decreased endothelial release of EDHF. The present results whereby the relaxations induced by the K_{ATP} opener cromakalim were attenuated in SHR and in L-NAME hypertensive rats suggest that the sensitivity of smooth muscle to hyperpolarizing factors was decreased. In addition, isoprenaline has been reported to hyperpolarize arterial smooth muscle via K_{ATP} and K_{Ca} (Randall and McCulloch 1995, Song and Simard 1995). Thus, the present finding whereby isoprenaline-induced relaxation was impaired in SHR and in L-NAME hypertensive rats is also in agreement with the view of reduced hyperpolarization of smooth muscle in these rats.

In our study, untreated SHR and L-NAME hypertensive rats showed attenuated endothelium-independent relaxations to SNP in both NA- and KCl-precontracted vascular rings, suggesting that the sensitivity of arterial smooth muscle to NO was decreased. Since the relaxations induced by isoprenaline and cromakalim were also impaired in SHR and L-NAME rats, these models of experimental hypertension were associated with attenuated vasorelaxant responses via cGMP, cAMP and the opening of K^+ channels, suggesting a general impairment of relaxation in arterial smooth muscle. Because these impairments were observed both in SHR and in L-NAME hypertensive rats, they are likely to result from the long-term elevation of blood pressure. This view is supported by the fact that the present antihypertensive effects of losartan and enalapril were accompanied by a complete normalisation of these changes. Furthermore, the improved vasodilator function of arterial smooth muscle of losartan- and

enalapril-treated rats could well explain the augmented endothelium-dependent relaxations in this study.

Vascular Na^+,K^+-ATPase function was evaluated indirectly by the readdition of potassium to the organ bath upon K^+-free medium-induced precontractions (Arvola et al. 1992). The return of potassium activates Na^+,K^+-ATPase which repolarizes the cell membrane and initiates smooth muscle relaxation (Bonaccorsi et al. 1977). Although general smooth muscle relaxation mechanisms are also involved in this response, previous results suggest that potassium relaxation reflects Na^+,K^+-ATPase activity in arterial smooth muscle (Arvola *et al.* 1992). The present results showed that potassium relaxation was slower in SHR than WKY rats, and enhanced in hypertensive rats by losartan and enalapril. The finding whereby potassium relaxation was inhibited by ouabain in all groups indicates the involvement of the sodium pump in this response. Moreover, the fact that especially the ouabain-sensitive part of the relaxation was augmented after the treatments suggests increased recovery rate of ionic gradients across the cell membrane via Na^+,K^+-ATPase in SHR following losartan and enalapril therapies. Some ouabain-resistant relaxation was detected particularly in the WKY rats, whereby the function of the sodium pump was not completely inhibited by ouabain, or additional mechanisms took part in the response. However, the fact that ouabain abolished the losartan- and enalapril-induced improvement of potassium relaxation supports the notion that Na^+,K^+-ATPase function was augmented in SHR following these treatments.

Several investigations have provided evidence for elevated levels of circulating sodium pump inhibitors in hypertensive subjects (Hamlyn and Manunta 1992) and experimental animals (Wauquier et al. 1988, Doris 1994). This digitalis-like factor augments natriuresis, but it also depolarizes smooth muscle via Na^+,K^+-ATPase inhibition, and increases Ca^{2+} influx through VOC. Subsequently, peripheral arterial resistance is elevated (Zhu et al. 1994). The non-pharmacological treatment of hypertension has lowered plasma ouabain-like activity in hypertensive rats (Doris 1988, Doris 1994), and quinapril therapy has reduced plasma digoxin-like immunoreactivity in SHR, possibly via an alteration of sodium balance (Kähönen et al. 1995a). In the present study, however, both losartan and enalapril treatments were without significant effects on plasma digoxin-like immunoreactivity in SHR. Thus, augmented potassium relaxation after losartan and enalapril therapies could not be explained by decreased plasma digoxin-like material, instead it resulted from the lowering of blood pressure. Previously, quinaprilat has increased the availability of NO in the forearm circulation of patients with chronic heart failure, whereas enalaprilat was without effect (Hornig et al. 1998). Therefore, it seems possible that differences exist in the long-term vascular effects of enalapril and quinapril, and on the basis of the present results the influences of these treatments on plasma digoxin-like immunoreactivity also appear to be dissimilar. It is noteworthy that the impaired potassium relaxation in arteries of untreated SHR was practically abolished by ouabain. Thus, the arteries of SHR were probably also more sensitive to the actions of circulating sodium pump inhibitors, which in turn could result in

smooth muscle depolarization, enhanced Ca^{2+} entry, and elevation of peripheral arterial resistance.

5 Arterial reactivity in experimental renal failure

In the rats with chronic renal failure, the contractile sensitivity to NA and KCl was not altered, the finding of which corresponds to previous observations in acute renal failure (Yates et al. 1985). In addition, the sensitivity of the KCl-induced constrictor responses to increasing organ bath Ca^{2+} concentrations in the absence and presence of nifedipine remained unchanged in the renal failure. However, some differences in the arterial contractions were found, since the maximal forces induced by KCl in endothelium-denuded rings, and by NA in endothelium-intact rings in the presence of L-NAME and diclofenac, were increased in chronic renal failure rats.

The relaxation to ACh was attenuated in the rats with renal failure, and although L-NAME diminished the relaxations in both groups, this effect was more pronounced in the renal failure rats than in controls. Hence, endothelium-mediated relaxations in the renal failure rats were predominantly mediated by NO, whereas the controls showed distinct L-NAME resistant relaxations to ACh. In contrast to L-NAME, diclofenac had no effect on ACh-induced relaxations in either group, suggesting that the products of the COX pathway were not playing a significant role in the responses to ACh in the blood vessels of these animals.

The distinct NOS and COX inhibitor-resistant relaxations to ACh were more pronounced in the sham-operated rats. The combination of apamin and charybdotoxin was without effect on the L-NAME and diclofenac-resistant relaxation to ACh in the renal failure rats, but it significantly inhibited the response in the control rats, such that the difference in the remaining relaxation to ACh between the groups was abolished. This suggests that decreased endothelium-dependent vasodilatation in the renal failure rats was associated with reduced relaxation via a mechanism which included the activation of K^+ channels and the subsequent hyperpolarization of arterial smooth muscle.

Several recent reports have discussed the role of reduced constitutive NO synthesis in the development of renal failure. The NO is synthesised from L-arginine by NOS (Moncada and Higgs 1993), and dietary L-arginine supplementation has been suggested to increase NO generation and enhance vasodilatation in experimental models of kidney disease (Peters and Noble 1996). However, elevated plasma levels of L-arginine have been observed in uremic patients even without dietary supplementation (Noris et al. 1993), and both increased and decreased basal NO production have been reported in the vasculature of rats with reduced renal mass (Aiello et al. 1997, Vaziri et al. 1998c). In this study, the total body NO generation was not altered by chronic renal failure, since the plasma concentration and urinary excretion of NO metabolites were similar in control rats and in rats with renal failure. However, this does not exclude the possibility that local changes in constitutive NO generation could have occurred in the arterial wall, since the contribution of NO to the endothelium-dependent

relaxation appeared to be more pronounced in the mesenteric artery of the renal failure rats than controls. This could represent a compensatory change in the vasculature in order to keep the blood pressure within the normal limits.

As previously reported, the sensitivity of arterial smooth muscle to NO was not altered in renal failure (Verbeke et al. 1994). However, the endothelium-independent relaxations induced by isoprenaline and cromakalim were impaired in the rats with renal failure. In addition to the elevation of intracellular cAMP, isoprenaline has been reported to open K_{ATP} in the smooth muscle of rat mesenteric artery (Randall and McCulloch 1995). Therefore, the impaired function of K^+ channels in smooth muscle could explain the reduced relaxations to the endothelium-independent agonists and the impaired endothelium-mediated hyperpolarization in experimental renal failure.

6 The synthesis of natriuretic peptides in experimental hypertension and renal failure and the influences of antihypertensive treatments

The changes in cardiac mass produced by losartan and enalapril treatments were accompanied by markedly reduced left ventricular ANP mRNA and ir-ANP levels in SHR and WKY rats. This reduction in ANP synthesis may reflect a direct effect of Ang II on ventricular ANP gene expression. Our results agree with a previous study in which ACE inhibitors and AT_1 receptor antagonists were shown to decrease ANP gene expression in hypertrophied myocardium independent of blood pressure levels (Kim et al. 1996). We also found that the behaviour of atrial ANP synthesis differs from that of ventricular ANP. The finding of decreased left atrial ANP storage in SHR as well as increased ANP concentration in the left atrium of SHR after losartan treatment can be explained by changes in ANP release from the atria secondary to alterations in left atrial pressure, because atrial ANP mRNA levels did not change in drug-treated SHR and the treatments did not influence atrial ANP synthesis in normotensive rats. These results on ventricular and atrial ANP gene expression are in line with earlier results obtained with several other models of experimental hypertension (Ruskoaho 1992, de Bold et al. 1996). The finding that left atrial ir-ANP levels in SHR increased less in response to ACE inhibitor treatment than during AT_1 receptor blocker treatment may be related to differential actions of these drugs on tissue levels of bradykinin, PGs and NO.

BNP gene expression in both atria and ventricles reacts more rapidly to haemodynamic overload than ANP (Magga et al. 1994). In the present study, the effect of chronic administration of ACE inhibitors or AT_1 receptor antagonists on ventricular BNP gene expression was different between SHR and WKY rats. This suggests, as previously reported (Ogawa et al. 1996), that the reduction in ventricular BNP gene expression could be more closely related to changes in systolic blood pressure than that of ventricular ANP gene expression. However, Ang II may directly contribute to the long term regulation of atrial BNP synthesis, since left atrial levels of ir-BNP were decreased in both rat strains in response to drug treatments. This potential differential role of Ang II in regulating atrial and ventricular

BNP gene expression is consistent with a recent study, in which ET-1 was reported to be an important paracrine regulator of BNP gene expression in the atria, but not in the left ventricle (Magga et al. 1997). Taken together, autocrine/paracrine factors may play a greater role in the regulation of ventricular ANP and atrial BNP gene expression than atrial ANP and ventricular BNP gene expression.

There was a dissociation between cardiac BNP mRNA and ir-BNP levels. The reason for this is not clear, but a similar dissociation between BNP mRNA levels and BNP peptide levels has been previously reported in response to acute and chronic haemodynamic overload in rats (Magga et al. 1994, Ogawa et al. 1996, Magga et al. 1997). The elevation of BNP mRNA levels could result from transcriptional and posttranscriptional mechanisms or from a combination of both mechanisms whereas the rate of release influences tissue peptide levels. Therefore, decreased BNP peptide levels together with increased BNP mRNA levels could be explained by an increased rate of release of BNP from the atria and ventricles. In the present study, we also found that ANP mRNA and ir-ANP levels were similar in SHR and WKY rats, although ventricular re-induction of the ANP gene has been demonstrated to occur simultaneously with the progression of hypertension and ventricular hypertrophy in the SHR strain (Arai et al. 1988, Ruskoaho et al. 1989, Matsubara et al. 1990). This observation may be due to the fact that the rats were studied in the early phase of hypertrophy and the difference in ANP mRNA levels between the strains was not yet statistically significant, as also described previously (Kinnunen et al. 1991, Ruskoaho 1992).

Despite the lack of the development of compensatory myocardial hypertrophy during L-NAME-induced hypertension, ventricular ANP mRNA and BNP mRNA levels and ir-ANP and ir-BNP levels increased significantly. These results show an interesting dissociation between the natriuretic peptide gene expression and myocardial hypertrophy during L-NAME-induced hypertension. Administration of losartan abolished the L-NAME-induced activation of the ventricular ANP and BNP expression, but was without effect on the increases in tissue natriuretic peptide levels. However, it is not clear whether the effect of Ang II on ANP release is secondary to the haemodynamic changes or due to direct receptor stimulation (Ruskoaho et al. 1997). Furthermore, AT_1 receptor antagonism has no effect on mechanical load-induced early activation of ventricular BNP gene expression, and thus Ang II is not obligatorily required for stretch to trigger the increased BNP expression in ventricular myocytes *in vivo* (Magga et al. 1997).

The experimental renal failure of this study was neither associated with elevated blood pressure nor cardiac hypertrophy. However, plasma NT-ANP levels and ventricular ANP mRNA, BNP mRNA and ir-BNP levels were increased. Therefore, the synthesis of natriuretic peptides appears to be stimulated in chronic renal failure, possibly reflecting increased ventricular wall stretch caused by volume retention. Furthermore, increased rate of ANP release from the ventricles in rats with renal failure seems likely due to the dissociation between ANP mRNA and ir-ANP levels.

7 Adrenomedullin in genetic hypertension and renal failure and the influences of long-term angiotensin receptor antagonism and angiotensin converting enzyme inhibition

The possible regulatory effects of AT_1 receptor antagonism or ACE inhibition on cardiac ADM gene expression were examined in SHR and WKY rats. ADM has been considered as representing tissue marker for left ventricular hypertrophy, because a positive correlation has been observed between left ventricular mass index and left ventricular ADM peptide concentration (Jougasaki et al. 1997, Morimoto et al. 1999). In this study, losartan and enalapril treatments had no effect on ventricular ADM gene expression suggesting that ventricular ADM synthesis is an insensitive marker of chronic changes in haemodynamic load or myocyte hypertrophy. In support of this, there was no correlation in SHR between cardiac mass reduction and ADM mRNA or ir-ADM levels, whereas a significant correlation between the decrease in cardiac hypertrophy and both ANP mRNA and ir-ANP levels was noted. Furthermore, there were no differences in ventricular ADM gene expression between SHR and WKY rats. This finding is consistent with the lack of change in ventricular ADM mRNA levels in other experimental models of pressure-induced hypertrophy including aortic banding (Kaiser et al. 1998) or hypertensive transgenic TGR(mREN-2)27 rats (Romppanen et al. 1997). Therefore, ventricular ADM gene expression appears not to be activated during the chronic phase of pressure-induced cardiac hypertrophy in rats.

The lack of change in ventricular ADM expression in the setting of significant alterations in cardiac mass suggests that ADM is not involved in the long term cardiac adaptive response to pressure overload in rats. Moreover, the absence of increased ADM expression in response to chronic pressure overload suggests that increased wall stress is not directly involved. However, acute cardiac pressure overload, produced by vasopressin infusion, significantly stimulates ADM gene expression in the left ventricle in normotensive rats suggesting that haemodynamic overload may regulate ADM gene expression (Romppanen et al. 1997). Cardiac overload produced by Ang II infusion also stimulates ventricular ADM gene expression (Romppanen et al. 1997). Therefore, the induction of ADM expression may be a part of a selective change in cardiac gene expression in response to acute, but not chronic haemodynamic load, and may play an important role in early cardiac failure and left ventricular hypertrophy.

Interestingly, the experimental renal failure of this study was associated with increased ventricular ADM expression although no increases in blood pressure or cardiac weight were observed. However, in the rats with renal failure, the expression of ADM in left atrium was decreased and in right atrium unchanged when compared with control rats. The synthesis of ADM in renal failure seems to differ from that in chronic pressure overload, because no changes in ADM synthesis were observed in genetic hypertension. The reason for increased ventricular ADM synthesis in renal failure is not clear. Chronic volume overload or endocrine changes associated with renal dysfunction may contribute to the synthesis of ADM in this condition (Ishimitsu et al. 1994).

SUMMARY AND CONCLUSIONS

The present study was designed to examine the effects of the long-term losartan and enalapril treatments on arterial function and on cardiac natriuretic peptide and ADM gene expression in SHR, as well as the effects of the long-term losartan treatment on arterial function and on the regulation of cardiac natriuretic peptides in NO-deficient hypertension in Wistar rats. The influence of renal failure on the control of arterial tone and cardiac natriuretic peptides and ADM in WKY rats was also evaluated.

The major findings and conclusions are:

1. The attenuated mesenteric arterial relaxations in different forms of experimental hypertension and volume overload seemed to be particularly related to reduced vasodilatation via potassium channels:

> 1.1. Long-term AT_1 receptor antagonist and ACE inhibitor therapies prevented the development of hypertension in SHR, an effect which was associated with enhanced arterial dilatation. The endothelium-mediated relaxation in enalapril- and losartan-treated SHR was augmented in the absence and presence of NOS inhibition but not under conditions preventing hyperpolarization, and endothelium-independent relaxation was enhanced during receptor- but not during depolarization-mediated precontractions. Therefore, the improved vasodilatation of mesenteric arteries following losartan and enalapril therapies could be attributed to enhanced hyperpolarization of arterial smooth muscle in genetic hypertension.

> 1.2. Chronic L-NAME hypertension was associated with the impairment of endothelium-dependent and -independent vasorelaxation in Wistar rat. Long-term AT_1 receptor antagonism clearly improved arterial dilatation in NO deficiency. The mechanisms underlying the augmented vasodilatation following losartan therapy in this model of experimental hypertension may have included enhanced arterial hyperpolarization, increased sensitivity to NO in smooth muscle, and decreased vascular production of superoxide and vasoconstrictor prostanoids.

> 1.3. Endothelium-mediated relaxation in rats with chronic renal failure was impaired in the absence and presence of NOS inhibition but not under conditions where hyperpolarization was blocked. In addition, endothelium-independent relaxations via the activation of β-adrenoceptors and the opening of K^+ channels were reduced. Therefore, impaired arterial relaxation in experimental renal failure could be attributed to reduced vasodilatation via potassium channels.

2. Long-term AT_1 receptor antagonism and ACE inhibition corrected the mesenteric arterial structural alterations, and normalised the increased dihydropyridine-sensitivity in arterial segments of SHR. Treatment with losartan and enalapril also augmented arterial potassium relaxation in SHR, suggesting an enhanced function of Na^+,K^+-ATPase, but this effect could not be attributed to changes in circulating sodium pump inhibitor concentration.

3. AT_1 receptor antagonism and ACE inhibition for 10 weeks resulted in the regression of cardiac hypertrophy associated with the increase in left ventricular ANP gene expression in normotensive and hypertensive rats. The changes in systolic blood pressure and cardiac hypertrophy induced by losartan and enalapril treatments had no effect on ventricular ADM gene expression, suggesting that ventricular ADM synthesis is an insensitive marker of chronic changes in haemodynamic load or myocyte hypertrophy in genetic hypertension. The expression of ADM, ANP and BNP was differently regulated both in the left ventricle and atria in response to AT_1 receptor antagonism and ACE inhibition.

4. Despite the lack of the development of compensatory myocardial hypertrophy during L-NAME-induced hypertension, ventricular ANP and BNP mRNA levels and ir-ANP and ir-BNP levels were significantly increased. Therefore, the natriuretic peptide gene expression and myocardial hypertrophy during L-NAME-induced hypertension appear to dissociate. Furthermore, the chronic L-NAME-induced hypertension and the associated activation of ventricular ANP and BNP gene expression are, at least in part, mediated by Ang II.

5. In chronic renal failure, the plasma NT-ANP levels and ventricular ANP mRNA, BNP mRNA and ADM mRNA levels were increased although no changes in blood pressure or cardiac weight were observed. Therefore, the synthesis of natriuretic peptides and ADM appears to be stimulated in chronic renal failure, possibly reflecting increased ventricular wall stretch caused by volume retention. Furthermore, the ventricular synthesis of ADM appears to be a marker of chronic volume overload associated with renal dysfunction, since its synthesis increases in renal failure but not in chronic pressure overload.

ACKNOWLEDGEMENTS

All the members of the Department of Pharmacological Sciences deserve my thanks for creating a friendly atmosphere to work in. I also thank the staff of the Experimental Animal Laboratory for their co-operation.

The brotherhood of merry gentlemen: Dr. Teppo Järvinen, M.D., Dr. Tero Järvinen, M.D., Dr. Janne Leinonen M.D. and Dr. Kimmo Lönnrot, M.D., my friends and colleagues, the memorable times round the old campfire are thankfully remembered.

I wish to extend my deepest and heartfelt thanks to my parents Marja and Pauli and my brothers Harri and Arttu for their continuous support and encouragement throughout these years. I also owe my gratitude to my in-laws Arja, Taisto and Pekka for their support and interest in my work.

Finally, my greatest thanks are due to my wife Annukka for her love and support. You are my sunshine.

Tampere, September 2000

Jarkko Kalliovalkama

REFERENCES

Abdel-Latif AA (1986): Calcium-mobilizing receptors, polyphosphoinositides and the generation of second messengers. Pharmacol Rev 38:227-272.

Ackerman MJ and Clapham DE (1997): Ion channels - Basic science and clinical medicine. New Engl J Med 336:1575-1586.

Adams MA, Bobik A and Korner PI (1989): Differential development of vascular and cardiac hypertrophy in genetic hypertension. Relation to sympathetic function. Hypertension 14:191-202.

Adeagbo ASO and Triggle CR (1993): Varying extracellular [K$^+$]: a functional approach to separating EDHF- and EDNO-related mechanisms in perfused rat mesenteric arterial bed. J Cardiovasc Pharmacol 21:423-429.

Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A, Corna D, Zoja C, Cavallotti D and Remuzzi G (1997): Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 52:171-181.

Akuzawa N, Nakamura T, Kurashina T, Saito Y, Hoshino J, Sakamoto H, Sumino H, Ono Z and Nagai R (1998): Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis. Am J Hypertens 11:697-707.

Alanko J, Riutta A, Mucha I, Vapaatalo H and Metsä-Ketelä T (1993): Modulation of arachidonic acid metabolism by phenols: relation to positions of hydroxyl groups and peroxyl radical scavenging properties. Free Radic Biol Med 14:19-25.

Allen BG and Walsh MP (1994): The biochemical basis of the regulation of smooth-muscle contraction. Trends Biochem Sci 19:362-368.

Amann K, Wolf B, Nichols C, Törnig J, Schwarz U, Zeier M, Mall G and Ritz E (1997): Aortic changes in experimental renal failure: Hyperplasia or hypertrophy of smooth muscle cells? Hypertension 29:770-775.

Anderstam B, Katzarski K and Bergström J (1997): Serum levels of N^G,N^G-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 8:1437-1442.

Andrea JE and Walsh MP (1992): Protein kinase C of smooth muscle. Hypertension 20:585-595.

Angus JA, Jennings GL and Sudhir K (1992): Enhanced contraction to noradrenaline, serotonin and nerve stimulation but normal endothelium-derived relaxing factor response in skin small arteries in human primary hypertension. Clin Exp Pharmacol Physiol Suppl 19:39-47.

Aoki K and Asano M (1986): Effects of Bay K 8644 and nifedipine on femoral arteries of spontaneously hypertensive rats. Br J Pharmacol 88:221-230.

Aoki K and Asano M (1987): Increased responsiveness to calcium agonist BAY K 8644 and calcium antagonist nifedipine in femoral arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol 10:S62-S64.

Arai H, Nakao K, Saito Y, Morii N, Sugawara A, Yamada T, Itoh H, Shiono S, Mukoyama M and Ohkubo H (1988): Augmented expression of atrial natriuretic polypeptide gene in ventricles of spontaneously hypertensive rats (SHR) and SHR-stroke prone. Circ Res 62:926-930.

Ardaillou R (1997): Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Curr Opin Nephrol Hypertens 6:28-34.

Arii T, Ohyanagi M, Shibuya J and Iwasaki T (1999): Increased function of the voltage-dependent calcium channels, without increase of Ca2+ release from the sarcoplasmic reticulum in the arterioles of spontaneous hypertensive rats. Am J Hypertens 12:1236-1242.

Arnal JF, El Amrani AI, Chatellier G, Ménard J and Michel JB (1993): Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 22:380-387.

Arvola P, Pörsti I, Vuorinen P, Pekki A and Vapaatalo H (1992): Contractions induced by potassium-free solution and potassium relaxation in vascular smooth muscle of hypertensive and normotensive rats. Br J Pharmacol 106:157-165.

Arvola P, Ruskoaho H, Wuorela H, Pekki A, Vapaatalo H and Pörsti I (1993): Quinapril treatment and arterial smooth muscle responses in spontaneously hypertensive rats. Br J Pharmacol 108:980-990.

Asano M, Masuzawa-Ito K and Matsuda T (1993a): Charybdotoxin-sensitive K$^+$ channels regulate the myogenic tone in the resting state of arteries from spontaneously hypertensive rats. Br J Pharmacol 108:214-222.

Asano M, Masuzawa-Ito K, Matsuda T, Imaizumi Y, Watanabe M and Ito K (1993b): Functional role of Ca^{2+}-activated K$^+$ channels in resting state of carotic arteries from SHR. Am J Physiol 265:H843-H851.

Asano M, Nomura Y, Ito K, Uyama Y, Imaizumi Y and Watanabe M (1995): Increased function of voltage-dependent Ca^{2+} channels and Ca^{2+}-activated K$^+$ channels in resting state of femoral arteries from spontaneously hypertensive rats at prehypertensive stage. J Pharmacol Exp Ther 275:775-783.

Ashida T, Kuramochi M and Omae T (1989): Increased sodium-calcium exchange in arterial smooth muscle of spontaneously hypertensive rats. Hypertension 13:890-895.

Auch-Schwelk W and Vanhoutte PM (1991): Endothelium-derived contracting factor released by serotonin in aorta of the spontaneously hypertensive rat. Am J Hypertens 4:769-772.

Auch-Schwelk W, Bossaller C, Claus M, Graf K, Gräfe M and Fleck E (1993): ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res 27:312-317.

Auch-Schwelk W, Duske E, Claus M, Graf M, Gräfe M and Fleck E (1995): Endothelium-mediated vasodilation during ACE inhibition. Eur Heart J 16:59-65.

Autelitano DJ, Tang F and Little PJ (1999): Rapid regulation of adrenomedullin in metabolically compromised vascular smooth muscle cells. J Hypertens 17:373-379.

Bagrov AY and Fedorova OV (1998): Effects of two putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na+, K+-pump in human mesenteric arteries. J Hypertens 16:1953-1958.

Bao G, Gohlke P and Unger T (1992): Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models. J Cardiovasc Pharmacol 20:S96-S99.

Barenbrock M, Spieker C, Laske V, Heidenreich S, Hohage H, Bachmann J, Hoeks APG and Rahn KH (1994): Studies of the vessel wall properties in hemodialysis patients. Kidney Int 44:1397-1400.

Barton M and Lüscher TF (1999): Endothelin antagonists for hypertension and renal disease. Curr Opin Nephrol Hypertens 8:549-556.

Bartunek J, Weinberg EO, Tajima M, Rohrbach S, Katz SE, Douglas PS and Lorell BH (2000): Chronic N^G-nitro-L-arginine methyl ester-induced hypertension: novel molecular adaptation to systolic load in absence of hypertrophy. Circulation 101:423-429.

Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I and Busse R (1996): Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94:3341-3347.

Baylis C, Mitruka B and Deng A (1992): Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90:278-281.

Beck KF, Eberhardt W, Frank S, Huwiler A, Messmer UK, Muhl H and Pfeilschifter J (1999): Inducible NO synthase: role in cellular signalling. J Exp Biol 202:645-653.

Bellinghieri G, Santoro D, Mazzaglia G and Savica V (1999): Hypertension in Dialysis Patients. Miner Electrolyte Metab 25:84-89.

Bendhack LM, Sharma RV and Bhalla RC (1992): Altered signal transduction in vascular smooth muscle cells of spontaneously hypertensive rats. Hypertension 19:II142-II148.

Benetos A, Levy BI, Lacolley P, Taillard F, Duriez M and Safar ME (1997): Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 17:3196-3201.

Bennett MA, Hillier C and Thurston H (1996): Endothelium-dependent relaxation in resistance arteries from spontaneously hypertensive rats: effect of long-term treatment with perindopril, quinapril, hydralazine or amlodipine. J Hypertens 14:389-397.

Benzing T, Fleming I, Blaukat A, Muller-Esterl W and Busse R (1999): Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 99:2034-2040.

Berk BC, Vallega G, Muslin AJ, Gordon HM, Canessa M and Alexander RW (1989): Spontaneously hypertensive rat vascular smooth muscle cells in culture exhibit increased growth and Na^+/K^+ exchange. J Clin Invest 83:822-829.

Berkenboom G, Brékine D, Unger P, Grosfils K, Staroukine M and Fontaine J (1995): Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta. Hypertension 26:738-743.

Bian K and Bukoski RD (1995): Myofilament calcium sensitivity of normotensive and hypertensive resistance arteries. Hypertension 25:110-116.

Bidani AK, Mitchell KD, Schwartz MM, Navar LG and Lewis EJ (1990): Absence of glomerular injury or nephron loss in a normotensive rat remnant kidney model. Kidney Int 38:28-38.

Bijlstra PJ, Smits P, Lutterman JA and Thien T (1995): Effect of long-term angiotensin-converting enzyme inhibition on endothelial function in patients with insulin-resistance syndrome. J Cardiovasc Pharmacol 25:658-664.

Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME and London GM (1998): Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 32:570-574.

Blaine EH, Cunningham JT, Hasser EM, Dale WE, Li Q and Sullivan M (1998): Angiotensin hypertension. Clin Exp Pharmacol Physiol Suppl 25:S16-S20.

Blaustein MP (1993): Physiological effects of endogenous ouabain: control of intracellular Ca^{2+} stores and cell responsiveness. Am J Physiol 264:C1367-C1387.

Bockman CS, Jeffries WB, Pettinger WA and Abel PW (1992): Enhanced release of endothelium-derived relaxing factor in mineralocorticoid hypertension. Hypertension 20:304-313.

Bolotina VM, Najibi S, Palacino JJ, Pagano PJ and Cohen RA (1994): Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 368:850-853.

Bolz SS, Fisslthaler B, Pieperhoff S, De Wit C, Fleming I, Busse R and Pohl U (2000): Antisense oligonucleotides against cytochrome P450 2C8 attenuate EDHF-mediated Ca(2+) changes and dilation in isolated resistance arteries. FASEB J 14:255-260.

Bonaccorsi A, Hermsmeyer K, Aprigliano O, Smith CB and Bohr DF (1977): Mechanisms of potassium relaxation of arterial muscle. Blood Vessels 14:261-276.

Bossaller C, Auch-Schwelk W, Weber F, Götze S, Gräfe M, Graf K and Fleck E (1992): Endothelium-dependent relaxations are augmented in rats chronically treated with the angiotensin-converting enzyme inhibitor enalapril. J Cardiovasc Pharmacol 20:91-95.

Boulanger CM (1999): Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardiol 31:39-49.

Bova S, Goldman WF, Yuan X-J and Blaustein MP (1990): Influence of Na^+ gradient on Ca^{2+} transients and contraction in vascular smooth muscle. Am J Physiol 259:H409-H423.

Braman RS and Hendrix SA (1989): Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem 61:2715-2718.

Bray K and Quast U (1991): Differences in the K^+-channels opened by cromakalim, acetylcholine and substance P in rat aorta and porcine coronary artery. Br J Pharmacol 102:585-594.

Brayden JE (1996): Potassium channels in vascular smooth muscle. Clin Exp Pharmacol Physiol 23:1069-1076.

Breithaupt-Grogler K and Belz GG (1999): Epidemiology of the arterial stiffness. Pathol Biol 47:604-613.

Brodde O-E and Michel MC (1992): Adrenergic receptors and their signal transduction mechanism in hypertension. J Hypertens 10:133-145.

Brosnihan KB, Li P and Ferrario CM (1996): Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27:523-528.

Brown NJ and Vaughan DE (1998): Angiotensin-converting enzyme inhibitors. Circulation 97:1411-1420.

Bruner CA and Webb RC (1990): Increased vascular reactivity to Bay K 8644 in genetic hypertension. Pharmacology 41:24-35.

Brunner HR (1998): Endothelin inhibition as a biological target for treating hypertension. Am J Hypertens 11:103-109.

Buemi M, Allegra A, Marino D, Marino MT, Medici MA, De Pasquale G, Ruello A, Corica F and Frisina N (1999): Does captopril have a direct pro-apoptotic effect? Nephron 81:99-101.

Bukoski RD (1998): The perivascular sensory nerve Ca^{2+} receptor and blood pressure regulation: a hypothesis. Am J Hypertens 11:1117-1123.

Bukoski RD, Lastelic BA, Xue H, Li J and Bian K (1994): Intracellular Ca^{2+} and force generation determined in resistance arteries of normotensive and hypertensive rats. J Hypertens 12:15-21.

Bülbring E and Tomita T (1987): Catecholamine action on smooth muscle. Pharmacol Rev 39:49-96.

Bunag RD, Eferakeya AE and Langdon DS (1975): Enhancement of hypothalamic pressor responses in spontaneously hypertensive rats. Am J Physiol 228:217-222.

Bunkenburg B, Schnell C, Baum HP, Cumin F and Wood JM (1991): Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences. Hypertension 18:278-288.

Bunkenburg B, van Amelsvoort T, Rogg H and Wood JM (1992): Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 20:746-754.

Burnett JC Jr (1999): Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens:S37-S43.

Busse R and Fleming I (1993): The endothelial organ. Curr Opin Cardiol 8:719-727.

Busse R and Fleming I (1995): Regulation and functional consequences of endothelial nitric oxide formation. Ann Med 27:331-340.

Busse R, Hecker M and Fleming I (1994): Control of nitric oxide and prostacyclin synthesis in endothelial cells. Arzneim-Forsch Drug Res 44:392-396.

Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM and Lahera V (1995): Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 26:236-243.

Calver A, Collier J, Moncada S and Vallance P (1992): Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 10:1025-1031.

Campbell WB and Harder DR (1999): Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 84:484-488.

Campbell WB, Gebremedhin D, Pratt PF and Harder DR (1996). Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78:415-423.

Caputo L, Tedgui A and Lévy B (1995): Control of carotid vasomotor tone by local renin-angiotensin system in normotensive and spontaneously hypertensive rats. Role of endothelium and flow. Circ Res 77:303-309.

Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO 3rd and Panza JA (1999): Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 33:753-758.

Carey RM, Wang ZQ and Siragy HM (2000): Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 35:155-163.

Catignani G and Bieri J (1983): Simultaneous determination of retinol and alpha tocopherol in serum or plasma by liquid chromatography. Clin Chem 29:708-712.

Cattaruzza M, Dimigen C, Ehrenreich H and Hecker M (2000): Stretch-induced endothelin B receptor-mediated apoptosis in vascular smooth muscle cells. FASEB J 14:991-998.

Celermajer DS (1997): Endothelial dysfunction: does it matter ? Is it reversible ? J Am Coll Cardiol 30:325-333.

Chalmers J, Arnolda L, Kapoor V, Llewellyn-Smith I, Minson J and Pilowsky P (1992): Amino acid neurotransmitters in the central control of blood pressure and in experimental hypertension. J Hypertens 10:S27-S37.

Charles CJ, Lainchbury JG, Lewis LK, Rademaker MT, Richards AM, Yandle TG and Nicholls MG (1999): The role of adrenomedullin. Am J Hypertens 12:166-173.

Chatziantoniou C, Daniels FH and Arendshorst WJ (1990): Exaggerated renal vascular reactivity to angiotensin and thromboxane in young genetically hypertensive rats. Am J Physiol 259:F372-F382.

Chirgwin JM, Przybyla AE, MacDonald RJ and Rutter WJ (1979): Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299.

Chun TH, Itoh H, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Doi K, Inoue M, Masatsugu K, Korenaga R, Ando J and Nakao K (1997): Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension 29:1296-1302.

Chung O, Stoll M and Unger T (1996): Physiological and pharmacological implications of AT_1 versus AT_2 receptors. Blood Pressure 5:47-52.

Cirillo M (1992): Intracellular calcium and blood pressure. Child Nephrol Urol 12:78-84.

Cirillo M, Capasso G, and De Santo NG (1992): Altered cellular calcium metabolism in hypertension: A reassessment and a hypothesis. Contrib Nephrol 100:35-47.

Clozel M, Gray GA, Breu V, Loffler BM and Osterwalder R (1992): The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 186:867-873.

Cockcroft JR, Chowienczyk PJ, Benjamin N, and Ritter JM (1994): Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 330:1036-1040.

Cockcroft JR, O'Kane KPJ and Webb DJ (1995): Tissue angiotensin generation and regulation of vascular tone. Pharmac Ther 65:193-213.

Cohen RA (1995): The role of nitric oxide and other endothelium-derived substances in vascular disease. Prog Cardiovasc Dis 38:105-128.

Cohen RA and Vanhoutte PM (1995): Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 92:3337-3349.

Colhoun H (1999): Confirmation needed for genes for hypertension. The Lancet 353:1200-1201.

Cormier-Regard S, Nguyen SV and Claycomb WC (1998): Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem 273:17787-17792.

Cowley AW (1997): Role of the renal medulla in volume and arterial pressure regulation. Am J Physiol 273:R1-R15.

Cowley AW and Roman RJ (1996): The role of the kidney in hypertension. JAMA 275:1581-1589.

Cox RH and Petrou S (1999): Ca(2+) influx inhibits voltage-dependent and augments Ca(2+)-dependent K(+) currents in arterial myocytes. Am J Physiol 277:C51-C63.

Creager MA and Roddy MA (1994): Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 24:499-505.

Culman T and Unger T (1992): Central mechanisms regulating blood pressure: Circuits and transmitters. Eur Heart J 13:10-17.

Culman J, von Heyer C, Piepenburg B, Rascher W and Unger T (1999): Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Eur J Pharmacol 367:255-265.

Danser AH (1996): Local renin-angiotensin systems. Mol Cell Biochem 157:211-216.

Danser AH, Saris JJ, Schuijt MP and van Kats JP (1999): Is there a local renin-angiotensin system in the heart? Cardiovasc Res 44:252-265.

Davies JE, Ng LL, Ameen M, Syme PD and Aronson JK (1991): Evidence for altered Na^+/K^+ antiport activity in cultured skeletal muscle cells and vascular smooth muscle cell from the spontaneously hypertensive rat. Clin Sci 80:509-516.

De Artinano AA and Gonzalez VL (1999): Endothelial dysfunction and hypertensive vasoconstriction. Pharmacol Res 40:113-124.

de Bold AJ, Bruneau BG and Kuroski de Bold ML (1996): Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 31:7-18.

de Gasparo M, Husain A, Alexander W, Catt KJ, Chiu AT, Drew M, Goodfriend T, Harding JW, Inagami T and Timmermans PBMWM (1995): Proposed update of angiotensin receptor nomenclature. Hypertension 25:924-927.

DeLong LJ and Blasie JK (1993): Effect of Ca^{2+} binding on the profile structure of the sarcoplasmic reticulum membrane using time-resolved x-ray diffraction. Biophys J 64:1750-1759.

Demuth K, Blacher J, Guerin AP, Benoit M-O, Moatti N, Safar ME and London GM (1998): Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol Dial Transplant 13:375-383.

Dendorfer A, Raasch W, Tempel K and Dominiak P (1998): Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic Res Cardiol 93:24-29.

Deng LY, Thibault G and Schiffrin EL (1993): Effect of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries in the rat. Clin Exp Hypertens 15:527-537.

Dickhout JG and Lee RM (1999): Apoptosis in the muscular arteries from young spontaneously hypertensive rats. J Hypertens 17:1413-1419.

Dieguez-Lucena JL, Aranda-Lara P, Ruiz-Galdón M, García-Villanova J, Morell-Ocaña M and Reyes-Engel A (1996): Angiotensin I-converting enzyme genotypes and angiotensin II receptors: response to therapy. Hypertension 28:98-103.

Dijkhorst-Oei LT, Beutler JJ, Stroes ES, Koomans HA and Rabelink TJ (1998): Divergent effects of ACE-inhibition and calcium channel blockade on NO-activity in systemic and renal circulation in essential hypertension. Cardiovasc Res 40:402-409.

Doggrell SA and Brown L (1998): Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 39:89-105.

Dohi Y, Aoki K, Fujimoto S, Kojima M and Matsuda T (1990): Alteration in sarcoplasmic reticulum-dependent contraction of tail arteries in response to caffeine and noradrenaline in spontaneously hypertensive rats. J Hypertens 8:261-267.

Dohi Y, Criscione L, Pfeiffer K and Lüscher TF (1994): Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: Studies on perfused mesenteric resistance arteries. J Cardiovasc Pharmacol 24:372-379.

Dominiczak AF and Bohr DF (1990): Cell membrane abnormalities and the regulation of intracellular calcium concentration in hypertension. Clin Sci 79:415-421.

Doris PA (1988): Digoxin-like immunoreactive factor in rat plasma: effect of sodium and calcium intake. Life Sci 42:783-790.

Doris PA (1992): Characterization and Scatchard binding analysis of adrenal digitalis-like material. Life Sci 50:1935-1941.

Doris PA (1994): Ouabain in plasma from spontaneously hypertensive rats. Am J Physiol 266:H360-H364.

Dowell FJ, Henrion D, Duriez M and Michel JB (1996): Vascular reactivity in mesenteric resistance arteries following chronic nitric oxide synthase inhibition in Wistar rats. Br J Pharmacol 117:341-346.

Durak I, Akyol Ö, Basesme E, Canbolat O, Kavutcu M (1994): Reduced erythrocyte defense mechanisms against free radical toxicity in patients with chronic renal failure. Nephron 66:76-80.

Dzau VJ, Gibbons GH, Kobilka BK, Lawn RM and Pratt RE (1995): Genetic models of human vascular disease. Circulation 91:521-531.

Edwards G and Weston AH (1990): Potassium channel openers and vascular smooth muscle relaxation. Pharmac Ther 48:237-258.

Edwards G and Weston AH (1998): Endothelium-derived hyperpolarizing factor--a critical appraisal. Prog Drug Res 50:107-133.

Edwards G, Dora KA, Gardener MJ, Garland CJ and Weston AH (1998): K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 396:269-272.

Edwards G, Feletou M, Gardener MJ, Thollon C, Vanhoutte PM and Weston AH (1999): Role of gap junctions in the responses to EDHF in rat and guinea-pig small arteries. Br J Pharmacol 128:1788-1794.

Endemann D, Touyz RM, Li JS, Deng LY and Schiffrin EL (1999): Altered angiotensin II-induced small artery contraction during the development of hypertension in spontaneously hypertensive rats. Am J Hypertens 12:716-723.

England SK, Woolridge TA, Stekiel WJ and Rusch NJ (1993): Enhanced single-channel K^+ current in arterial membranes from genetically hypertensive rats. Am J Physiol 264:H1337-H1345.

Esler M (1995). Sympathetic nervous system: Contribution to human hypertension and related cardiovascular disease. J Cardiovasc Pharmacol 26:24-28.

Falkenhahn M, Gohlke P, Paul M, Stoll M and Unger T (1994): The renin-angiotensin system in the heart and vascular wall: New therapeutic aspects. J Cardiovasc Pharmacol 24:6-13.

Ferrario CM and Iyer SN (1998): Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. Regul Pept 78:13-18.

Finch EA, Turner TJ and Goldin SM (1991): Calcium as a coagonist of inositol 1,4,5-trisphosphate-induced calcium release. Science 252:443-446.

Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I and Busse R (1999): Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 30:493-497.

Floras JS and Hara K (1993): Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens 11:647-655.

Flynn TG, Davies PL, Kennedy BP, de Bold ML and de Bold AJ (1985): Alignment of rat cardionatrin sequences with the preprocardionatrin sequence from complementary DNA. Science 228:323-325.

Folkow B (1993): Early structural changes in hypertension: pathophysiology and clinical consequences. J Cardiovasc Pharmacol 22:1-6.

Folkow B and Svanborg A (1993): Physiology of cardiovascular aging. Physiol Rev 73:725-764.

Fornage M, Amos CI, Kardia S, Sing CF, Turner ST and Boerwinkle E (1998): Variation in the region of the angiotensin-converting enzyme gene influences interindividual differences in blood pressure levels in young white males. Circulation 97:1773-1779.

Fort P, Marty L, Piechaczyk M, el Sabrouty S, Dani CX, Jeanteur P and Blanchard JM (1985): Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 13:1431-1442.

Forte P, Copland M, Smith LM, Milne E, Sutherland J and Benjamin N (1997): Basal nitric oxide synthesis in essential hypertension. Lancet 349:837-842.

Freeman EJ, Chisolm GM, Ferrario CM and Tallant EA (1996): Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28:104-108.

Frohlich ED (1997): Arthur C. Corcoran Memorial Lecture. Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension 29:188-193.

Fukuda N, Satoh C, Hu WY, Soma M, Kubo A, Kishioka H, Watanabe Y, Izumi Y and Kanmatsuse K (1999): Production of angiotensin II by homogeneous cultures of vascular smooth muscle cells from spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 19:1210-1217.

Fujii K, Tominaga M, Ohmori S, Kobayashi K, Koga T, Takata Y and Fujishima M (1992): Decreased endothelium-dependent hyperpolarization to acetylcholine in smooth muscle of the mesenteric artery of spontaneously hypertensive rats. Circ Res 70:660-669.

Fujino K (1984): Brain catecholamines in spontaneously hypertensive and DOCA-salt hypertensive rats. Acta Med Okayama 38:325-340.

Fukami H, Okunishi H and Miyazaki M (1998): Chymase: its pathophysiological roles and inhibitors. Curr Pharm Des 4:439-453.

Fukuo K, Hata S, Suhara T, Nakahashi T, Shinto Y, Tsujimoto Y, Morimoto S and Ogihara T (1996): Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension 27:823-826.

Furchgott RF and Zawadzki JV (1980): The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376.

Furspan PB and Webb RC (1993): Decreased ATP sensitivity of a K^+ channel and enhanced vascular smooth muscle relaxation in genetically hypertensive rats. J Hypertens 11:1067-1072.

Furuya M, Yoshida M, Hayashi Y, Ohnuma N, Minamino N, Kangawa K and Matsuo H (1991): C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun 177:927-931.

Gainer JV, Morrow JD, Loveland A, King DJ and Brown NJ (1998): Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339:1285-1292.

Gardner DG, Deschepper CF, Ganong WF, Hane S, Fiddes J, Baxter JD and Lewicki J (1986): Extra-atrial expression of the gene for atrial natriuretic factor. Proc Natl Acad Sci USA 83:6697-6701.

Garland CJ, Plane F, Kemp BK and Cocks TM (1995): Endothelium-dependent hyperpolarization: a role in the control of vascular tone. Trends Pharmacol Sci 16:23-30.

Ge ZD, Zhang XH, Fung PCW and He GW (2000): Endothelium-dependent hyperpolarization and relaxation resistance to N^G-nitro-L-arginine and indomethacin in coronary circulation. Cardiovasc Res 46:547-556.

Gelband CH, Wang H, Gardon ML, Keene K, Goldberg DS, Reaves PY, Katovich MJ and Raizada MK (2000): Angiotensin I-converting enzyme antisense prevents altered renal vascular reactivity, but not high blood pressure, in spontaneously hypertensive rats. Hypertension 35:209-213.

Gerbes AL, Dagnino L, Nguyen T and Nemer M (1994): Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. J Clin Endocrinol Metab 78:1307-1311.

Gillies LK, Lu M, Wang H and Lee RM (1997): AT1 receptor antagonist treatment caused persistent arterial functional changes in young spontaneously hypertensive rats. Hypertension 30:1471-1478.

Girerd X, Giannattasio C, Moulin C, Safar M, Mancia G and Laurent S (1998): Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients. J Am Coll Cardiol 31:1064-1073.

Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A and Unger T (1994): Angiotensin converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 23:411-418.

Gohlke P, Linz W, Schölkens BA, Wiemer G and Unger T (1996): Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 28:397-402.

Gohlke P, Pees C and Unger T (1998): AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31:349-355.

Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo M-W, McWilliams Jr. EJ and Bjornsson TD (1993): Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteer. Hypertension 21:704-713.

Goldstein DS (1983): Plasma catecholamines and essential hypertension: an analytical review. Hypertension 5:86-99.

Gonzalez JM and Suki WN (1995): Cell calcium and arterial blood pressure. Semin Nephrol 15:564-568.

Gonzalez-Juanatey JR, Reino AP, Garcia-Acuna JM, Varela Roman A, Calvo Gomez C and Cabezas-Cerrato J (1998): Effects on left ventricular mass and function of low doses of enalapril for systemic hypertension. Am J Cardiol 81:87-90.

Graf K, Gräfe M, Dümmler U, O'Connor A, Regitz-Zagrosek V, Kunkel G, Auch-Schwelk W and Fleck E (1993): Regulation of β-adrenergic receptors on endothelial cells in culture. Eur Heart J 14:173-176.

Grassi G, Catteneo BM, Seravalle G, Lanfranchi A and Mancia G (1998): Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 31:68-72.

Griendling KK, Minieri CA, Ollerenshaw JD and Alexander WR (1994): Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148.

Grimm D, Kromer EP, Bocker W, Bruckschlegel G, Holmer SR, Riegger GA and Schunkert H (1998): Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition. J Hypertens 16:1345-1355.

Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr DF and Malinski T (1995): Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension 26:854-857.

Gryglewski RJ (1995): Interactions between endothelial mediators. Pharmacol Toxicol 77:1-9.

Guia A, Wan X, Courtemanche M and Leblanc N (1999): Local Ca^{2+} entry through L-type Ca^{2+} channels activates Ca^{2+}-dependent K^+ channels in rabbit coronary myocytes. Circ Res 84:1032-1042.

Gupta S, McArthur C, Grady C and Ruderman NB (1994): Stimulation of vascular Na^+-K^+-ATPase activity by nitric oxide: A cGMP-independent effect. Am J Physiol 266:H2146-H2151.

Guyton A, Coleman T, Cowley A, Scheel K, Manning R, Norman R (1972): Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52:584-594.

Guzzetti S, Piccaluga E, Casati R, Cerutti P, Lombardi F, Pagani M and Malliani A (1988): Sympathetic predominance in essential hypertension: A study employing spectral analysis of heart rate variability. J Hypertens 6:711-717.

Hall JE, Brands MW and Henegar JR (1999): Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol 10:258-265.

Hamlyn JM and Manunta P (1992): Ouabain, digitalis-like factors and hypertension. J Hypertens 10:99-111.

Hamlyn JM, Hamilton BP and Manunta P (1996): Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis. J Hypertens 14:151-167.

Hatton DC and McCarron DA (1994): Dietary calcium and blood pressure in experimental models of hypertension. Hypertension 23:513-530.

Haynes WG and Webb DJ (1998): Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16:1081-1098.

Head GA (1995): Baroreflexes and cardiovascular regulation in hypertension. J Cardiovasc Pharmacol 26:7-16.

Hecker M, Pörsti I, Bara AT and Busse R (1994): Potentiation by ACE inhibitors of the dilator responses to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol 111:238-244.

Heller J and Hellerova S (1998): Long-term effect on blood pressure of early brief treatment by different antihypertensive agents: a study in the prague hypertensive rat. Kidney Blood Press Res 21:445-451.

Henrion D, Laher I, Laporte R and Bevan JA (1992): Further evidence from an elastic artery that angiotensin II amplifies noradrenaline-induced contraction through activation of protein kinase C. Eur J Pharmacol 224:13-20.

Henrion D, Dowell FJ, Levy BI and Michel JB (1996): In vitro alteration of aortic vascular reactivity in hypertension induced by chronic N^G-nitro-L-arginine methyl ester. Hypertension 28:361-366.

Henrion D, Dechaux E, Dowell FJ, Maclour J, Samuel JL, Levy BI and Michel JB (1997): Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2. Br J Pharmacol 121:83-90.

Hermsmeyer RK (1987): Vascular muscle membrane cation mechanisms and total peripheral resistance. Hypertension 10:20-22.

Herrera-Acosta J (1994): The role of systemic and glomerular hypertension in progressive glomerular injury. Kidney Int 45:6-10.

Higashi Y, Oshima T, Sasaki S, Nakano Y, Kambe M, Matsuura H and Kajiyama G (1998): Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension. Hypertension 32:16-24.

Höhle S, Blume A, Lebrun C, Climan J and Unger T (1995): Angiotensin receptors in the brain. Pharmacol Toxicol 77:306-315.

Hori M and Karaki H (1998): Regulatory mechanisms of calcium sensitization of contractile elements in smooth muscle. Life Sci 62:1629-1633.

Horiuchi M, Akishita M and Dzau VJ (1999): Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33:613-621.

Hornig B, Kohler C and Drexler H (1997): Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95:1115-1118.

Hornig B, Arakawa N, Haussmann D and Drexler H (1998): Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 98:2842-2848.

Horowitz A, Menice CB, Laporte R and Morgan KG (1996): Mechanisms of smooth muscle contraction. Physiol Rev 76:967-1003.

Hropot M, Grotsch H, Klaus E, Langer KH, Linz W, Wiemer G and Scholkens BA (1994): Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency. Naunyn Schmiedebergs Arch Pharmacol 350:646-652.

Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA and Fishman MC (1995): Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377:239-242.

Hutri-Kähönen N, Kähönen M, Tolvanen J-P, Wu X, Sallinen K and Pörsti I (1997): Ramipril therapy improves arterial dilation in experimental hypertension. Cardiovasc Res 33:188-195.

Hutri-Kähönen N, Kähönen M, Wu X, Sand J, Nordback I, Taurio J and Pörsti I (1999): Control of vascular tone in isolated mesenteric arterial segments from hypertensive patients. Br J Pharmacol 127:1735-1743.

Ignarro LJ (1996): Physiology and pathophysiology of nitric oxide. Kidney Int 49:2-5.

Intengan HD, Thibault G, Li JS and Schiffrin EL (1999): Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 100:2267-2275.

Ishida-Kainouchi M, Matsuura H, Ishida T, Kajiyama G and Oshima T (1993): Platelet calcium handling in spontaneously hypertensive rats and in three strains of normotensive rats. J Hypertens 11:509-514.

Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, Matsuo H, Omae T and Matsuoka H (1994): Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 94:2158-2161.

Ishioka N and Bukoski RD (1999): A role for N-arachidonylethanolamine (anandamide) as the mediator of sensory nerve-dependent Ca^{2+}-induced relaxation. J Pharmacol Exp Ther 289:245-250.

Ishizaka H, Gudi SR, Frangos JA and Kuo L (1999): Coronary arteriolar dilation to acidosis: role of ATP-sensitive potassium channels and pertussis toxin-sensitive G proteins. Circulation 99:558-563.

Ito S and Carretero OA (1992): Impaired response to acetylcholine despite intact endothelium-derived relaxing factor/nitric oxide in isolated microperfused afferent arterioles of the spontaneously hypertensive rats. J Cardiovasc Pharmacol 20:187-189.

Jaiswal N, Diz DI, Tallant EA, Khosla MC and Ferrario CM (1991): The nonpeptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin synthesis. Am J Hypertens 4:228-233.

Jaiswal N, Diz DI, Chappell MC, Khosla MC and Ferrario CM (1992): Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension 19:49-55.

Jameson M, Dai F, Lüscher T, Skopec J, Diederich A and Diederich D (1993): Endothelium-derived contracting factors in resistance arteries of young spontaneously hypertensive rats before development of overt hypertension. Hypertension 21:280-288.

Jelicks LA and Gupta RK (1990): NMR measurement of cytosolic free calcium, free magnesium, and intra-cellular sodium in the aorta of the normal and spontaneously hypertensive rat. J Biol Chem 265:1394-1400.

Joannides R, Bakkali EH, Le Roy F, Rivault O, Godin M, Moore N, Fillastre JP and Thuillez C (1997): Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant 12:2623-2628.

John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG and Smithies O (1995): Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 267:679-681.

Johnson ML, Ely DL and Turner ME (1992): Genetic divergence between the Wistar-Kyoto rat and spontaneously hypertensive rat. Hypertension 19:425-427.

Jougasaki M, Stevens TL, Borgeson DD, Luchner A, Redfield MM and Burnett JC Jr (1997): Adrenomedullin in experimental congestive heart failure: cardiorenal activation. Am J Physiol 273:R1392-R1399.

Jover B, Herizi A, Ventre F, Dupont M and Mimran A (1993): Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension 21:944-948.

Julius S (1996): The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. Clin Exp Hypertens 18:305-321.

Kagota S, Yamaguchi Y, Nakamura K and Kunitomo M (1999): Characterization of nitric oxide- and prostaglandin-independent relaxation in response to acetylcholine in rabbit renal artery. Clin Exp Pharmacol Physiol 26:790-796.

Kähönen M, Mäkynen H, Arvola P and Pörsti I (1994): Enhancement of arterial relaxation by long-term atenolol treatment in spontaneously hypertensive rats. Br J Pharmacol 112:925-933.

Kähönen M, Doris PA, Mäkynen H and Pörsti I (1995a): Plasma digoxin immunoreactivity and arterial potassium relaxation after quinapril therapy in hypertensive rats. J Pharmacol Exp Ther 275:832-837.

Kähönen M, Mäkynen H, Wu X, Arvola P and Pörsti I (1995b): Endothelial function in spontaneously hypertensive rats: influence of quinapril treatment. Br J Pharmacol 115:859-867.

Kähönen M, Mäkynen H, Wu X, Arvola P, Pekki A and Pörsti I (1996): Angiotensin-converting enzyme inhibition attenuates arterial constrictor responses in experimental hypertension. J Pharmacol Exp Ther 277:1701-1709.

Kaiser M, Shimada Y, Smith P, Kelly M, Mahadeva H, Adams M, Lodwick D, Aalkjaer C, Avkiran M and Samani N (1998): Differential regulation of ventricular adrenomedullin and atrial natriuretic peptide gene expression in pressure and volume overload in the rat. Clin Sci 94:359-365.

Kanagy NL and Fink GD (1993): Losartan prevents salt-induced hypertension in reduced renal mass rats. J Pharmacol Exp Ther 265:1131-1136.

Kanagy NL and Webb RC (1994): Enhanced vascular reactivity to mastoparan, a G protein activator, in genetically hypertensive rats. Hypertension 23:946-950.

Kanagy NL, Ansari MN, Ghosh S and Webb RC (1994): Recycling and buffering of intracellular calcium in vascular smooth muscle from genetically hypertensive rats. J Hypertens 12:1365-1372.

Kang PM, Landau AJ, Eberhardt RT and Frishman WH (1994): Angiotensin II receptor antagonists: A new approach to blockade of the renin-angiotensin system. Am Heart J 127:1388-1401.

Kangawa K, Kitamura K, Minamino N, Eto T and Matsuo H (1996): Adrenomedullin: a new hypotensive peptide. J Hypertens 14:105-110.

Kano H, Kohno M, Yasunari K, Yokokawa K, Horio T, Ikeda M, Minami M, Hanehira T, Takeda T and Yoshikawa J (1996): Adrenomedullin as a novel antiproliferative factor of vascular smooth muscle cells. J Hypertens 14:209-213.

Kaplan NM (1998): Clinical hypertension. Williams and Wilkins, Baltimore.

Karaki H and Weiss GB (1988): Calcium release in smooth muscle. Life Sci 42:111-122.

Karam H, Heudes D, Bruneval P, Gonzales M-F, Löffler BM, Clozel M and Clozel J-P (1996): Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension 28:379-385.

Kato J, Kitamura K, Kangawa K and Eto T (1995): Receptors for adrenomedullin in human vascular endothelial cells. Eur J Pharmacol 289:383-385.

Kato J, Kitamura K, Matsui E, Tanaka M, Ishizaka Y, Kita T, Kangawa K and Eto T (1999a): Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res 22:61-65.

Kato N, Sugiyama T, Morita H, Nabika T, Kurihara H, Yamori Y and Yazaki Y (1999b): Lack of evidence for association between the endothelial nitric oxide synthase gene and hypertension. Hypertension 33:933-936.

Katoh T, Takahashi K, Klahr S, Reyes AA and Badr KF (1994): Dietary supplementation with L-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy. J Am Soc Nephrol 4:1690-1694.

Katusic ZS (1996): Superoxide anion and endothelial regulation of arterial tone. Free Radic Biol Med 20:443-448.

Kawaguchi H, Sano H, Okada H, Iizuka K, Okamoto H, Kudo T, Murakami T and Kitabatake A (1993): Increased calcium release from sarcoplasmic reticulum stimulated by inositol trisphosphate in spontaneously hypertensive rat heart cells. Mol Cell Biochem 119:51-57.

Keaton AK, White CR and Berecek KH (1998): Captopril treatment and its withdrawal prevents impairment of endothelium-dependent responses in the spontaneously hypertensive rat. Clin Exp Hypertens 20:847-866.

Kelly RA, O'Hara DS, Mitch WE, Steinman TI, Goldszer RC, Solomon HS and Smith TW (1986): Endogenous digitalis-like factors in hypertension and chronic renal insufficiency. Kidney Int 30:723-729.

Kemp GJ, Thompson CH and Radda GK (1992): Proton efflux from rat skeletal muscle in vivo: changes in hypertension. Clin Sci 82:489-491.

Kendall MJ (1998): Therapeutic advantages of AT1 blockers in hypertension. Basic Res Cardiol 93:47-50.

Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM and Frolich JC (1999): Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10:594-600.

Kim S, Ohta K, Hamaguchi A, Yukimura TX, Miura K and Iwao H (1996): Effects of an AT_1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Br J Pharmacol 118:549-556.

Kimura K and Nishio I (1999): Impaired endothelium-dependent relaxation in mesenteric arteries of reduced renal mass hypertensive rats. Scand J Clin Lab Invest 59:199-204.

Kinnunen P, Taskinen T, Järvinen M and Ruskoaho H (1991): Effect of phorbol ester on the release of atrial natriuretic peptide from the hypertrophied rat myocardium. Br J Pharmacol 102:453-461.

Kinnunen P, Vuolteenaho O and Ruskoaho H (1993): Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 132:1961-1970.

Kiowski W, Linder L, Nuesch R and Martina B (1996): Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension 27:371-376.

Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H and Eto T (1993): Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192:553-560.

Kitazono T, Faraci FM, Taguchi H and Heistad DD (1995): Role of potassium channels in cerebral blood vessels. Stroke 26:1713-1723.

K-Laflamme A, Oster L, Cardinal R and de Champlain J (1997): Effects of renin-angiotensin blockade on sympathetic reactivity and beta-adrenergic pathway in the spontaneously hypertensive rat. Hypertension 30:278-287.

Kobayashi S, Ishida A, Moriya H, Mori N, Fukuda T and Takamura T (1999): Angiotensin II receptor blockade limits kidney injury in two-kidney, one-clip Goldblatt hypertensive rats with special reference to phenotypic changes. J Lab Clin Med 133:134-143.

Kohara K, Brosnihan KB and Ferrario CM (1993): Angiotensin (1-7) in the spontaneously hypertensive rat. Peptides 14:883-891.

Kohno M, Kano H, Horio T, Yokokawa K, Yasunari K and Takeda T (1995): Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells. Hypertension 25:1185-1190.

Kohno M, Yokokawa K, Kano H, Yasunari K, Minami M, Hanehira T and Yoshikawa J (1997): Adrenomedullin is a potent inhibitor of angiotensin II-induced migration of human coronary artery smooth muscle cells. Hypertension 29:1309-1313.

Kohno M, Yokokawa K, Minami M, Yasunari K, Maeda K, Kano H, Hanehira T and Yoshikawa J (1999): Plasma levels of nitric oxide and related vasoactive factors following long-term treatment with angiotensin-converting enzyme inhibitor in patients with essential hypertension. Metabolism 48:1256-1259.

Kojda G and Harrison D (1999): Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 43:562-571.

Kojima M, Aoki K, Asano M, Fujimoto S and Matsuda T (1991): Malfunction of arterial sarcoplasmic reticulum leading to faster and greater contraction induced by high-potassium depolarization in young spontaneously hypertensive rats. J Hypertens 9:783-788.

Kubo T, Taguchi K and Ueda M (1998): L-type calcium channels in vascular smooth muscle cells from spontaneously hypertensive rats: effects of calcium agonist and antagonist. Hypertens Res 21:33-37.

Kubo T, Saito E, Hosokawa H, Ibusuki T, Kambe T and Fukumori R (1999): Local renin-angiotensin system and mitogen-activated protein kinase activation in rat aorta. Eur J Pharmacol 365:103-110.

Kuchan MJ and Frangos JA (1993): Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol 264:H150-H156.

Küng CF and Lüscher TF (1995): Different mechanisms of endothelial dysfunction with ageing and hypertension in rat aorta. Hypertension 25:194-200.

Küng CF, Moreau P, Takase H and Lüscher TF (1995): L-NAME hypertension alters endothelial and smooth muscle function in rat aorta: prevention by trandolapril and verapamil. Hypertension 26:744-751.

Kureishi Y, Kobayashi S, Nishimura J, Nakano T and Kanaide H (1995): Adrenomedullin decreases both cytosolic Ca2+ concentration and Ca(2+)-sensitivity in pig coronary arterial smooth muscle. Biochem Biophys Res Commun 212:572-579.

Kuriyama S, Kaguchi Y, Nakamura K, Hashimoto T and Sakai O (1992): Effect of serum on cell membrane Na-K transport of vascular smooth muscle in culture: a comparative study between normotensive and hypertensive rats. Pharmacol Res 25:155-165.

Kurtz TW and Morris RC Jr (1987): Biological variability in Wistar-Kyoto rats. Implications for research with the spontaneously hypertensive rat. Hypertension 10:127-131.

Kwan CY and Daniel EE (1982): Arterial muscle membrane abnormalities of hydralazine-treated spontaneously hypertensive rats. Eur J Pharmacol 82:187-190.

Lacy PS, Pilkington G, Hanvesakul R, Fish HJ, Boyle JP and Thurston H (2000): Evidence against potassium as an endothelium-derived hyperpolarizing factor in rat mesenteric small arteries. Br J Pharmacol 129:605-611.

Lafayette RA, Mayer G, Park SK and Meyer TW (1992): Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90:766-761.

Lamb FS, Moreland RS and Webb RC (1988): Calcium and contractile responses to ouabain and potassium-free solution in aorta from spontaneously hypertensive rats. J Hypertens 6:821-828.

Le Marquer-Domagala F and Finet M (1997): Comparison of the nitric oxide and cyclo-oxygenase pathway in mesenteric resistance vessels of normotensive and spontaneously hypertensive rats. Br J Pharmacol 121:588-594.

Lee RMKW, Berecek KH, Tsoporis J, McKenzie R and Triggle CR (1991): Prevention of hypertension and vascular changes by captopril treatment. Hypertension 17:141-150.

Levin ER, Gardner DG and Samson WK (1998): Natriuretic peptides. N Engl J Med 339:321-328.

Levitsky DO, Clergue M, Lambert F, Souponitskaya MV, Le Jemtel TH, Lecarpentier Y and Lompré A-M (1993): Sarcoplasmic reticulum calcium transport and Ca^{2+}-ATPase gene expression in thoracic and abdominal aortas of normotensive and spontaneously hypertensive rats. J Biol Chem 268:8325-8331.

Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, Poitevin P and Samuel JL (1996): Chronic blockade of AT_2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 98:418-425.

Li JS and Schiffrin EL (1994): Resistance artery structure and neuroeffector mechanisms in hypertension induced by inhibition of nitric oxide synthase. Am J Hypertens 7:996-1004.

Li JS, Sharifi AM and Schiffrin EL (1997a): Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR. J Cardiovasc Pharmacol 30:75-83.

Li P, Chappell MC, Ferrario CM and Brosnihan KB (1997b): Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 29:394-400.

Li P, Ferrario CM and Brosnihan KB (1997c): Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A_2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 281:1065-1070.

Li P, Ferrario CM and Brosnihan KB (1998): Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 32:198-205.

Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC and Koomans HA (1999): Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340:1321-1328.

Lincoln TM, Komalavilas P and Cornwell TL (1994): Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension 23:1141-1147.

Lindpaintner K, Kreutz R and Ganten D (1992): Genetic variation in hypertensive and 'control' strains. What are we controlling for anyway? Hypertension 19:428-430.

Linz W, Becker RH, Scholkens BA, Wiemer G, Keil M and Langer KH (1998): Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats. Kidney Int 54:2037-2044.

Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT and Burnett JC Jr (1998): Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol 275:F410-F414.

Liu Y, Jones AW and Sturek M (1994): Increased barium influx and potassium current in stroke-prone spontaneously hypertensive rats. Hypertension 23:1091-1095.

Liu Y, Fredricks KT, Roman RJ and Lombard JH (1997): Response of resistance arteries to reduced Po_2 and vasodilators during hypertension and elevated salt intake. Am J Physiol 273: H869-H877.

Liu Y, Hudetz AG, Knaus HG and Rusch NJ (1998): Increased expression of Ca^{2+}-sensitive K^+ channels in the cerebral microcirculation of genetically hypertensive rats: evidence for their protection against cerebral vasospasm. Circ Res 82:729-737.

London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M and Metivier F (1996): Cardiac and arterial interactions in end-stage renal disease. Kidney Int 50:600-608.

Longhurst PA, Rice PJ, Taylor DA and Flemming WW (1988): Sensitivity of caudal arteries and the mesenteric vascular bed to norepinephrine in DOCA-salt hypertension. Hypertension 12:133-142.

Luik AJ, Spek JJ, Charra B, van Bortel LM, Laurent G and Leunissen KM (1997): Arterial compliance in patients on long-treatment-time dialysis. Nephrol Dial Transplant 12:2629-2632.

Luke RG (1998): Chronic renal failure - a vasculopathic state. N Engl J Med 339:841-843.

Lüscher TF and Noll G (1995): The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis 118:81-90.

Lüscher TF and Vanhoutte PM (1986): Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 8:344-348.

Lüscher TF, Boulanger CM, Dohi Y and Yang Z (1992): Endothelium-derived contracting factors. Hypertension 19:117-130.

Lüscher TF, Oemar BS, Boulanger CM and Hahn AWA (1993a): Molecular and cellular biology of endothelin and its receptors-Part II. J Hypertens 11:121-126.

Lüscher TF, Seo B and Bühler FR (1993b): Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. Hypertension 21:752-757.

Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA and Lewicki JA (1987): Physiological role of silent receptors of atrial natriuretic factor. Science 238:675-678.

MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH and Ritz E (1996): Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11:2449-2452.

Maeso R, Navarro-Cid J, Muños-García R, Rodrigo E, Ruilope LM, Lahera V and Cachofeiro V (1996): Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors. Hypertension 28:967-972.

Magga J, Marttila M, Mäntymaa P, Vuolteenaho O and Ruskoaho H (1994): Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats. Endocrinology 134:2505-2515.

Magga J, Vuolteenaho O, Marttila M and Ruskoaho H (1997): Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: Acute effects of mixed ET_A/ET_B and AT_1 receptor antagonists in vivo and iv vitro. Circulation 96:3053-3062.

Major TC, Overhiser RW, Taylor DG and Panek RL (1993): Effects of quinapril, a new angiotensin-converting enzyme inhibitor, on vasoconstrictor activity in the isolated, perfused mesenteric vasculature of hypertensive rats. J Pharmacol Exp Ther 265:187-193.

Mäkynen H, Kähönen M, Arvola P, Wuorela H, Vapaatalo H and Pörsti I (1995): Dietary calcium and magnesium supplements in spontaneously hypertensive rats and isolated arterial reactivity. Br J Pharmacol 115:1455-1462.

Mäkynen H, Kähönen M, Arvola P, Wu X, Wuorela H and Pörsti I (1996). Endothelial function in deoxycorticosterone-NaCl hypertension: effect of calcium supplementation. Circulation 93:1000-1008.

Mancia G, Grassi G, Giannattasio C and Seravalle G (1999): Sympathetic activation in the pathogenesis of

hypertension and progression of organ damage. Hypertension 34:724-728.

Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Kilbaner MI, Haber HE, Uprichard ACG, Pepine CJ and Pitt B (1996): Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (trial on reversing endothelial dysfunction) study. Circulation 94:258-265.

Manjeet S and Sim MK (1987): Decreased $Na^+K^+ATPase$ activity in the aortic endothelium and smooth muscle of the spontaneously hypertensive rats. Clin Exp Hypertens 9:797-812.

Marescau B, Nagels G, Possemiers I, De Broe ME, Becaus I, Billiouw J-M, Lornoy W and De Deyn PP (1997): Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 46:1024-1031.

Marin-Grez M, Fleming JT and Steinhausen M (1986): Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 324:473-476.

Marks AR (1992): Calcium channels expressed in smooth muscle. Circulation 86:61-67.

Martin-Mateo MC, del Canto-Jafiez E and Barrero-Martinez MJ (1998): Oxidative stress and enzyme activity in ambulatory renal patients undergoing continuous peritoneal dialysis. Ren Fail 20:117-124.

Martonosi AN, Jona I, Molnar E, Seidler NW, Buchet R and Varga S (1990): Emerging views on the structure and dynamics of the Ca^{2+}-ATPase in sarcoplasmic reticulum. FEBS Lett 268:365-370.

Masaki T (1998): The discovery of endothelins. Cardiovasc Res 39:530-533.

Masugi F, Ogihara T, Hasegawa T and Kumahara Y (1987): Ouabain-like and non-ouabain-like factors in plasma of patients with essential hypertension. Clin Exp Hypertens 9:1233-1242.

Matsubara H, Mori Y, Yamamoto J and Inada M (1990): Diabetes-induced alterations in atrial natriuretic peptide gene expression in Wistar-Kyoto and spontaneously hypertensive rats. Circ Res 67:803-813.

Matsubara BB, Matsubara LS, Zornoff LA, Franco M and Janicki JS (1998): Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats. Basic Res Cardiol 93:173-181.

Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR and Nussberger J (2000): Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 35:985-991.

McCulloch AI, Bottrill FE, Randall MD and Hiley CR (1997): Characterization and modulation of EDHF-mediated relaxations in the rat isolated superior mesenteric arterial bed. Br J Pharmacol 120:1431-1438.

Medina R, Cardona-Sanclemente LE, Born GVR and Brown MJ (1997): Effect of captopril and losartan on blood pressure and accumulation of LDL and fibrinogen by aortic wall and other tissues in normotensive and hypertensive rats. J Cardiovasc Pharmacol 29:125-129.

Mervaala EMA, Müller DN, Park JK, Schmidt F, Löhn M, Breu V, Dragun D, Ganten D, Haller H and Luft FC (1999): Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 33:389-395.

Millgard J, Hagg A, Sarabi M and Lind L (1998): Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J Hum Hypertens 12:511-516.

Minneman KP (1988): Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca^{2+}. Pharmacol Rev 40:87-119.

Minshall RD, Tan F, Nakamura F, Rabito SF, Becker RP, Marcic B and Erdös EG (1997): Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B_2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res 81:848-856.

Mishra SK and Hermsmeyer (1994): Selective inhibition of T-type Ca^{2+} channels by Ro 40-5967. Circ Res 75:144-148.

Miura K, Ebara T, Okumura M, Matsuura T, Kim S, Yukimura T and Iwao H (1995): Attenuation of adrenomedullin-induced renal vasodilatation by NG-nitro L-arginine but not glibenclamide. Br J Pharmacol 115:917-924.

Miyata M, Tsuchida K and Otomo S (1990): Functional changes in potassium channels in carotid arteries from stroke-prone spontaneously hypertensive rats. Eur J Pharmacol 182:209-210.

Mizuno K, Tani M, Hashimoto S, Niimura S, Sanada H, Watanabe H, Ohtsuki M and Fukuchi S (1992): Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 51:367-374.

Moncada S and Higgs A (1993): The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012.

Moncada S, Palmer RMJ and Higgs EA (1991): Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142.

Monteith GR, Kable EP, Chen S and Roufogalis BD (1996): Plasma membrane calcium pump-mediated calcium efflux and bulk cytosolic free calcium in cultured aortic smooth muscle cells from spontaneously hypertensive and Wistar-Kyoto normotensive rats. J Hypertens 14:435-442.

Monteith GR, Kable EP, Kuo TH and Roufogalis BD (1997): Elevated plasma membrane and sarcoplasmic reticulum Ca^{2+} pump mRNA levels in cultured aortic smooth muscle cells from spontaneously hypertensive rats. Biochem Biophys Res Comm 230:344-346.

Moreau P (1998): Endothelin in hypertension: a role for receptor antagonists? Cardiovasc Res 39:534-542.

Morimoto A, Nishikimi T, Yoshihara F, Horio T, Nagaya N, Matsuo H, Dohi K and Kangawa K (1999): Ventricular adrenomedullin levels correlate with the extent of cardiac hypertrophy in rats. Hypertension 33:1146-1152.

Mourad JJ, Girerd X, Boutouyrie P, Laurent S, Safar M and London G (1997): Increased stiffness of radial artery wall material in end-stage renal disease. Hypertension 30:1425-1430.

Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Zulli R, Corbellini C, Brun C and Agabiti-Rosei E (1999): Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 33:575-580.

Mulrow PJ and Franco-Saenz R (1996): The adrenal renin-angiotensin system: a local hormonal regulator of aldosterone production. J Hypertens 14:173-176.

Mulvany MJ (1999): Vascular remodelling of resistance vessels: can we define this? Cardiovasc Res 41:9-13.

Mulvany MJ, Persson AEG and Andersen J (1991): No persistent effect of angiotensin converting enzyme inhibitor treatment in Milan hypertensive rats despite regression of vascular structure. J Hypertens 9:589-593.

Munzenmaier DH and Greene AS (1994): Stimulation of soluble guanylate cyclase activity by angiotensin II is mediated by a non-AT_1 receptor mechanism in rat aorta. (Abstract). Faseb J 8:A367.

Murphy ME and Brayden JE (1995): Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. J Physiol 486:47-58.

Nahorski SR, Wilcox RA, Mackrill JJ and Chaliss RAJ (1994): Phosphoinositide-derived second messengers and the regulation of Ca^{2+} in vascular smooth muscle. J Hypertens 12: 133-143.

Nakata K, Nishimura K, Takada T, Ikuse T, Yamauchi H and Iso T (1987): Effects of an angiotensin-converting enzyme (ACE) inhibitor, SA446, on tissue ACE activity in normotensive, spontaneously hypertensive and renal hypertensive rats. J Cardiovasc Pharmacol 9:305-310.

Nava E and Lüscher TF (1995): Endothelium-derived vasoactive factors in hypertension: nitric oxide and endothelin. J Hypertens 13:39-48.

Navar LG (1997): The kidney in blood pressure regulation and development of hypertension. Med Clin North Am 5:1165-1198.

Nelson MT (1993): Ca^{2+}-activated potassium channels and ATP-sensitive potassium channels as modulators of vascular tone. Trends Cardiovasc Med 3:54-60.

Nelson MT and Quayle JM (1995): Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268:C799-C822.

Nelson MT, Patlak JB, Worley JF and Standen NB (1990): Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol 259:C3-C18.

Neusser M, Tepel M, Golinski P, Holthues J, Spieker C, Zhu Z and Zidek W (1994): Different calcium storage pools in vascular smooth muscle cells from spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Hypertens 12:533-538.

Nguyen PV, Yang X-P, Li G, Deng LY, Flückiger J-P and Schiffrin EL (1993): Contractile responses and signal transduction of endothelin-1 in aorta and mesenteric vasculature of adult spontaneously hypertensive rats. Can J Physiol Pharmacol 71:473-483.

Nicholls MG, Charles CJ, Crozier IG, Espiner EA, Ikram H, Rademaker MJ, Richards AM and Yandle TG (1994): Blockade of renin-angiotensin system. J Hypertens 12:95-103.

Nishizuka Y (1995): Protein kinase C and lipid signaling for sustained cellular responses. FASEB 9:484-496.

Noll G, Wenzel RR, Schneider M, Oesch V, Binggeli C, Shaw S, Weidmann P and Lüscher TF (1996): Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation 93:866-869.

Noris M, Benigni A, Boccardo P, Aiello S, Gaspari F, Todeschini M, Figliuzzi M and Remuzzi G (1993): Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. Kidney Int 44:445-450.

Novosel D, Lang MG, Noll G and Lüscher TF (1994): Endothelial dysfunction in aorta of the spontaneously hypertensive, stroke-prone rat: Effect of therapy with verapamil and trandolapril alone and in combination. J Cardiovasc Pharmacol 24:979-985.

Numaguchi K, Egashira K, Sakata M, Shimokawa H and Takeshita A (1996): Coronary vascular ATP-sensitive potassium channels are activated to a greater extent in spontaneously hypertensive rats than in Wistar-Kyoto rats. J Hypertens 14:183-189.

Oddie CJ, Dilley RJ, Kanellakis P and Bobik A (1993): Chronic angiotensin II type 1 receptor antagonism in genetic hypertension: effects on vascular structure and reactivity. J Hypertens 11:717-724.

O'Donnell ME and Owen NE (1994): Regulation of ion pumps and carriers in vascular smooth muscle. Physiol Rev 74:683-721.

Ogawa Y, Nakao K, Mukoyama M, Hosoda K, Shirakami GX, Arai H, Saito Y, Suga S, Jougasaki M and Imura H (1991): Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res 69:491-500.

Ogawa T, Linz W, Stevenson M, Bruneau BG, Kuroski de Bold ML, Chen JH, Eid H, Schölkens BA and de Bold AJ (1996): Evidence for load-dependent and load independent determinants of cardiac natriuretic peptide production. Circulation 93:2059-2067.

Ohya Y, Setoguchi M, Fujii K, Nagao T, Abe I and Fujishima M (1996): Impaired action of levcromakalim on ATP-sensitive K^+ channels in mesenteric artery cells from spontaneously hypertensive rats. Hypertension 27:1234-1239.

Okamoto K and Aoki K (1963): Development of a strain of spontaneously hypertensive rats. Jpn Circ J 27:282-293.

Okamura K, Kondo J, Yoshino M, Ishikawa K, Asano H, Hashimoto H and Ito T (1992): Enalapril reduces the enhanced 1,2-diacylglycerol content and RNA synthesis in spontaneously hypertensive rat hearts before established hypertension. Mol Cell Biochem 112:15-21.

Oliveira MA, Fortes ZB, Santos RA, Kosla MC and De Carvalho MH (1999): Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides 20:1195-201.

Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O and Maeda N (1997): Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 94:14730-14735.

Onaka U, Fujii K, Abe I and Fujishima M (1998): Antihypertensive treatment improves endothelium-dependent hyperpolarization in the mesenteric artery of spontaneously hypertensive rats. Circulation 98:175-182.

Orlov SN, Resink TJ, Bernhardt J and Bühler FR (1992): Na^+-K^+ pump and Na^+-K^+ co-transport in cultured vascular smooth muscle cells from spontaneously hypertensive and normotensive rats: baseline activity and regulation. J Hypertens 10:733-740.

Orlov S, Resink TJ, Bernhard J, Ferracin F and Buhler FR (1993): Vascular smooth muscle cell calcium fluxes. Regulation by angiotensin II and lipoproteins. Hypertension 21:195-203.

Oshima T, Young EW and McCarron DA (1991): Abnormal platelet and lymphocyte calcium handling in prehypertensive rats. Hypertension 18:111-115.

Otsuka S, Sugano M, Makino N, Sawada S, Hata T and Niho Y (1998): Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats. Hypertension 32:467-472.

Pacák K, Yadid G, Jakab G, Lenders JWM, Kopin IJ and Goldstein DS (1993): In vivo hypothalamic release and synthesis of catecholamines in spontaneously hypertensive rats. Hypertension 22:467-478.

Palmer RMJ, Ferrige AG and Moncada S (1987): Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526.

Palmer RMJ, Ashton DS and Moncada S (1988): Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664-666.

Panfilov VV and Reid JL (1994): Brain and autonomic mechanisms in hypertension. J Hypertens 12:337-343.

Panza JA, Quyyumi AA, Brush Jr. JE and Epstein SE (1990): Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323:22-27.

Papageorgiou P and Morgan KG (1991): Intracellular free Ca^{2+} is elevated in hypertrophic aortic muscle from hypertensive rats. Am J Physiol 260:H507-H515.

Papapetropoulos A, Rudic RD and Sessa WC (1999): Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res 43:509-520.

Paran E, Nemenoff RA and Schrier RW (1995): Role of the renin-angiotensin system in essential hypertension. Curr Opin Nephrol Hypertens 4:295-299.

Perry PA and Webb RC (1991): Agonist-sensitive calcium stores in arteries from steroid hypertensive rats. Hypertension 17:603-611.

Peters H and Noble NA (1996): Dietary L-Arginine in renal disease. Semin Nephrol 16:567-575.

Pidgeon GB, Lewis LK, Yandle TG, Richards AM and Nicholls MG (1996): Endogenous ouabain, sodium balance and blood pressure. J Hypertens 14:169-171.

Pollock DM, Polakowski JS, Divish BJ and Opgenorth TJ (1993): Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 21:660-666.

Pörsti I, Bara AT, Busse R and Hecker M (1994): Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 111:652-654.

Prasad A, Husain S and Quyyumi AA (1999): Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin. J Am Coll Cardiol 33:796-804.

Prats MV, Serra MM, Artero JB, Benito GM, Escuder PT and Nicolas JMM (1996): Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension. Kidney Int 49 :104-106.

Preston RA (1999): Renoprotective effects of antihypertensive drugs. Am J Hypertens 12:19-32.

Prieto D, Nilsson H, and Mulvany MJ (1996): ATP-sensitive K^+ channels are involved in the hyperpolarization elicited by activation of adenylate cyclase in rat mesenteric small arteries. J Vasc Res 33:39.

Qiu HY, Henrion D and Levy BI (1994): Endogenous angiotensin II enhances phenylephrine-induced tone in hypertensive rats. Hypertension 24:317-321.

Quast U, Guillon J-M and Cavero I (1994): Cellular pharmacology of potassium channel openers in vascular smooth muscle. Cardiovasc Res 28:805-810.

Quayle JM and Standen NB (1994): K_{ATP} channels in vascular smooth muscle. Cardiovasc Res 28:797-804.

Quilley J, Fulton D and McGiff JC (1997): Hyperpolarizing factors. Biochem Pharmacol 54:1059-1070.

Rabelink TJ and Koomans HA (1997): Endothelial function and the kidney. Drugs 53:11-19.

Radaelli A, Mircoli L, Mori I, Mancia G and Ferrari AU (1998): Nitric oxide dependent vasodilation in young spontaneously hypertensive rats. Hypertension 32:735-739.

Rahn KH (1998): Renal function in treated and untreated hypertension. J Hum Hypertens 12:599-601.

Rahn KH, Barenbrock M and Hausberg M (1999): The sympathetic nervous system in the pathogenesis of hypertension. J Hypertens 17:11-14.

Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA and Griendling KK (1996): Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 97:1916-1923.

Randall MD and Kendall DA (1998): Endocannaboids: a new class of vasoactive substances. Trends Pharmacol Sci 19:55-58.

Randall MD and McCulloch AI (1995): The involvement of ATP-sensitive potassium channels in β-adrenoceptor-mediated vasorelaxation in the rat isolated mesenteric arterial bed. Br J Pharmacol 115:607-612.

Rayson BM and Gilbert MT (1992): Regulation of Na^+,K^+-ATPase in hypertension. Semin Nephrol 12:72-75.

Reaves PY, Gelband CH, Wang H, Yang H, Lu D, Berecek KH, Katovich MJ and Raizada MK (1999): Permanent cardiovascular protection from hypertension by the AT(1) receptor antisense gene therapy in hypertensive rat offspring. Circ Res 85:44-50.

Redondo J, Peiró C, Rodríguez-Mañas L, Salaices M, Marín J and Sánchez-Ferrer CF (1995): Endothelial stimulation of sodium pump in cultured vascular smooth muscle. Hypertension 26:177-185.

Reid JL (1994): Hypertension and the brain. Br Med Bull 50:371-380.

Rembold CM (1992): Regulation of contraction and relaxation in arterial smooth muscle. Hypertension 20:129-137.

Rhaleb NE, Peng H, Alfie ME, Shesely EG and Carretero OA (1999): Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice: do kinin B2 receptors play a role? Hypertension 33:329-334.

Ribeiro MO, Antunes E, De Nucci G, Lovisolo SM and Zatz R (1992): Chronic inhibition of nitric oxide synthesis, a new model of arterial hypertension. Hypertension 20:298-303.

Rinaldi G and Bohr D (1989): Endothelium-mediated spontaneous response in aortic rings of deoxycorti-costerone acetate-hypertensive rats. Hypertension 13:256-261.

Riordan JF (1995): Angiotensin II: Biosynthesis, molecular recognition, and signal transduction. Cell Mol Neurobiol 15:637-651.

Ritter JM, Barrow SE, Doktor HS, Stratton PD, Edwards JS, Henry JA and Gould S (1993): Thromboxane A_2 receptor antagonism and synthase inhibition in essential hypertension. Hypertension 22:197-203.

Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P, Giulini SM and Agabiti-Rosei E (1996): Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 28:785-790.

Rizzoni D, Muiesan ML, Porteri E, Castellano M, Zulli R, Bettoni G, Salvetti M, Monteduro C and Agabiti-Rosei E (1997): Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens 15:197-204.

Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Tiberio G, Giulini SM, Rossi G, Bernini G and Agabiti-Rosei E (1998a): Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension 31:335-341.

Rizzoni D, Porteri E, Bettoni G, Piccoli A, Castellano M, Muiesan ML, Pasini G, Guelfi D and Rosei EA (1998b): Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol 32:798-806.

Rizzoni D, Porteri E, Piccoli A, Castellano M, Bettoni G, Muiesan ML, Pasini G, Guelfi D, Mulvany MJ and Agabiti Rosei E (1998c): Effects of losartan and enalapril on small artery structure in hypertensive rats. Hypertension 32:305-310.

Rodrigo E, Maeso R, Muñoz-García R, Navarro-Cid J, Ruilope LM, Cachofeiro V and Lahera V (1997): Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan and captopril. J Hypertens 15:613-618.

Romppanen H (1999): Regulation of adrenomedullin gene expression in the rat heart. Acta Univ Oul D 568.

Romppanen H, Marttila M, Magga J, Vuolteenaho O, Kinnunen P, Szokodi I and Ruskoaho H (1997): Adrenomedullin gene expression in the rat heart is stimulated by acute pressure overload: Blunted effect in experimental hypertension. Endocrinology 138:2636-2639.

Rothermund L and Paul M (1998): Hypertension and the renin-angiotensin system - evidence from genetic and transgenic studies. Basic Res Cardiol 93:1-6.

Rubanyi GM (1993): The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 22:1-14.

Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS and Sessa WC (1998): Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 101:731-736.

Ruegg JC (1999): Smooth muscle: PKC-induced Ca^{2+} sensitisation by myosin phosphatase inhibition. J Physiol 520:3.

Ruoff GE (1998): The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther 20:376-387.

Rusch NJ and Hermsmeyer K (1998): Calcium currents are altered in the vascular smooth muscle cell membrane of spontaneously hypertensive rats. Circ Res 63:997-1002.

Rusch NJ and Runnels AM (1994): Remission of high blood pressure reverses arterial potassium channel alterations. Hypertension 23:941-945.

Rusch NJ, Liu Y and Pleyte KA (1996): Mechanisms for regulation of arterial tone by Ca^{2+}-dependent K^+ channels in hypertension. Clin Exp Pharmacol Physiol 23:1077-1081.

Ruschitzka F, Noll G and Lüscher TF (1999): Angiotensin converting enzyme inhibitors and vascular protection in hypertension. J Cardiovasc Pharmacol 34:3-12.

Ruskoaho H (1992): Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 44:479-602.

Ruskoaho H and Leppäluoto J (1988): Immunoreactive atrial natriuretic peptide in ventricles, atria, hypothalamus, and plasma of genetically hypertensive rats. Circ Res 62:384-394.

Ruskoaho H, Kinnunen P, Taskinen T, Vuolteenaho O, Leppäluoto J and Takala TES (1989): Regulation of ventricular atrial natriuretic peptide release in hypertrophied rat myocardium. Effect of exercise. Circulation 80:390-400.

Saavedra JM, Correa FMA, Seltzer A, Pinto JEB, Viglione P and Tsutsumi K (1992): Enhanced angiotensin converting enzyme binding in arteries from spontaneously hypertensive rats. J Hypertens 10:1353-1359.

Sada T, Koike H, Ikeda M, Sato K, Ozaki H and Karaki H (1990): Cytosolic free calcium of aorta in hypertensive rats. Chronic inhibition of angiotensin converting enzyme. Hypertension 16:245-251.

Sakata K, Shirotani M, Yoshida H and Kurata C (1998): Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol 32:438-443.

Sakata K, Shirotani M, Yoshida H and Kurata C (1999): Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG. J Nucl Med 40:6-11.

Sakurai T, Yanagisawearly essential hypertension assessed by 123I-MIBG. J Nucl Med 40:6-11.

Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Goto K and Masaki TK (1990): Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348:732-735.

Salvetti A, Adbel-Haq B, Magagna A and Pedrinelli R (1987): Indomethacin reduces the antihypertensive action of enalapril. Clin Exp Hypertens 9:559-567.

Samson WK (1999): Adrenomedullin and the control of fluid and electrolyte homeostasis. Annu Rev Physiol 61:363-389.

dos Santos CM, Moreira ED, Krieger EM and Michelini LC (1998): Chronic AT1 receptor blockade alters aortic nerve activity in hypertension. Hypertension 31:973-977.

Scheuer DA and Perrone MH (1993): Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 264:R917-R923.

Schiffrin EL (1995): Endothelin: Potential role in hypertension and vascular hypertrophy. Hypertension 25:1135-1143.

Schiffrin EL (1999): Role of endothelin-1 in hypertension. Hypertension 34:876-881.

Schiffrin EL and Deng L-Y (1995): Comparison of effects of angiotensin I-converting enzyme inhibition and β-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 25:699-703.

Schmieder RE, Weilprecht H, Schobel H, John S, Weidinger G, Gatzka C and Veelken R (1997): Is endothelial function of the radial artery altered in human essential hypertension ? Am J Hypertens 10:323-331.

Schoemaker RG, Leenen FH and Harmsen E (1994): Age-related increase in sensitivity for ischemic ATP breakdown in hypertrophic hearts of SHR normalized by enalapril. J Mol Cell Cardiol 26:649-660.

Schulz R and Triggle CR (1994): Role of NO in vascular smooth muscle and cardiac muscle function. Trends Pharmacol Sci 15:255-259.

Seguchi H, Nishimura J, Kobayashi S, Kumazawa J and Kanaide H (1995): Autocrine regulation of the renal arterial tone by adrenomedullin. Biochem Biophys Res Commun 215:619-625.

Seyedi N, Xu X, Nasjletti A and Hintze TH (1995): Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 26:164-170.

Shah J and Jandhyala (1995): Age-dependent alterations in Na^+K^+-ATPase activity in the central nervous system of spontaneously hypertensive rats: Relationship to the development of high blood pressure. Clin Exp Hypertens 17:751-767.

Sharifi AM and Schiffrin EL (1998): Apoptosis in vasculature of spontaneously hypertensive rats: effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. Am J Hypertens 11:1108-1116.

Sharifi AM, Li JS, Endemann D and Schiffrin EL (1998): Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 16:457-466.

Shesely EG, Maeda N, Kim H-S, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC and Smithies O (1996): Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 93:13176-13181.

Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T, Nagao T, Egashira K, Fujishima M and Takeshita A (1996): The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 28:703-711.

Shionoiri H, Sugimoto K, Kosaka T, Kita E, Oda H, Ushikubo T, Goto T, Takasaki I and Yasuda G (1998): Long-term therapy with an ACE inhibitor, temocapril, reduces microalbuminuria in essential hypertension. Hypertens Res 21:81-87.

Shoemaker RL and Worrel RT (1991): Ca^{2+}-sensitive K^+ channel in aortic smooth muscle of rat. Proc Soc Exp Biol Med 196:325-332.

Simonsen U, Wadsworth RM, Buus NH and Mulvany MJ (1999): In vitro simultaneous measurements of relaxation and nitric oxide concentration in rat superior mesenteric artery. J Physiol 516:271-282.

Singh S and Evans TW (1997): Nitric oxide, the biological mediator of the decade: fact or fiction? Eur Respir J 10:699-707.

Siragy HM, Inagami T, Ichiki T and Carey RM (1999): Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 96:6506-6510.

Skov K, Fenger-Gron J and Mulvany MJ (1996): Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure. Hypertension 28:464-471.

Sleight P (1991): Role of baroreceptor reflexes in circulatory control, with particular reference to hypertension. Hypertension 18:31-35.

Smith TL and Hutchins PM (1979): Central hemodynamics in the developmental stage of spontaneous hypertension in the unanesthetized rat. Hypertension 1:508-517.

Soltis EE (1993): Alterations in vascular structure and function after short-term losartan treatment in spontaneously hypertensive rats. J Pharmacol Exp Ther 266:642-646.

Somlyo AP, Wu X, Walker LA and Somlyo AV (1999): Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. Rev Physiol Biochem Pharmacol 134:201-234.

Song Y and Simard JM (1995): β-adrenoceptor stimulation activates large-conductance Ca^{2+}-activated K^+ channels in smooth muscle cells from basilar artery of guinea pig. Pflügers Arch Eur J Physiol 430:983-993.

Spedding M and Paoletti R (1992): Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol Rev 44:363-376.

Spieker C, Heck D, Zidek W and Vetter H (1986): Ca^{2+} metabolism in arteries of spontaneously hypertensive rats: assessment by proton-induced X-ray emission. J Hypertens 4:122-125.

Standen NB and Quayle JM (1998): K^+ channel modulation in arterial smooth muscle. Acta Physiol Scand 164:549-557.

Steckelings U, Lebrun C, Qadri F, Veltmar A and Unger T (1992): Role of brain angiotensin in cardiovascular regulation. J Cardiovasc Pharmacol 19:72-79.

Steinhelper ME, Cochrane KL and Field LJ (1990): Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 16:301-307.

St. Lezin E, Simonet L, Pravenec M and Kurtz TW (1992): Hypertensive strains and normotensive "control" strains. How closely are they related. Hypertension 19:419-424.

Stock P, Liefeldt L, Paul M and Ganten D (1995): Local renin-angiotensin systems in cardiovascular tissues: localization and functional role. Cardiology 86:2-8.

Stoll M, Stecklings UM, Paul M, Bottari SP, Metzger R and Unger T (1995): The angiotensin AT_2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95:651-657.

Storm DS, Stuenkel EL and Webb RC (1992): Calcium channel activation in arterioles from genetically hypertensive rats. Hypertension 20:380-388.

Story DF and Ziogas J (1987): Interaction of angiotensin with noradrenergic neuroeffector transmission. Trends Pharmacol Sci 8:269-271.

Stull JT, Gallagher PJ, Herring BP and Kamm KE (1991): Vascular smooth muscle contractile elements. Cellular regulation. Hypertension 17:723-732.

Sugiyama T, Yoshizumi M, Takaku F and Yazaki Y (1990): Abnormal calcium handling in vascular smooth muscle of spontaneously hypertensive rats. J Hypertens 8:369-375.

Sunano S, Watanabe H, Tanaka S, Sekiguchi F and Shimamura K (1999): Endothelium-derived relaxing, contracting and hyperpolarizing factors of mesenteric arteries of hypertensive and normotensive rats. Br J Pharmacol 126:709-716.

Szokodi I, Kinnunen P and Ruskoaho H (1996): Inotropic effect of adrenomedullin in the isolated perfused rat heart. Acta Physiol Scand 156:151-152.

Szokodi I, Kinnunen P, Tavi P, Weckstrom M, Toth M and Ruskoaho H (1998): Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation 97:1062-1070.

Taddei S, Virdis A, Mattei P and Salvetti A (1993): Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 21:929-933.

Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I and Salvetti A (1996). Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 94:1298-1303.

Taddei S, Virdis A, Mattei P, Ghiadoni L, Fasolo CB, Sudano I and Salvetti A (1997a): Hypertension causes premature ageing of endothelial functti A (1997b): Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 29:274-279.

Taddei S, Virdis A, Ghiadoni L and Salvetti A (1998a): Endothelial dysfunction in hypertension: fact or fancy? J Cardiovasc Pharmacol 32:41-47.

Taddei S, Virdis A, Ghiadoni L, Mattei P and Salvetti A (1998b): Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 16:447-456.

Tagawa T and Dampney RA (1999): AT(1) receptors mediate excitatory inputs to rostral ventrolateral medulla pressor neurons from hypothalamus. Hypertension 34:1301-1307.

Takami S, Wong ZY, Stebbing M and Harrap SB (1999): Linkage analysis of endothelial nitric oxide synthase gene with human blood pressure. J Hypertens 17:1431-1436.

Takase H, Dohi Y, Kojima M and Sato K (1994): Changes in the endothelial cyclo-oxygenase pathway in resistance arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol 23:326-330.

Takase H, Moreau P, Küng CF, Nava E and Lüscher TF (1996): Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertension 27:25-31.

Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K and Takeshita A (1997): Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99:278-287.

Takuwa Y (1996): Regulation of vascular smooth muscle contraction. The roles of Ca^{2+}, protein kinase C and myosin light chain phosphatase. Jpn Heart J 37:793-813.

Tamura H, Hopp L, Kino M, Tokushige A, Searle BM, Khalil F and Aviv A (1986): Na^+-K^+ regulation in cultured vascular smooth muscle cell of the spontaneously hypertensive rat. Am J Physiol 250:C939-C947.

Tedesco MA, Ratti G, Aquino D, Limongelli G, di Salvo G, Mennella S, Galzerano D, Iarussi D and Iacono A (1998): Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 12:505-510.

Tesfamariam B and Ogletree ML (1995): Dissociation of endothelial cell dysfunction and blood pressure in SHR. Am J Physiol 269:H189-H194.

Thibault G, Amiri F and Garcia R (1999): Regulation of natriuretic peptide secretion by the heart. Annu Rev Physiol 61:193-217.

Thompson LE, Rinaldi GJ and Bohr DF (1990): Decreased activity of the sodium-calcium exchanger in tail artery of stroke-prone spontaneously hypertensive rats. Blood Vessels 27:197-201.

Timmermans PBMWM and Smith RD (1996): The diversified pharmacology of angiotensin II-receptor blockade. Blood Pressure 5:53-61.

Timmermans PBMW, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM and Smith RD (1993): Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205-251.

Tolvanen JP, Wu X, Kahonen M, Sallinen K, Makynen H, Pekki A and Porsti I (1996): Effect of celiprolol therapy on arterial dilatation in experimental hypertension. Br J Pharmacol 119:1137-1144.

Tschudi MR and Lüscher TF (1995): Age and hypertension differently affect coronary contractions to endothelin-1, serotonin, and angiotensins. Circulation 91:2415-2422.

Tschudi MR, Criscione L, Novosel D, Pfeiffer K and Lüscher TF (1994): Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation 89:2212-2218.

Tschudi MR, Mesaros S, Lüscher TF and Malinski T (1996): Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension 27:32-35.

Turla MB and Webb RC (1990): Augmented phosphoinositide metabolism in aortas from genetically hypertensive rats. Am J Physiol 258:H173-H175.

Umans JG and Levi R (1995): Nitric oxide in the regulation of blood flow and arterial pressure. Annu Rev Physiol 57:771-790.

Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Hohle S, Meffert S, Stoll M, Stroth U and Zhu YZ (1996): Angiotensin receptors. J Hypertens 14:95-103.

Unger T, Culman J and Gohlke P (1998): Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens 16:3-9.

Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K and Takeshita A (1997): Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest 100:2793-2799.

Ushio-Fukai M, Abe S, Kobayashi S, Nishimura J and Kanaide H (1993): Effects of isoprenaline on cytosolic calcium concentrations and on tension in the porcine coronary artery. J Physiol 462:679-696.

Usui M, Ichiki T, Katoh M, Egashira K and Takeshita A (1998): Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 32:527-533.

Usui M, Egashira K, Kitamoto S, Koyanagi M, Katoh M, Kataoka C, Shimokawa H and Takeshita A (1999): Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension 34:546-551.

Vacher E, Richer C and Giudicelli J-F (1996): Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats. J Hypertens 14:1341-1348.

Vallance P, Leone A, Calver A, Collier J and Moncada S (1992): Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-575.

Van Breemen C and Saida K (1989): Cellular mechanisms regulating $[Ca^{2+}]_i$ smooth muscle. Annu Rev Physiol 51:315-329.

Van de Voorde J, Vanheel B and Leusen I (1992): Endothelium-dependent relaxation and hyperpolarization in aorta from control and renal hypertensive rats. Circ Res 70:1-8.

van Guldener C, Lambert J, Janssen MJFM, Donker AJM and Stehouwer CDA (1997): Endothelium-dependent vasodilatation and distensibility of large arteries in chronic hemodialysis patients. Nephrol Dial Transplant 12:14-18.

Vane JR and Botting RM (1993): Formation by the endothelium of prostacyclin, nitric oxide and endothelin. J Lipid Mediat 6:395-404.

Vanhoutte PM and Mombouli J-V (1996): Vascular endothelium: Vasoactive mediators. Prog Cardiovasc Dis 39:229-238.

Vanhoutte PM, Boulanger CM, Illiano SC, Nagao T, Vidal M and Mombouli J-V (1993): Endothelium-dependent effects of converting-enzyme inhibitors. J Cardiovasc Pharmacol 22:10-16.

Vanhoutte PM, Boulanger CM and Mombouli JV (1995): Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol 76:3-12.

Van Zwieten PA (1997): Endothelial dysfunction in hypertension. A critical evaluation. Blood Press 2:67-70.

Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, Gil MJ, Monreal I and Diez J (1999): Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 17:107-114.

Vaziri ND, Ni Z and Oveisi F (1998a): Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension 31:1248-1254.

Vaziri ND, Oveisi F and Ding Y (1998b): Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 53:1748-1754.

Vaziri ND, Ni Z, Wang XQ, Oveisi F and Zhou XJ (1998c): Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol 274:642-649.

Verbeke M, Van de Voorde J, de Ridder L and Lameire N (1994): Functional analysis of vascular dysfunction in cyclosporin treated rats. Cardiovasc Res 28:1152-1156.

Verhagen AM, Rabelink TJ, Braam B, Opgenorth TJ, Grone HJ, Koomans HA and Joles JA (1998): Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition. J Am Soc Nephrol 9:755-762.

Vicaut E and Hou X (1994): Local renin-angiotensin system in the microcirculation of spontaneously hypertensive rats. Hypertension 24:70-76.

Vila E, Tabernero A and Ivorra MD (1993): Inositol phosphate formation and contractile response linked to alpha 1-adrenoceptor in tail artery and aorta from spontaneously hypertensive and Wistar-Kyoto rats. J Cardiovasc Pharmacol 22:191-197.

Vuolteenaho O, Arjamaa O and Ling N (1985): Atrial natriuretic polypeptides (ANP): rat atria store high molecular weight precursor but secrete processed peptides of 25-35 amino acids. Biochem Biophys Res Commun 129:82-88.

Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhäusl W and Binder BR (1992): Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267:16066-16068.

Walsh MP (1994): Regulation of vascular smooth muscle tone. Can J Physiol Pharmacol 72:919-936.

Wang XL, Mahaney MC, Sim AS, Wang J, Wang J, Blangero J, Almasy L, Badenhop RB and Wilcken DE (1997): Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler Thromb Vasc Biol 17:3147-3153.

Warrens AN, Cassidy MJD, Takahashi K, Ghatei MA and Bloom SR (1990): Endothelin in renal failure. Nephrol Dial Transplant 5:418-422.

Wauquier I, Pernollet MG, Grichois ML, Lacour B, Meyer P and Devynck MA (1988): Endogenous digitalislike circulating substances in spontaneously hypertensive rats. Hypertension 12:108-116.

Webb DJ and Strachan FE (1998): Clinical experience with endothelin antagonist. Am J Hypertens 11:71-79.

Weber AA, Zucker TP, Hasse A, Bonisch D, Wittpoth M and Schror K (1998a): Antimitogenic effects of vasodilatory prostaglandins in coronary artery smooth muscle cells. Basic Res Cardiol 93:54-57.

Weber MA (1997): Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. J Hypertens 15:31-36.

Wei CC, Meng QC, Palmer R, Hageman GR, Durand J, Bradley WE, Farrell DM, Hankes GH, Oparil S and Dell'Italia LJ (1999): Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation 99:2583-2589.

Weir MR and Saunders E (1998): Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril Multicenter Study Group. J Hum Hypertens 12:189-194.

Wiemer G, Schölkens BA, Wagner A, Heitsch H and Linz W (1993): The possible role of angiotensin II subtype AT_2 receptors in endothelial cells and ischemic rat hearts. J Hypertens 11:234-235.

Wiemer G, Linz W, Hatrik S, Schölkens BA and Malinski T (1997): Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. Hypertension 30:1183-1190.

Wilkins MR, Redondo J and Brown LA (1997): The natriuretic-peptide family. Lancet 349:1307-1310.

Winder SJ, Allen BG, Clement-Chomienne O and Walsh MP (1998): Regulation of smooth muscle actin-myosin interaction and force by calponin. Acta Physiol Scand 164:415-426.

Wolf SC, Brehm BR, Gaschler F, Brehm S, Klaussner M, Smykowski J, Amann K, Osswald H, Erley CM and Risler T (1999): Protective effects of endothelin antagonists in chronic renal failure. Nephrol Dial Transplant 14:29-30.

Wright JW, Krebs LT, Stobb JW and Harding JW (1995): The angiotensin IV system: Functional implications. Front Neuroendocrinol 16:23-52.

Wu C-C, Hong H-J, Chou T-C, Ding Y-A and Yen M-H (1996): Evidence for inducible nitric oxide synthase in spontaneously hypertensive rats. Biochem Biophys Res Comm 228:459-466.

Yamamoto K, Chappell MC, Brosnihan KB and Ferrario CM (1992): In vivo metabolism of angiotensin I by neural endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19:692-696.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K and Masaki T (1988): A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415.

Yang BC, Lippton H, Gumusel B, Hyman A and Mehta JL (1996): Adrenomedullin dilates rat pulmonary artery rings during hypoxia: role of nitric oxide and vasodilator prostaglandins. J Cardiovasc Pharmacol 28:458-462.

Yates MS, Askey EA, Wilmot SE and Bowmer CJ (1985): Vascular reactivity in experimental acute renal failure. J Pharm Pharmacol 37:486-90.

Yonemochi H, Yasunaga S, Teshima Y, Iwao T, Akiyoshi K, Nakagawa M, Saikawa T and Ito M (1998): Mechanism of beta-adrenergic receptor upregulation induced by ACE inhibition in cultured neonatal rat cardiac myocytes: roles of bradykinin and protein kinase C. Circulation 97:2268-2273.

Young EW, Bukoski RD and McCarron DA (1988): Calcium metabolism in experimental hypertension. Proc Soc Exp Biol Med 187:123-141.

Zhao H, Shimokawa H, Uragami-Harasawa L, Igarashi H and Takeshita A (1999): Long-term vascular effects of Nomega-nitro-L-arginine methyl ester are not soley mediated by inhibition of endothelial nitric oxide synthesis in the rat mesenteric artery. J Cardiovasc Pharmacol 33:554-566.

Zhu Z, Neusser M, Tepel M, Spieker C, Golinski P and Zidek W (1994): Effect of Na,K-ATPase inhibition on cytosolic free calcium ions in vascular smooth muscle cells of spontaneously hypertensive and normotensive rats. J Hypertens 12:1007-1012.

ORIGINAL COMMUNICATIONS